Defensin polynucleotides and methods of use

FIELD OF INVENTION

The invention relates to the field of the genetic manipulation of plants, particularly the modulation of gene activity and development in plants and increased disease resistance.

BACKGROUND OF THE INVENTION

Disease in plants is caused by biotic and abiotic causes. Biotic causes include fungi, viruses, bacteria, and nematodes. An example of the importance of plant disease is illustrated by phytopathogenic fungi, which cause significant annual crop yield losses as well as devastating epidemics. Plant disease outbreaks have resulted in catastrophic crop failures that have triggered famines and caused major social change. All of the approximately 300,000 species of flowering plants are attacked by pathogenic fungi; however, a single plant species can be host to only a few fungal species, and similarly, most fungi usually have a limited host range. Generally, the best strategy for plant disease control is to use resistant cultivars selected or developed by plant breeders for this purpose. However, the potential for serious crop disease epidemics persists today, as evidenced by outbreaks of the Victoria blight of oats and southern corn leaf blight. Molecular methods of crop protection have the potential to implement novel mechanisms for disease resistance and can also be implemented more quickly than traditional breeding methods. Accordingly, molecular methods are needed to supplement traditional breeding methods to protect plants from pathogen attack.

A host of cellular processes enable plants to defend themselves against diseases caused by pathogenic agents. These defense mechanisms are activated by initial pathogen infection in a process known as elicitation. In elicitation, the host plant recognizes a pathogen-derived compound known as an elicitor; the plant then activates disease gene expression to limit further spread of the invading organism. It is generally believed that to overcome these plant defense mechanisms, plant pathogens must find a way to suppress elicitation as well as to overcome more physically-based barriers to infection, such as reinforcement and/or rearrangement of the actin filament networks near the cell's plasma membrane.

Thus, the present invention solves needs for enhancement of the plant's defensive elicitation response via a molecularly based mechanism which can be quickly incorporated into commercial crops.

SUMMARY OF THE INVENTION

Compositions and methods relating to disease resistance are provided. Particularly, isolated nucleic acid molecules having nucleotide and amino acid sequences for defensins from plants are provided. The nucleotide sequences of the invention encode small cysteine-rich proteins and are variously annotated or described as defensins, defensin-like proteins, antimicrobial peptides, anti-pathogenic peptides, thionins, antifungal peptides, protease inhibitors, amylase inhibitors, scorpion toxin-like proteins and small cysteine-rich peptides. They are referred to herein as defensins as they exhibit similarity in primary structure to insect defensins. Transformed plants can be obtained having altered metabolic states with respect to the defense response.

The defensin genes of the present invention may find use in enhancing the plant pathogen defense system. The compositions and methods of the invention can be used for enhancing resistance to plant pathogens including fungal pathogens, plant viruses, microorganisms, nematodes, insects, and the like. The method involves stably transforming a plant with a nucleotide sequence capable of modulating the plant pathogen defense system operably linked with a promoter capable of driving expression of a gene in a plant cell. The defensin genes additionally find use in manipulating these processes in transformed plants and plant cells.

Transformed plants, plant cells, and seeds, as well as methods for making such plants, plant cells, and seeds are additionally provided. It is recognized that a variety of promoters will be useful in the invention, the choice of which will depend in part upon the desired level of expression of the disclosed genes. It is recognized that the levels of expression can be controlled to modulate the levels of expression in the plant cell.

BRIEF DESCRIPTION OF THE DRAWINGS

<figref idref="f0001">Figure 1</figref> depicts an alignment of several defensin genes and a consensus defensin sequence (SEQ ID NO:469). Zm-PDF1 is set forth in SEQ ID NO:465; Zm-PDF2 is set forth in SEQ ID NO:463; Zm-PDF3 is set forth in SEQ ID NO:235; Zm-PDF4 is set forth in SEQ ID NO:1; Zm-PDF6 is set forth in SEQ ID NO:4; and Zm-PDF13 is set forth in SEQ ID NO:10.

DETAILED DESCRIPTION OF THE INVENTION

Overview

The present invention provides, inter alia, compositions and methods for modulating the total level of polypeptides of the present invention and/or altering their ratios in a plant. By "modulation" an increase or decrease in a particular character, quality, substance, or response is intended.

The compositions comprise nucleotide and amino acid sequences from numerous plant species. Particularly, the nucleotide and amino acid sequences for 85 groups of defensins are provided. By "plant defensin genes" is intended genes that are structurally related to plant defensins, and include thionins, small cysteine-rich peptides, proteinase inhibitors, amylase inhibitors, and the like. They are called defensin genes after a structural classification of proteins (SCOP) classification system. Defensins play a role in defense, more specifically plant defense against pathogens, and they share similarity in primary and secondary structure with insect defensins. Defensins of the invention are classified in the superfamily of Scorpion toxin-like proteins and in the Plant Defensin family. While not bound by any mechanism of action, expression of the sequences and related genes around disease induced lesions may control symptom development, as in a hypersensitive response (HR), by controlling the protease mediated cell death mechanism. The compositions may also function directly as antipathogenic proteins by inhibiting proteases produced by pathogens or by binding cell wall components of pathogens. Thirdly, they may also act as amphipathic proteins that perturb membrane function, leading to cellular toxicity of the pathogens. The defensins are generally small cysteine-rich peptides and demonstrate antimicrobial activity. By "antimicrobial" or "antimicrobial activity" antibacterial, antiviral, nematocidal, insecticidal, or and antifungal activity is intended. Accordingly, the polypeptides of the invention may enhance resistance to insects and nematodes. Any one defensin exhibits a spectrum of antimicrobial activity that may involve one or more antibacterial, antifungal, antiviral, insecticidal, nematocidal, or antipathogenic activities. They may also be useful in regulating seed storage protein turnover and metabolism.

Plant defensins generally comprise about 45-54 amino acids with four disulfide bridges (<nplcit id="ncit0001" npl-type="s"><text>Broekaert et al. (1995) Plant Physiol. (Bethesda) 108:1353-1358</text></nplcit>). The defensins of the invention inhibit the growth of a broad range of pathogens, including but not limited to fungi, nematocides, bacteria, insects, and viruses at micromolar concentrations. Thus, by "defensin-like activity" it is intended that the peptides inhibit pathogen growth or damage caused by a variety of pathogens, including but not limited to, fungi, insects, nematodes, viruses and bacteria. Defensins inhibit pathogen damage through a variety of mechanisms including, but not limited to, alteration of membrane ion permeability and induction of hyphal branching in fungal targets (<nplcit id="ncit0002" npl-type="s"><text>Garcia-Olmeda et al. (1998) Biopolymers, Peptide Science 47:479-491</text></nplcit>, herein incorporated by reference).

The compositions of the invention can be used in a variety of methods whereby the protein products can be expressed in crop plants to function as antimicrobial proteins. Expression will result in alterations or modulation of the level, tissue, or timing of expression to achieve enhanced disease, insect, nematode, viral, fungal, or stress resistance. The compositions of the invention may be expressed in the native species including, but not limited to <i>Arachis hypogaea, Vitis vinifera, Licania michauxii, Cyamopsis tetragonoloba, Parthenium argentatum, Nicotiana benthamiana, Eucalyptus grandis, Tropaeolum majus, Ricinus communis, Vernonia mespilifolia, Chrysobalanus icaco, Glycine max, Triticum aestivum, Oryza sativa, Zea mays, Brassica napus, Tulipa gesneriana, Beta vulgaris, Allium porrum, Amaranthus retroflexus, Hedera helix, Picramnia penatandra, Taraxacum kok-saghyz., Tulipa fosteriana, Momordica charantia,</i> or alternatively, can be heterologously expressed in any plant of interest. In this manner, the coding sequence for the defensin can be used in combination with a promoter that is introduced into a crop plant. In one embodiment, a high-level expressing constitutive promoter may be utilized and would result in high levels of expression of the defensin. In other embodiments, the coding sequence may be operably linked to a tissue-preferred promoter to direct the expression to a plant tissue known to be susceptible to a pathogen. Likewise, manipulation of the timing of expression may be utilized. For example, by judicious choice of promoter, expression can be enhanced early in plant growth to prime the plant to be responsive to pathogen attack. Likewise, pathogen inducible promoters can be used wherein expression of the defensin is turned on in the presence of the pathogen.

If desired, a transit peptide can be utilized to direct cellular localization of the protein product. In this manner, the native transit peptide or a heterologous transit peptide can be used. However, it is recognized that both extracellular expression and intracellular expression are encompassed by the methods of the invention.

Sequences of the invention, as discussed in more detail below, encompass coding sequences, antisense sequences, and fragments and variants thereof. Expression of the sequences of the invention can be used to modulate or regulate the expression of corresponding defensin proteins.

The defensin genes of the present invention additionally find use in enhancing the plant pathogen defense system. The compositions and methods of the invention can be used for enhancing resistance to plant pathogens including fungal pathogens, plant viruses, insect pathogens, bacterial pathogens, nematodes, and the like. The method involves stably transforming a plant with a nucleotide sequence capable of modulating the plant pathogen defense system operably linked with a promoter capable of driving expression of a gene in a plant cell. By "enhancing resistance" increasing the tolerance of the plant to pathogens is intended. That is, the defensin may slow or prevent pathogen infection and/or spread.

Compositions

Compositions of the invention include nucleotide sequences that have been identified as defensins. Defensins are involved in defense response and development. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequences shown in SEQ ID NO:2, 3, 5, 6, 8, 9, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 32, 33, 35, 36, 38, 39, 41, 42, 44, 45, 47, 48, 50, 51, 53, 54, 56, 57, 59, 60, 62, 63, 65, 66, 68, 69, 71, 72, 74, 75, 77, 78, 80, 81, 83, 84, 86, 87, 89, 90, 92, 93, 95, 96, 98, 99, 101, 102, 104, 105, 107, 108, 110, 111, 113,114, 116,117, 119, 120, 122, 123, 125,126,128, 129, 131, 132, 134, 135, 137, 138,140, 141, 143, 144, 146, 147, 149, 150, 152, 153, 155, 156, 158, 159, 161, 162, 164, 165, 167, 168, 170, 171, 173, 174, 176, 177, 179, 180, 182, 183, 185, 186, 188, 189, 191, 192, 194, 195, 197, 198, 200, 201, 203, 204, 206, 207, 209, 210, 212, 213, 215, 216, 218, 219, 221, 222, 224, 225, 227, 228, 230, 231, 233, 234, 236, 237, 239, 240, 242, 243, 245, 246, 248, 249, 251, 252, 254, 255, 257, 258, 260, 261, 263, 264, 266, 267, 269, 270, 272, 273, 275, 276, 278, 279, 281, 282, 284, 285, 287, 288, 290, 291, 293, 294, 296, 297, 299, 300, 302, 303, 305, 306, 308, 309, 11, 312, 314, 315, 317, 318, 320, 321, 323, 324,326, 327, 329, 330, 332, 333, 335, 336, 338, 339, 341, 342, 344, 345, 347, 348, 350, 351, 353, 354, 356, 357, 359, 360, 362, 363, 365, 366, 368, 369, 371, 372, 374, 375, 377, 378, 380, 381, 383, 384, 386, 387, 389, 390, 392, 393, 395, 396, 398, 399, 401, 402, 404, 405, 407, 408, 410, 411, 413, 414, 416, 417, 419, 420, 422, 423, 425, 426, 428, 429, 431, 432, 434, 435, 437, 438, 440, 441, 443, 444, 446, 447, 449, 450, 452, 453, 455, 456, 458, 459, 461, 462, 464, 466, or 468. In particular the invention provides the mature polypeptides having the amino acid sequences set forth in SEQ ID NO:3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 117, 120, 123, 126, 129, 132, 135, 138, 141, 144, 147, 150, 153, 156, 159, 162, 165, 169, 171, 174, 177, 180, 183, 186, 189, 192, 195, 198, 201, 204, 207, 210, 213, 216, 219, 222, 225, 228, 231, 234, 237, 240, 243, 246, 249, 252, 255, 258, 261, 264, 267, 270, 273, 276, 279, 282, 285, 288, 291, 294, 297, 300, 303, 306, 309, 312, 315, 318, 321, 324, 327, 330, 333, 336, 339, 342, 345, 348, 351, 354, 357, 360, 363, 366, 369, 372, 375, 378, 381, 384, 387, 390, 393, 396, 399, 402, 405, 408, 411, 414, 417, 420, 423, 426, 429, 432, 435, 438, 441, 444, 447, 450, 453, 456, 459,or 462. Further provided are polypeptides having an amino acid sequence encoded by a nucleic acid molecule described herein, for example those set forth in SEQ ID NO:1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76, 79, 82, 85, 88, 91, 94, 97, 100, 103, 106, 109, 112, 115, 118, 121, 124, 127, 130, 133, 136, 139, 142, 145, 148, 151, 154, 157, 160, 163, 166, 169, 172, 175, 178, 181, 184, 187, 190, 193, 196, 199, 202, 205, 208, 211, 214, 217, 220, 223, 226, 229, 232, 235, 238, 241, 244, 247, 250, 253, 256, 259, 262, 265, 268, 271, 274, 277, 280, 283, 286, 289, 292, 295, 298, 301, 304, 307, 310, 313, 316, 319, 322, 325, 328, 331, 334, 337, 340, 343, 346, 349, 352, 355, 358, 361, 364, 367, 370, 373, 376, 379, 382, 385, 388, 391, 394, 397, 400, 403, 406, 409, 412, 415, 418, 421, 424, 427, 430, 433, 436, 439, 442, 445, 448, 451, 454, 457, 460, 463, 465, or 467.

The nucleotide sequences of the invention are sequences comprising a protein superfamily including defensins, thionins, protease inhibitors, amylase inhibitors, scorpion toxin-like proteins, and small cysteine-rich peptides. The claimed sequences are members of the plant defensin class of genes and polypeptides. The plant defensins are identified herein as "CS" followed by a three-digit number. The defensins of the invention fall into 85 groups based on sequence homology. As indicated elsewhere herein, some of the maize plant defensins are identified as "Zm-PDF" for <i>Zea mays</i> plant defensins and designated as numbers ZmPDF or PDF (e.g. Zm-PDF1 or PDF1). The Zm-PDF and PDF nomenclature has been described previously in <patcit id="pcit0001" dnum="US300152P"><text>U.S. Patent Applications Nos.60/300,152</text></patcit>, and <patcit id="pcit0002" dnum="US60300241P"><text>60/300,241</text></patcit>, both filed June 22, 2001, and herein incorporated by reference in their entirety.

The defensins of the invention are aligned to a diverse set of mostly plant, some non-plant and some animal, proteinase-inhibitors, thionins, especially gamma-thionins, and defensins, and antifungal proteins. A consensus sequence (SEQ ID NO:469) for some of the maize nucleotide sequences of the invention can be seen in <figref idref="f0001">Figure 1</figref>. There are homologs to these sequences in soybeans, rice, wheat, and other crops. They represent a diverse and conserved supergene family in plants. <ul id="ul0001" list-style="none" compact="compact"><li>Group 1 comprises three nucleotide sequences, of which CS004 (SEQ ID NO:1, PDF4) is the representative sequence. The CS004 polypeptide (SEQ ID NOS:2 and 3), encoded by the nucleotide sequence set forth in SEQ ID NO:1, is expressed in a tassel-preferred pattern. The full-length CS004 polypeptide (SEQ ID NO:2) appears to include a signal peptide, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:3. CS004 is extracellular. CS006 (SEQ ID NO:4, PDF6) appears to be preferentially expressed in the tassel. The full length CS006 polypeptide (SEQ ID NO:5) appears to include a signal peptide, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:6. CS006 is extracellular. The CS031 nucleotide sequence (SEQ ID NO:7) was obtained from <i>Oryza sativa.</i> The full length CS031 polypeptide (SEQ ID NO:8) appears to include a signal peptide, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:9.</li><li>Group 2 comprises CS013 (SEQ ID NO:10, PDF13), a maize gene. PDF13 is widely expressed. The full length CS013 polypeptide (SEQ ID NO:11) is expected to have a signal peptide, thus the mature protein (SEQ ID NO: 12) would be extracellular.</li><li>Group 3 comprises two maize sequences, of which CS017 (SEQ ID NO: 13, PDF17) is the representative sequence. The CS017 sequence appears to be preferentially expressed in kernels. The full length CS017 (SEQ ID NO:14) appears to include a signal peptide, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:15. Thus, the predicted CS017 polypeptide would be extracellular. CS018 (SEQ ID NO:16, PDF18) is expressed in the kernel endosperm and may be expressed elsewhere. The full length polypeptide (SEQ ID NO: 17) appears to include a signal peptide, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:18.</li><li>Group 4 comprises 13 sequences of which CS065 (SEQ ID NO:43) is the representative sequence. CS065, having the nucleotide sequence set forth in SEQ ID NO:43 and encoding the polypeptides set forth in SEQ ID NOS:44 and 45, was isolated from <i>Triticum aestivum.</i> The nucleotide sequences for CS040 (SEQ ID NO:25), CS041 (SEQ ID NO:28), CS051 (SEQ ID NO:31), CS057 (SEQ ID NO:34), CS059 (SEQ ID NO:37), CS062 (SEQ ID NO:40), CS066 (SEQ ID NO:46), CS069 (SEQ ID NO:49), CS070 (SEQ ID NO:52), and CS073 (SEQ ID NO:55) were isolated from <i>Triticum aestivum</i> also. These nucleotide sequences encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:26, 29, 32, 35, 38,41,47, 50,53, and 56, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:27, 30, 33, 36, 39, 42, 48, 51, 54, and 57, respectively. The nucleotide sequences for CS028 (SEQ ID NO:19) and CS029 (SEQ ID NO:22) were isolated from <i>Oryzae sativa.</i> These nucleotide sequences encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:20 and 23, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:21 and 24, respectively.</li><li>Group 5 comprises four sequences of which CS032 (SEQ ID NO:58) is the representative sequence. CS032, having the nucleotide sequence set forth in SEQ ID NO:58 and encoding the full-length and mature polypeptides set forth in SEQ ID NOS:59 and 60, was isolated from <i>Glycine max.</i> The nucleotide sequences for CS034 (SEQ ID NO:61) and CS035 (SEQ ID NO:64) were isolated from <i>Glycine max</i> also. These nucleotide sequences encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:62 and 65, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:63 and 66, respectively. The nucleotide sequences for CS052 (SEQ ID NO:67) was isolated from <i>Triticum aestivum.</i> This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:68, which when processed yields a mature polypeptide having the amino acid sequences set forth in SEQ ID NO:69.</li><li>Group 6 comprises two <i>Triticum aestivum</i> sequences of which CS044 (SEQ ID NO:70) is the representative sequence. CS044 (SEQ ID NO:70) and CS050 (SEQ ID NO:73) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:71 and 74, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:72 and 75, respectively.</li><li>Group 7 comprises two <i>Triticum aestivum</i> sequences of which CS074 (SEQ ID NO:79) is the representative sequence. CS063 (SEQ ID NO:76) and CS074 (SEQ ID NO:79) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:77 and 80, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:78 and 81, respectively.</li><li>Group 8 comprises two <i>Beta vulgaris</i> sequences of which CS078 (SEQ ID NO:85) is the representative sequence. CS079 (SEQ ID NO:82) and CS078 (SEQ ID NO:85) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:83 and 86, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:84 and 87, respectively.</li><li>Group 9 comprises CS084 (SEQ ID NO:88), a <i>Hedera helix</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:89, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:90.</li><li>Group 10 comprises two sequences of which CS091 (SEQ ID NO:91) is the representative sequence. CS091 (SEQ ID NO:91) and CS098 (SEQ ID NO:94) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:92 and 95, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:93 and 96, respectively. CS091 was isolated from <i>Tulipa fosteriana,</i> and CS098 was isolated from <i>Tulipa gesneriana.</i></li><li>Group 11 comprises four sequences of which CS092 (SEQ ID NO: 1 00) is the representative sequence. CS092, having the nucleotide sequence set forth in SEQ ID NO: 100 and encoding the full-length and mature polypeptides set forth in SEQ ID NOS:101 and 102, was isolated from <i>Tulipa fosteriana.</i> CS094 (SEQ ID NO:97), CS093 (SEQ ID NO:103), and CS099 (SEQ ID NO:106) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:98, 104, and 107, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:99, 105, and 108, respectively.</li><li>Group 12 comprises two <i>Tulipa gesneriana</i> sequences of which CS097 (SEQ ID NO:112) is the representative sequence. CS102 (SEQ ID NO:109) and CS097 (SEQ ID NO:112) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:110 and 113, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:111 and 114, respectively.</li><li>Group 13 comprises two <i>Tulipa gesneriana</i> sequences of which CS101 (SEQ ID NO:115) is the representative sequence. CS101 (SEQ ID NO:115) and CS 154 (SEQ ID NO: 118) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:116 and 119, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:117 and 120, respectively.</li><li>Group 14 comprises two <i>Momordica charantia</i> sequences of which CS104 (SEQ ID NO:121) is the representative sequence. CS104 (SEQ ID NO:121) and CS105 (SEQ ID NO:124) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:122 and 125, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:123 and 126, respectively.</li><li>Group 15 comprises two <i>Nicotiana benthamiana</i> sequences of which CS112 (SEQ ID NO:127) is the representative sequence. CS112 (SEQ ID NO:127) and CS166 (SEQ ID NO:130) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:128 and 131, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:129 and 132, respectively.</li><li>Group 16 comprises two sequences of which CS128 (SEQ ID NO:133) is the representative sequence. CS128 (SEQ ID NO:133) and CS153 (SEQ ID NO:136) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:134 and 137, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:135 and 138, respectively. CS128 was isolated from <i>Tulipa fosteriana,</i> and CS153 was isolated from <i>Tulipa gesneriana.</i></li><li>Group 17 comprises 24 <i>Taraxacum kok-saghyz</i> sequences of which CS130 (SEQ ID NO:142) is the representative sequence. CS129 (SEQ ID NO:139), CS130 (SEQ ID NO:142), CS131 (SEQ ID NO:145), CS132 (SEQ ID NO:148), CS133 (SEQ ID NO:151), CS134 (SEQ ID NO:154), CS135 (SEQ ID NO:157), CS136 (SEQ ID NO:160), CS137 (SEQ ID NO: 163), CS138 (SEQ ID NO: 166), CS139 (SEQ ID NO: 169), CS140 (SEQ ID NO:172), CS141 (SEQ ID NO:175), CS142 (SEQ ID NO:178), CS143 (SEQ ID NO:181), CS144 (SEQ ID NO:184), CS145 (SEQ ID NO:187), CS 146 (SEQ ID NO: 190), CS147 (SEQ ID NO: 193), CS 148 (SEQ ID NO: 196), CS149 (SEQ ID NO: 199), CS150 (SEQ ID NO:202), CS151 (SEQ ID NO:205), and CS152 (SEQ ID NO:208) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:140, 143, 146, 149, 152, 155, 158, 161, 164, 167, 170, 173, 176, 179, 182, 185, 188, 191, 194, 197, 200, 203, 206, and 209, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:141, 144, 147, 150, 153, 156, 159, 162, 165, 168, 171, 174, 177, 180, 183, 186, 189, 192, 195, 98, 201, 204, 207, and 210, respectively.</li><li>Group 18 comprises five <i>Picramnia pentandra</i> sequences of which CS 161 (SEQ ID NO:211) is the representative sequence. CS161 (SEQ ID NO:211), CS164 (SEQ ID NO:214), CS 160 (SEQ ID NO:217), CS162 (SEQ ID NO:220), and CS163 (SEQ ID NO:223) encode full length polypeptides having the amino acid sequences set forth in SEQ TD NOS:212, 215, 218, 221, and 224, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:213, 216, 219, 222, and 225, respectively.</li><li>Group 19 comprises three <i>Nicotiana benthamiana</i> sequences of which CS165 (SEQ ID NO:226) is the representative sequence. CS165(SEQ ID NO:226), CS168 (SEQ ID NO:229), and CS169 (SEQ ID NO:232) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:227, 230, and 233, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:228, 231, and 234, respectively.</li><li>Group 20 comprises CS003 (SEQ ID NO:235, PDF3), a maize gene. The full length CS003 polypeptide (SEQ ID NO:236) is expected to have a signal peptide, thus the mature protein (SEQ ID NO:237) is likely to be secreted or extracellular.</li><li>Group 21 comprises CS007 (SEQ ID NO:238, PDF7), a maize gene. PDF7 is likely to be expressed in a kernel-specific or kernel-preferred expression pattern. The full length CS007 polypeptide (SEQ ID NO:239) is expected to have a signal peptide, thus the mature protein (SEQ ID NO:240) would be extracellular.</li><li>Group 22 comprises CS008 (SEQ ID NO:241, PDF8), a maize gene. PDF8 is expressed in a kernel-preferred expression pattern. The full length CS008 polypeptide (SEQ ID NO:242) is expected to have a signal peptide, thus the mature protein (SEQ ID NO:243) would be extracellular. PDF8 may be secreted.</li><li>Group 23 comprises CS009 (SEQ ID NO:244, PDF9), a maize gene. PDF9 is expressed in a kernel-preferred pattern, particularly an endosperm- and pericarp-preferred expression pattern. The full length CS009 polypeptide (SEQ ID NO:245) includes a predicted transit peptide, thus the mature protein (SEQ ID NO:246) would be extracellular.</li><li>Group 24 comprises CS010 (SEQ ID NO:247, PDF10), a maize gene. The full length CS010 polypeptide (SEQ ID NO:248) is expected to have a signal peptide, thus the mature protein (SEQ ID NO:249) is likely to be secreted or extracellular. Expression appears to be kernel-specific or kernel-preferred.</li><li>Group 25 comprises CS014 (SEQ ID NO:250, PDF14), a maize gene. PDF14 is expressed in a tassel-preferred manner. The full length CS014 polypeptide (SEQ ID NO:251) appears to include a signal peptide, thus the mature protein (SEQ ID NO:252) would be secreted.</li><li>Group 26 comprises CS016 (SEQ ID NO:253, PDF16), a maize gene. The PDF16 nucleotide sequence appears to be expressed preferentially in the kernel, particularly in the endosperm and scutellum. The full length CS016 polypeptide (SEQ ID NO:254) is predicted to have a signal peptide ending at amino acid position 22, thus the mature protein (SEQ ID NO:255) is likely to be an extracellular polypeptide.</li><li>Group 27 comprises CS019 (SEQ ID NO:256, PDF19), a maize gene. Expression of the sequence appears to be kernel-preferred. The protein is likely extracellular as the full length CS019 polypeptide (SEQ ID NO:257) contains a signal peptide, thus the mature protein (SEQ ID NO:258) appears to be secreted or extracellular.</li><li>Group 28 comprises CS020 (SEQ ID NO:259, PDF20), a maize gene. Expression of PDF20 appears to be kernel-preferred. The predicted protein appears to be extracellular as it has a predicted signal peptide. The full length CS020 polypeptide (SEQ ID NO:260) is expected to have a signal peptide, thus the mature protein (SEQ ID NO:261) is likely to be secreted or extracellular.</li><li>Group 29 comprises CS043 (SEQ ID NO:262), a <i>Triticum aestivum</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:263, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:264.</li><li>Group 30 comprises CS045 (SEQ ID NO:265), a <i>Tritium aestivum</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:266, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:267.</li><li>Group 31 comprises CS046 (SEQ ID NO:268), a <i>Triticum aestivum</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:269, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:270.</li><li>Group 32 comprises CS048 (SEQ ID NO:271), a <i>Triticum aestivum</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:272, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:273.</li><li>Group 33 comprises CS049 (SEQ ID NO:274), a <i>Triticum aestivum</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequences set forth in SEQ ID NO:275, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:276.</li><li>Group 34 comprises CS060 (SEQ ID NO:277), a <i>Triticum aestivum</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:278, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:279.</li><li>Group 35 comprises CS061 (SEQ ID NO:280), a <i>Triticum aestivum</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:281, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:282.</li><li>Group 36 comprises CS068 (SEQ ID NO:283), a <i>Triticum aestivum</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:284, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:285.</li><li>Group 37 comprises CS071 (SEQ ID NO:286), a <i>Triticum aestivum</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:287, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:288.</li><li>Group 38 comprises CS072 (SEQ ID NO:289), a <i>Triticum aestivum</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:290, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:291.</li><li>Group 39 comprises CS076 (SEQ ID NO:292), a <i>Beta vulgaris</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:293, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:294.</li><li>Group 40 comprises CS085 (SEQ ID NO:295), a <i>Hedera helix</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:296, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:297.</li><li>Group 41 comprises CS103 (SEQ ID NO:298), a <i>Tulipa gesneriana</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:299, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:300.</li><li>Group 42 comprises CS124 (SEQ ID NO:301), an <i>Amaranthus retrof lexus</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:302, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:303.</li><li>Group 43 comprises CS159 (SEQ ID NO:304), an <i>Allium porrum</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:305, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:306.</li><li>Group 44 comprises CS113 (SEQ ID NO:307), a <i>Nicotiana benthaniiana</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:308, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:309.</li><li>Group 45 comprises CS095 (SEQ ID NO:310), a <i>Tulipa gesneriana</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:311, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:312.</li><li>Group 46 comprises CS077 (SEQ ID NO:313), a <i>Beta vulgaris</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:314, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:315.</li><li>Group 47 comprises three <i>Cyamopsis tetragonoloba</i> sequences of which CS108 (SEQ ID NO:316) is the representative sequence. CS108(SEQ ID NO:316), CS156 (SEQ ID NO:319), and CS 157 (SEQ ID NO:322) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:317, 320, and 323, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:318, 321, and 324, respectively.</li><li>Group 48 comprises three sequences of which CS005 (SEQ ID NO:325, PDF5) is the representative sequence. CS005 was isolated from <i>Zea mays.</i> The PDF5 expression pattern suggests fairly wide-distribution of expression. However, there is strong representation of CS005 in endosperms and embryos of kernels. The mature peptide appears to be extracellular, as a signal peptide is included in the sequence. CS005 (SEQ ID NO:325), CS042 (SEQ ID NO:328) and CS067 (SEQ ID NO:331) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:326, 329, and 332, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:327, 330, and 333, respectively. CS042 and CS067 were isolated from <i>Triticum aestivum.</i></li><li>Group 49 comprises four sequences of which CS053 (SEQ ID NO:337) is the representative sequence. CS100 (SEQ ID NO:334), CS053 (SEQ ID NO:337), CS064 (SEQ ID NO:340), and CS096 (SEQ ID NO:343) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:335, 338, 341, and 344, which when processed yield mature polypeptides having the amino id sequences set forth in SEQ ID NOS:336, 339, 342, and 345, respectively. CS100 and CS096 were isolated from <i>Tulipa gesneriana.</i> CS053 and CS064 were isolated from <i>Triticum aestivum.</i></li><li>Group 50 comprises CS036 (SEQ ID NO:346) a <i>Glycine max</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:347, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:348.</li><li>Group 51 comprises CS125 (SEQ ID NO:349), a <i>Brassica napus</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:350, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:351.</li><li>Group 52 comprises CS056 (SEQ ID NO:352), a <i>Triticum aestivum</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:353, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:354.</li><li>Group 53 comprises CS047 (SEQ ID NO:355), a <i>Triticum aestivum</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:356, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:357.</li><li>Group 54 comprises CS021 (SEQ ID NO:358, PDF21), <i>a Zea mays</i> sequence. PDF21 may be predominately expressed in the kernel. The sequence appears to be extracellular as it includes a signal peptide. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:359, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:360.</li><li>Group 55 comprises CS122 (SEQ ID NO:361), a <i>Vernonia mespilifolia</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:362, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:363.</li><li>Group 56 comprises CS111 (SEQ ID NO:364), a <i>Picramnia pentandra</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:365, which when processed yields a mature polypeptide having the amino acid sequence set-forth in SEQ ID NO:366.</li><li>Group 57 comprises CS 171 (SEQ ID NO:367), a <i>Vernonia mespilifolia</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:368, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:369.</li><li>Group 58 comprises CS172 (SEQ ID NO:370), a <i>Vernonia mespilifolia</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:371, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:372.</li><li>Group 59 comprises CS030 (SEQ ID NO:373), an <i>Oryza sativa</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:374, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:375.</li><li>Group 60 comprises CS088 (SEQ ID NO:376), a <i>Parthenium argentatum</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:377, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:378.</li><li>Group 61 comprises CS107 (SEQ ID NO:379), a <i>Cyamopsis tetragonoloba</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:380, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:381.</li><li>Group 62 comprises CS058 (SEQ ID NO:382), a <i>Triticum aestivum</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:383, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:384.</li><li>Group 63 comprises CS037 (SEQ ID NO:385), a <i>Glycine max</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:386, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:387.</li><li>Group 64 comprises two sequences of which CS082 (SEQ ID NO:391) is the representative sequence. CS086 (SEQ ID NO:388) and CS082 (SEQ ID NO:391) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:389 and 392, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:390 and 393, respectively. CS086 was isolated from <i>Licania michauxii,</i> and CS082 was isolated from <i>Chrysobalanus icaco.</i></li><li>Group 65 comprises CS081 (SEQ ID NO:394), a <i>Ricinus communis</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:395, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:396.</li><li>Group 66 comprises two <i>Vernonia mespilifolia</i> sequences of which CS121 (SEQ ID NO:400) is the representative sequence. CS123 (SEQ ID NO:397) and CS121 (SEQ ID NO:400) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:398 and 401, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:399 and 402, respectively.</li><li>Group 67 comprises CS080 (SEQ ID NO:403), a <i>Ricinus communis</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:404, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:405.</li><li>Group 68 comprises two sequences of which CS083 (SEQ ID NO:406) is the representative sequence. CS083 (SEQ ID NO:406) and CS087 (SEQ ID NO:409) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:407 and 410, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:408 and 411, respectively. CS083 was isolated from <i>Eucalyptus grandis,</i> and CS087 was isolated from <i>Tropaeolum majus.</i></li><li>Group 69 comprises CS155 (SEQ ID NO:412), a <i>Cyamopsis tetragonoloba</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:413, which when processed yields a mature polypeptide having the amino acid sequence set forth in-SEQ ID NO:414.</li><li>Group 70 comprises three <i>Vitis vinifera</i> sequences of which CS 117 (SEQ ID NO:421) is the representative sequence. CS119 (SEQ ID NO:415), CS116 (SEQ ID NO:418), and CS117 (SEQ ID NO:421) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:416, 419, and 422, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:417, 420, and 423, respectively.</li><li>Group 71 comprises CS 126 (SEQ ID NO:424), a <i>Eucalyptus grandis</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:425, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:426.</li><li>Group 72 comprises CS109 (SEQ ID NO:427), a <i>Cyamopsis tetragonoloba</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:428, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:429.</li><li>Group 73 comprises CS 115 (SEQ ID NO:430), a <i>Nicotiana benthamiana</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:431, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:432.</li><li>Group 74 comprises CS089 (SEQ ID NO:433), a <i>Parthenium argentatum</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:434, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:435.</li><li>Group 75 comprises CS110 (SEQ ID NO:436), a <i>Cyamopsis tetragonoloba</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:437, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ.ID NO:438.</li><li>Group 76 comprises CS158 (SEQ ID NO:439), a <i>Cyamopsis tetragonoloba</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:440, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:441.</li><li>Group 77 comprises CS127 (SEQ ID NO:442), a <i>Licania michauxii</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:443, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:444.</li><li>Group 78 comprises two <i>Vitis vinifera.</i> sequences of which CS 118 (SEQ ID NO:445) is the representative sequence. CS118 (SEQ ID NO:445) and CS170 (SEQ ID NO:448) encode full length polypeptides having the amino acid sequences set forth in SEQ ID NOS:446 and 449, which when processed yield mature polypeptides having the amino acid sequences set forth in SEQ ID NOS:447 and 450, respectively.</li><li>Group 79 comprises CS090 (SEQ ID NO:451), an <i>Arachis hypogaea</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:452, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:453.</li><li>Group 80 comprises CS075 (SEQ ID NO:454), <i>a Brassica napus.</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:455, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:456.</li><li>Group 81 comprises CS011 (SEQ ID NO:457, PDF11), a <i>Zea mays</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:458, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:459. PDF11 expression seems to be tassel-preferred. The mature peptide may be secreted or extracellular as the sequence includes a signal peptide.</li><li>Group 82 comprises CS012 (SEQ ID NO:460, PDF12), a <i>Zea mays</i> sequence. This nucleotide sequence encodes a full length polypeptide having the amino acid sequence set forth in SEQ ID NO:461, which when processed yields a mature polypeptide having the amino acid sequence set forth in SEQ ID NO:462. The sequence may be preferentially expressed in kernels. PDF12 encodes a signal peptide, and thus would be secreted.</li><li>Group 83 comprises CS002 (SEQ ID NO:463, PDF2), a <i>Zea mays</i> sequence. This nucleotide sequence encodes a full-length polypeptide having the amino acid sequence set forth in SEQ ID NO:464. PDF2 is expressed in a kernel-preferred pattern.</li><li>Group 84 comprises CS015 (SEQ ID NO:465, PDF15), a <i>Zea mays</i> sequence. This nucleotide sequence encodes a full-length polypeptide having the amino acid sequence set forth in SEQ ID NO:466. PDF15 is preferentially expressed in kernels. The Zm-PDF15 sequence differs from Zm-ES-4 (<nplcit id="ncit0003" npl-type="s"><text>Cordts et al. (2001) Plant J. 25:103-114</text></nplcit>) by one amino acid residue. The gene appears to encode an extracellularly localized protein as there is a signal peptide.</li><li>Group 85 comprises CS001 (SEQ ID NO:467, PDF1), a <i>Zea mays</i> sequence. This nucleotide sequence encodes a full-length polypeptide having the amino acid sequence set forth in SEQ ID NO:468. Zm-PDF1 is predicted to be an extracellular protein.</li></ul>

The invention encompasses isolated or substantially purified nucleic acid or protein compositions. An "isolated" or "purified" nucleic acid molecule or protein, or biologically active portion thereof, is substantially or essentially free from components that normally accompany or interact with the nucleic acid molecule or protein as found in its naturally occurring environment. Thus, an isolated or purified nucleic acid molecule or protein is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. Preferably, an "isolated" nucleic acid is free of sequences (preferably protein encoding sequences) that naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of nucleotide sequences that naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. A protein that is substantially free of cellular material includes preparations of protein having less than about 30%, 20%, 10%, 5%, or 1% (by dry weight) of contaminating protein. When the protein of the invention or biologically active portion thereof is recombinantly produced, preferably culture medium represents less than about 30%, 20%, 10%, 5%, or 1% (by dry weight) of chemical precursors or non-protein-of-interest chemicals.

Fragments and variants of the disclosed nucleotide sequences and proteins encoded thereby are also encompassed by the present invention. By "fragment" is intended a portion of the nucleotide sequence or a portion of the amino acid sequence and hence protein encoded thereby. Fragments of a nucleotide sequence may encode protein fragments that retain the biological activity of the native protein and hence have defensin-like activity and thereby affect development, developmental pathways, and defense responses. Alternatively, fragments of a nucleotide sequence that are useful as hybridization probes generally do not encode fragment proteins retaining biological activity. Thus, fragments of a nucleotide sequence may range from at least about 20 nucleotides, about 50 nucleotides, about 100 nucleotides, and up to the full-length nucleotide sequence encoding the proteins of the invention.

A fragment of a defensin nucleotide sequence that encodes a biologically active portion of a defensin protein of the invention will encode at least 15, 25, 30, 50, 100, 150, 153, 200, 250, 300 contiguous amino acids, or up to the total number of amino acids present in a full-length protein of the invention. Fragments of a defensin nucleotide sequence that are useful as hybridization probes for PCR primers generally need not encode a biologically active portion of a defensin protein.

Thus, a fragment of a defensin nucleotide sequence may encode a biologically active portion of a defensin protein, or it may be a fragment that can be used as a hybridization probe or PCR primer using methods disclosed below. A biologically active portion of a defensin protein can be prepared by isolating a portion of one of the defensin nucleotide sequences of the invention, expressing the encoded portion of the defensin protein (<i>e.g</i>., by recombinant expression <i>in vitro</i>), and assessing the activity of the encoded portion of the defensin protein. Nucleic acid molecules that are fragments of a defensin nucleotide sequence comprise at least 16, 20, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 683, 700, 800, or 900 nucleotides, or up to the number of nucleotides present in a full-length defensin nucleotide sequence disclosed herein By "variants" substantially similar sequences are intended. For nucleotide sequences, conservative variants include those sequences that, because of the degeneracy of the genetic code, encode the amino acid sequence of one of the defensin polypeptides of the invention. Naturally occurring allelic variants such as these can be identified with the use of well-known molecular biology techniques, as, for example, with polymerase chain reaction (PCR) and hybridization techniques as outlined below. Variant nucleotide sequences also include synthetically derived nucleotide sequences, such as those generated, for example, by using site-directed mutagenesis but which still encode a defensin protein of the invention. Generally, variants of a particular nucleotide sequence of the invention will have at least about 50%, 60%, 65%, 70%, generally at least about 75%, 80%, 85%, preferably at least about 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, and more preferably at least about 98%, 99% or more sequence identity to that particular nucleotide sequence as determined by sequence alignment programs described elsewhere herein using default parameters.

By "variant protein" a protein derived from the native protein by deletion (so-called truncation) or addition of one or more amino acids to the N-terminal and/or C-terminal end of the native protein; deletion or addition of one or more amino acids at one or more sites in the native protein; or substitution of one or more amino acids at one or more sites in the native protein is intended. Variant proteins encompassed by the present invention are biologically active, that is they continue to possess the desired biological activity of the native protein, that is, defensin-like activity as described herein. Such variants may result from, for example, genetic polymorphism or from human manipulation. Biologically active variants of a native defensin protein of the invention will have at least about 40%, 50%, 60%, 65%, 70%, generally at least about 75%, 80%, 85%, preferably at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, and more preferably at least about 98%, 99% or more sequence identity to the amino acid sequence for the native protein as determined by sequence alignment programs described elsewhere herein using default parameters. A biologically active variant of a protein of the invention may differ from that protein by as few as 1-15 amino acid residues, as few as 1-10, such as 6-10, as few as 5, as few as 4, 3, 2, or even 1 amino acid residue.

Biological activity of the defensin polypeptides (<i>i.e</i>., influencing the plant defense response and various developmental pathways, including, for example, influencing cell division) can be assayed by any method known in the art. Biological activity of the polypeptides of the present invention can be assayed by any method known in the art (see for example, <patcit id="pcit0003" dnum="US5614395A"><text>U.S. Patent No. 5,614,395</text></patcit>; <nplcit id="ncit0004" npl-type="s"><text>Thomma et al. (1998) Plant Biology 95:15107-15111</text></nplcit>; <nplcit id="ncit0005" npl-type="s"><text>Liu et al. (1994) Plant Biology 91:1888-1892</text></nplcit>; <nplcit id="ncit0006" npl-type="s"><text>Hu et al. (1997) Plant Mol. Biol. 34:949-959</text></nplcit>; <nplcit id="ncit0007" npl-type="s"><text>Cammue et al. (1992) J. Biol. Chem. 267:2228-2233</text></nplcit>; and <nplcit id="ncit0008" npl-type="s"><text>Thevissen et al. (1996) J. Biol. Chem. 271:15018-15025</text></nplcit>, all of which are herein incorporated by reference). Furthermore, assays to detect defensin-like activity include, for example, assessing antifungal and/or antimicrobial activity (<nplcit id="ncit0009" npl-type="s"><text>Terras et al. (1992) J. Biol. Chem. 267:14301-15309</text></nplcit>; <nplcit id="ncit0010" npl-type="s"><text>Terras et al. (1993) Plant Physiol (Bethesda) 103:1311-1319</text></nplcit>; <nplcit id="ncit0011" npl-type="s"><text>Terras et al. (1995) Plant Cell 7:573-588</text></nplcit>, <nplcit id="ncit0012" npl-type="s"><text>Moreno et al. (1994) Eur. J. Biochem. 223:135-139</text></nplcit>; and <nplcit id="ncit0013" npl-type="s"><text>Osborn et al. (1995) FEBS Lett. 368:257-262</text></nplcit>, all of which are herein incorporated by reference).

The polypeptides of the invention may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions. Novel proteins having properties of interest may be created by combining elements and fragments of proteins of the present invention as well as other proteins. Methods for such manipulations are generally known in the art. For example, amino acid sequence variants of the defensin proteins can be prepared by mutations in the DNA. Methods for mutagenesis and nucleotide sequence alterations are well known in the art. See, for example, <nplcit id="ncit0014" npl-type="s"><text>Kunkel (1985) Proc. Natl. Acad. Sci. USA 82:488-492</text></nplcit>; <nplcit id="ncit0015" npl-type="s"><text>Kunkel et al. (1987) Methods in Enzymol. 154:367-382</text></nplcit>; <patcit id="pcit0004" dnum="US4873192A"><text>U.S. Patent No. 4,873,192</text></patcit>; <nplcit id="ncit0016" npl-type="b"><text>Walker and Gaastra, eds. (1983) Techniques in Molecular Biology (Macmillan Publishing Company, New York</text></nplcit>) and the references cited therein. Guidance as to appropriate amino acid substitutions that do not affect biological activity of the protein of interest may be found in the model of <nplcit id="ncit0017" npl-type="b"><text>Dayhoff et al. (1978) Atlas of Protein Sequence and Structure (NatL Biomed. Res. Found., Washington, D.C</text></nplcit>.), herein incorporated by reference. Conservative substitutions, such as exchanging one amino acid with another having similar properties, may be preferred.

Thus, the genes and nucleotide sequences of the invention include both the naturally occurring sequences as well as mutant forms. Likewise, the proteins of the invention encompass naturally occurring proteins as well as variations and modified forms thereof. Such variants will continue to possess the desired developmental activity, or defense response activity. Obviously, the mutations that will be made in the DNA encoding the variant must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure. See, <patcit id="pcit0005" dnum="EP75444A"><text>EP Patent Application Publication No. 75,444</text></patcit>.

The deletions, insertions, and substitutions of the protein sequences encompassed herein are not expected to produce radical changes in the characteristics of the protein. However, when it is difficult to predict the exact effect of the substitution, deletion, or insertion in advance of doing so, one skilled in the art will appreciate that the effect will be evaluated by routine screening assays. That is, the activity can be evaluated by defensin activity assays. See, for example, <nplcit id="ncit0018" npl-type="s"><text>Lancaster et al. (1994) J. Biol. Chem. 14:1137-1142</text></nplcit> and <nplcit id="ncit0019" npl-type="s"><text>Terras et al. (1995) Plant Cell 7:537-588</text></nplcit>, herein incorporated by reference. Additionally, differences in the expression of specific genes between uninfected and infected plants can be determined using gene expression profiling. RNA was analyzed using the gene expression profiling process (GeneCalling®) as described in <patcit id="pcit0006" dnum="US5871697A"><text>U.S. Patent No. 5,871,697</text></patcit>, herein incorporated by reference.

Variant nucleotide sequences and proteins also encompass sequences and proteins derived from a mutagenic and recombinogenic procedure such as DNA shuffling. With such a procedure, one or more different defensin coding sequences can be manipulated to create a new defensin protein possessing the desired properties. In this manner, libraries of recombinant polynucleotides are generated from a population of related sequence polynucleotides comprising sequence regions that have substantial sequence identity and can be homologously recombined <i>in vitro</i> or <i>in vivo.</i> Strategies for such DNA shuffling are known in the art. See, for example, <nplcit id="ncit0020" npl-type="s"><text>Stemmer (1994) Proc. Natl. Acad. Sci. USA 91:10747-10751</text></nplcit>; <nplcit id="ncit0021" npl-type="s"><text>Stemmer (1994) Nature 370:389-391</text></nplcit>; <nplcit id="ncit0022" npl-type="s"><text>Crameri et al. (1997) Nature Biotech. 15:436-438</text></nplcit>; <nplcit id="ncit0023" npl-type="s"><text>Moore et al. (1997) J. Mol. Biol. 272:336-347</text></nplcit>; <nplcit id="ncit0024" npl-type="s"><text>Zhang et al. (1997) Proc. Natl. Acad. Sci. USA 94:4504-4509</text></nplcit>; <nplcit id="ncit0025" npl-type="s"><text>Crameri et al. (1998) Nature 391:288-291</text></nplcit>; and <patcit id="pcit0007" dnum="US5605793A"><text>U.S. Patent Nos. 5,605,793</text></patcit> and <patcit id="pcit0008" dnum="US5837458A"><text>5,837,458</text></patcit>.

The nucleotide sequences of the invention can be used to isolate corresponding sequences from other organisms, particularly other plants. In this manner, methods such as PCR, hybridization, and the like can be used to identify such sequences based on their sequence homology to the sequences set forth herein. Sequences isolated based on their sequence identity to the entire defensin sequences set forth herein or to fragments thereof are encompassed by the present invention. Such sequences include sequences that are orthologs of the disclosed sequences. By "orthologs" genes derived from a common ancestral gene and which are found in different species as a result of speciation is intended. Genes found in different species are considered orthologs when their nucleotide sequences and/or their encoded protein sequences share substantial identity as defined elsewhere herein. Functions of orthologs are often highly conserved among species. Thus, isolated sequences that encode a defensin and which hybridize under stringent conditions to the defensin sequences disclosed herein, or to fragments thereof, are encompassed by the present invention.

In a PCR approach, oligonucleotide primers can be designed for use in PCR reactions to amplify corresponding DNA sequences from cDNA or genomic DNA extracted from any plant of interest. Methods for designing PCR primers and PCR cloning are generally known in the art and are disclosed in <nplcit id="ncit0026" npl-type="b"><text>Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York</text></nplcit>). See also <nplcit id="ncit0027" npl-type="b"><text>Innis et al., eds. (1990) PCR Protocols: A Guide to Methods and Applications (Academic Press, New York</text></nplcit>); <nplcit id="ncit0028" npl-type="b"><text>Innis and Gelfand, eds. (1995) PCR Strategies (Academic Press, New York</text></nplcit>); and <nplcit id="ncit0029" npl-type="b"><text>Innis and Gelfand, eds. (1999) PCR Methods Manual (Academic Press, New York</text></nplcit>). Known methods of PCR include, but are not limited to, methods using paired primers, nested primers, single specific primers, degenerate primers, gene-specific primers, vector-specific primers, partially-mismatched primers, and the like.

In hybridization techniques, all or part of a known nucleotide sequence is used as a probe that selectively hybridizes to other corresponding nucleotide sequences present in a population of cloned genomic DNA fragments or cDNA fragments (<i>i.e.,</i> genomic or cDNA libraries) from a chosen organism. The hybridization probes may be genomic DNA fragments, cDNA fragments, RNA fragments, or other oligonucleotides, and may be labeled with a detectable group such as ³²P, or any other detectable marker. Thus, for example, probes for hybridization can be made by labeling synthetic oligonucleotides based on the defensin sequences of the invention. Methods for preparation of probes for hybridization and for construction of cDNA and genomic libraries are generally known in the art and are disclosed in <nplcit id="ncit0030" npl-type="b"><text>Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York</text></nplcit>).

For example, an entire defensin sequence disclosed herein, or one or more portions thereof, may be used as a probe capable of specifically hybridizing to corresponding defensin sequences and messenger RNAs. To achieve specific hybridization under a variety of conditions, such probes include sequences that are unique among defensin sequences and are preferably at least about 10 nucleotides in length, and most preferably at least about 20 nucleotides in length. Such probes may be used to amplify corresponding sequences from a chosen organism by PCR. This technique may be used to isolate additional coding sequences from a desired organism or as a diagnostic assay to determine the presence of coding sequences in an organism. Hybridization techniques include hybridization screening of plated DNA libraries (either plaques or colonies; see, for example, <nplcit id="ncit0031" npl-type="b"><text>Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York</text></nplcit>).

Hybridization of such sequences may be carried out under stringent conditions. By "stringent conditions" or "stringent hybridization conditions" conditions under which a probe will hybridize to its target sequence to a detectably greater degree than to other sequences (e.g., at least 2-fold over background) is intended. Stringent conditions are sequence-dependent and will be different in different circumstances. By controlling the stringency of the hybridization and/or washing conditions, target sequences that are 100% complementary to the probe can be identified (homologous probing). Alternatively, stringency conditions can be adjusted to allow some mismatching in sequences so that lower degrees of similarity are detected (heterologous probing). Generally, a probe is less than about 1000 nucleotides in length, preferably less than 500 nucleotides in length.

Typically, stringent conditions will be those in which the salt concentration is less than about 1.5 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringency conditions include hybridization with a buffer solution of 30 to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl sulphate) at 37°C, and a wash in 1X to 2X SSC (20X SSC = 3.0 M NaCl/0.3 M trisodium citrate) at 50 to 55°C. Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1.0 M NaCl, 1% SDS at 37°C, and a wash in 0.5X to 1X SSC at 55 to 60°C. Exemplary high stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 0.1X SSC at 60 to 65°C. Optionally, wash buffers may comprise about 0.1% to about 1% SDS. Duration of hybridization is generally less than about 24 hours, usually about 4 to about 12 hours.

Specificity is typically the function of post-hybridization washes, the critical factors being the ionic strength and temperature of the final wash solution. For DNA-DNA hybrids, the T_m can be approximated from the equation of <nplcit id="ncit0032" npl-type="s"><text>Meinkoth and Wahl (1984) Anal. Biochem. 138:267-284</text></nplcit>: T_m = 81.5°C + 16.6 (log M) + 0.41 (%GC) - 0.61 (% form) - 500/L; where M is the molarity of monovalent cations, %GC is the percentage of guanosine and cytosine nucleotides in the DNA, % form is the percentage of formamide in the hybridization solution, and L is the length of the hybrid in base pairs. The T_m is the temperature (under defined ionic strength and pH) at which 50% of a complementary target sequence hybridizes to a perfectly matched probe. T_m is reduced by about 1°C for each 1% of mismatching; thus, T_m, hybridization, and/or wash conditions can be adjusted to hybridize to sequences of the desired identity. For example, if sequences with ≥90% identity are sought, the T_m can be decreased 10°C. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence and its complement at a defined ionic strength and pH. However, severely stringent conditions can utilize a hybridization and/or wash at 1, 2, 3, or 4°C lower than the thermal melting point (T_m); moderately stringent conditions can utilize a hybridization and/or wash at 6, 7, 8, 9, or 10°C lower than the thermal melting point (T_m); low stringency conditions can utilize a hybridization and/or wash at 11, 12, 13, 14, 15, or 20°C lower than the thermal melting point (T_m). Using the equation, hybridization and wash compositions, and desired T_m, those of ordinary skill will understand that variations in the stringency of hybridization and/or wash solutions are inherently described. If the desired degree of mismatching results in a T_m of less than 45°C (aqueous solution) or 32°C (formamide solution), it is preferred to increase the SSC concentration so that a higher temperature can be used. An extensive guide to the hybridization of nucleic acids is found in <nplcit id="ncit0033" npl-type="b"><text>Tijssen (1993) Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes, Part I, Chapter 2 (Elsevier, New York</text></nplcit>); and <nplcit id="ncit0034" npl-type="b"><text>Ausubel et al., eds. (1995) Current Protocols in Molecular Biology, Chapter 2 (Greene Publishing and Wiley-Interscience, New York</text></nplcit>). See <nplcit id="ncit0035" npl-type="b"><text>Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York</text></nplcit>).

Thus, isolated sequences that encode a defensin polypeptide and which hybridize under stringent conditions to the defensin sequences disclosed herein, or to fragments thereof, are encompassed by the present invention.

The following terms are used to describe the sequence relationships between two or more nucleic acids or polynucleotides: (a) "reference sequence", (b) "comparison window", (c) "sequence identity", (d) "percentage of sequence identity", and (e) "substantial identity". <ul id="ul0002" list-style="none" compact="compact"><li>(a) As used herein, "reference sequence" is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset or the entirety of a specified sequence; for example, as a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence.</li><li>(b) As used herein, "comparison window" makes reference to a contiguous and specified segment of a polynucleotide sequence, wherein the polynucleotide sequence in the comparison window may comprise additions or deletions (<i>i.e</i>., gaps) compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Generally, the comparison window is at least 20 contiguous nucleotides in length, and optionally can be 30, 40, 50, 100, or longer. Those of skill in the art understand that to avoid a high similarity to a reference sequence due to inclusion of gaps in the polynucleotide sequence a gap penalty is typically introduced and is subtracted from the number of matches. Methods of alignment of sequences for comparison are well known in the art. Thus, the determination of percent identity between any two sequences can be accomplished using a mathematical algorithm. Non-limiting examples of such mathematical algorithms are the algorithm of <nplcit id="ncit0036" npl-type="s"><text>Myers and Miller (1988) CABIOS 4:11-17</text></nplcit>; the local homology algorithm of <nplcit id="ncit0037" npl-type="s"><text>Smith et al. (1981) Adv. Appl. Math. 2:482</text></nplcit>; the homology alignment algorithm of <nplcit id="ncit0038" npl-type="s"><text>Needleman and Wunsch (1970) J. Mol. Biol. 48:443-453</text></nplcit>; the search-for-similarity-method of <nplcit id="ncit0039" npl-type="s"><text>Pearson and Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448</text></nplcit>; the algorithm of <nplcit id="ncit0040" npl-type="s"><text>Karlin and Altschul (1990) Proc. Natl. Acad Sci. USA 87:2264</text></nplcit>, modified as in <nplcit id="ncit0041" npl-type="s"><text>Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877</text></nplcit>. Computer implementations of these mathematical algorithms can be utilized for comparison of sequences to determine sequence identity. Such implementations include, but are not limited to: CLUSTAL in the PC/Gene program (available from Intelligenetics, Mountain View, Califomia); the ALIGN program (Version 2.0) and GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Version 8 (available from Genetics Computer Group (GCG), 575 Science Drive, Madison, Wisconsin, USA). Alignments using these programs can be performed using the default parameters. The CLUSTAL program is well described by <nplcit id="ncit0042" npl-type="s"><text>Higgins et al. (1988) Gene 73:237-244 (1988</text></nplcit>); <nplcit id="ncit0043" npl-type="s"><text>Higgins et al. (1989) CABIOS 5:151-153</text></nplcit>; <nplcit id="ncit0044" npl-type="s"><text>Corpet et al. (1988) Nucleic Acids Res. 16:10881-90</text></nplcit>;<nplcit id="ncit0045" npl-type="s"><text> Huang et al. (1992) CABIOS 8:155-65</text></nplcit>; and <nplcit id="ncit0046" npl-type="s"><text>Pearson et al. (1994) Meth. Mol. Biol. 24:307-331</text></nplcit>. The ALIGN program is based on the algorithm of Myers and Miller (1988) <i>supra.</i> A PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used with the ALIGN program when comparing amino acid sequences. The BLAST programs of <nplcit id="ncit0047" npl-type="s"><text>Altschul et al. (1990) J. Mol. Biol. 215:403 </text></nplcit>are based on the algorithm of Karlin and Altschul (1990) <i>supra.</i> BLAST nucleotide searches can be performed with the BLASTN program, score = 100, wordlength = 12, to obtain nucleotide sequences homologous to a nucleotide sequence encoding a protein of the invention. BLAST protein searches can be performed with the BLASTX program, score = 50, wordlength = 3, to obtain amino acid sequences homologous to a protein or polypeptide of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST (in BLAST 2.0) can be utilized as described in <nplcit id="ncit0048" npl-type="s"><text>Altschul et al. (1997) Nucleic Acids Res. 25:3389</text></nplcit>. Alternatively, PSI-BLAST (in BLAST 2.0) can be used to perform an iterated search that detects distant relationships between molecules. See Altschul <i>et al.</i> (1997) <i>supra.</i> When utilizing BLAST, Gapped BLAST, PSI-BLAST, the default parameters of the respective programs (<i>e.g</i>., BLASTN for nucleotide sequences, BLASTX for proteins) can be used. See http://www.ncbi.hlm.nih.gov. Alignment may also be performed manually by inspection. Unless otherwise stated, sequence identity/similarity values provided herein refer to the value obtained using GAP Version 10 using the following parameters: % identity using GAP Weight of 50 and Length Weight of 3; % similarity using Gap Weight of 12 and Length Weight of 4, or any equivalent program. By "equivalent program" is intended any sequence comparison program that, for any two sequences in question, generates an alignment having identical nucleotide or amino acid residue matches and an identical percent sequence identity when compared to the corresponding alignment generated by the preferred program. GAP uses the algorithm of <nplcit id="ncit0049" npl-type="s"><text>Needleman and Wunsch (1970) J. Mol. Biol. 48:443-453</text></nplcit>, to find the alignment of two complete sequences that maximizes the number of matches and minimizes the number of gaps. GAP considers all possible alignments and gap positions and creates the alignment with the largest number of matched bases and the fewest gaps. It allows for the provision of a gap creation penalty and a gap extension penalty in units of matched bases. GAP must make a profit of gap creation penalty number of matches for each gap it inserts. If a gap extension penalty greater than zero is chosen, GAP must, in addition, make a profit for each gap inserted of the length of the gap times the gap extension penalty. Default gap creation penalty values and gap extension penalty values in Version 10 of the Wisconsin Genetics Software Package for protein sequences are 8 and 2, respectively. For nucleotide sequences the default gap creation penalty is 50 while the default gap extension penalty is 3. The gap creation and gap extension penalties can be expressed as an integer selected from the group of integers consisting of from 0 to 200. Thus, for example, the gap creation and gap extension penalties can be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 or greater. GAP presents one member of the family of best alignments. There may be many members of this family, but no other member has a better quality. GAP displays four figures of merit for alignments: Quality, Ratio, Identity, and Similarity. The Quality is the metric maximized in order to align the sequences. Ratio is the quality divided by the number of bases in the shorter segment. Percent Identity is the percent of the symbols that actually match. Percent Similarity is the percent of the symbols that are similar. Symbols that are across from gaps are ignored. A similarity is scored when the scoring matrix value for a pair of symbols is greater than or equal to 0.50, the similarity threshold. The scoring matrix used in Version 10 of the Wisconsin Genetics Software Package is BLOSUM62 (see <nplcit id="ncit0050" npl-type="s"><text>Henikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915</text></nplcit>).</li><li>(c) As used herein, "sequence identity" or "identity" in the context of two nucleic acid or polypeptide sequences makes reference to the residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (<i>e.g</i>., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. When sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences that differ by such conservative substitutions are said to have "sequence similarity" or "similarity". Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, <i>e.g</i>., as implemented in the program PC/GENE (Intelligenetics, Mountain View, California).</li><li>(d) As used herein, "percentage of sequence identity" means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (<i>i.e</i>., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity.</li><li>(e)(i) The term "substantial identity" of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 70% sequence identity, preferably at least 80%, more preferably at least 90%, and most preferably at least 95%, compared to a reference sequence using one of the alignment programs described using standard parameters. One of skill in the art will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning, and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 60%, more preferably at least 70%, 80%, 90%, and most preferably at least 95%. Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under stringent conditions. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. However, stringent conditions encompass temperatures in the range of about 1°C to about 20°C, depending upon the desired degree of stringency as otherwise qualified herein. Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides they encode are substantially identical. This may occur, <i>e.g</i>., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. One indication that two nucleic acid sequences are substantially identical is when the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid.</li></ul><ul id="ul0003" list-style="none" compact="compact"><li>(e)(ii) The term "substantial identity" in the context of a peptide indicates that a peptide comprises a sequence with at least 70% sequence identity to a reference sequence, preferably 80%, more preferably 85%, most preferably at least 90% or 95% sequence identity to the reference sequence over a specified comparison window. Preferably, optimal alignment is conducted using the homology alignment algorithm of <nplcit id="ncit0051" npl-type="s"><text>Needleman et al. (1970) J. Mol. Biol. 48:443</text></nplcit>. An indication that two peptide sequences are substantially identical is that one peptide is immunologically reactive with antibodies raised against the second peptide. Thus, a peptide is substantially identical to a second peptide, for example, where the two peptides differ only by a conservative substitution. Peptides that are "substantially similar" share sequences as noted above except that residue positions that are not identical may differ by conservative amino acid changes.</li></ul>

Disease and Pests

Compositions and methods for controlling pathogenic agents are provided. The anti-pathogenic compositions comprise plant defensin nucleotide and amino acid sequences. Particularly, the plant nucleic acid and amino acid sequences and fragments and variants thereof set forth herein possess anti-pathogenic activity. Accordingly, the compositions and methods are useful in protecting plants against fungal pathogens, viruses, nematodes, insects, and the like. Additionally provided are transformed plants, plant cells, plant tissues and seeds thereof.

By "plant pathogen" or "plant pest" any organism that can cause harm to a plant, by inhibiting or slowing the growth of a plant, by damaging the tissues of a plant, by weakening the immune system of a plant, reducing the resistance of a plant to abiotic stresses, and/or by causing the premature death of the plant, etc. is intended. Plant pathogens and plant pests include insects, nematodes, and organisms such as fungi, viruses, and bacteria.

By "disease resistance" or "pathogen resistance" it is intended that the organisms avoid the disease symptoms which are the outcome of organism-pathogen interactions. That is, pathogens are prevented from causing diseases and the associated disease symptoms, or alternatively, the disease symptoms caused by the pathogen is minimized or lessened.

By "anti-pathogenic compositions" is intended that the compositions of the invention are capable of suppressing, controlling, and/or killing the invading pathogenic organism. An antipathogenic composition of the invention will reduce the disease symptoms resulting from pathogen challenge by at least about 5% to about 50%, at least about 10% to about 60%, at least about 30% to about 70%, at least about 40% to about 80%, or at least about 50% to about 90% or greater. Hence, the methods of the invention can be utilized to protect plants from disease, particularly those diseases that are caused by plant pathogens.

An "antimicrobial agent," a "pesticidal agent," a "defensin," an "antiviral agent," and "insecticidal agent," and/or a "fungicidal agent" will act similarly to suppress, control, and/or kill the invading pathogen.

A defensive agent will possess defensive activity. By "defensive activity" an antipathogenic, antimicrobial, antiviral, insecticidal, or antifungal activity is intended.

By "antipathogenic compositions" it is intended that the compositions of the invention have activity against pathogens; including fungi, microorganisms, viruses, insects and nematodes, and thus are capable of suppressing, controlling, and/or killing the invading pathogenic organism. An antipathogenic composition of the invention will reduce the disease symptoms resulting from pathogen challenge by at least about 5% to about 50%, at least about 10% to about 60%, at least about 30% to about 70%, at least about 40% to about 80%, or at least about 50% to about 90% or greater. Hence, the methods of the invention can be utilized to protect organisms, particularly plants, from disease, particularly those diseases that are caused by invading pathogens.

Assays that measure antipathogenic activity are commonly known in the art, as are methods to quantitate disease resistance in plants following pathogen infection. See, for example, <patcit id="pcit0009" dnum="US5614395A"><text>U.S. Patent No. 5,614,395</text></patcit>, herein incorporated by reference. Such techniques include, measuring over time, the average lesion diameter, the pathogen biomass, and the overall percentage of decayed plant tissues. For example, a plant either expressing an antipathogenic polypeptide or having an antipathogenic composition applied to its surface shows a decrease in tissue necrosis (<i>i.e.,</i> lesion diameter) or a decrease in plant death following pathogen challenge when compared to a control plant that was not exposed to the antipathogenic composition. Alternatively, antipathogenic activity can be measured by a decrease in pathogen biomass. For example, a plant expressing an antipathogenic polypeptide or exposed to an antipathogenic composition is challenged with a pathogen of interest. Over time, tissue samples from the pathogen-inoculated tissues are obtained and RNA is extracted. The percent of a specific pathogen RNA transcript relative to the level of a plant specific transcript allows the level of pathogen biomass to be determined. See, for example, <nplcit id="ncit0052" npl-type="s"><text>Thomma et al. (1998) Plant Biology 95:15107-15111</text></nplcit>, herein incorporated by reference.

Furthermore, <i>in vitro</i> antipathogenic assays include, for example, the addition of varying concentrations of the antipathogenic composition to paper disks and placing the disks on agar containing a suspension of the pathogen of interest. Following incubation, clear inhibition zones develop around the discs that contain an effective concentration of the antipathogenic polypeptide (<nplcit id="ncit0053" npl-type="s"><text>Liu et al. (1994) Plant Biology 91:1888-1892</text></nplcit>, herein incorporated by reference). Additionally, microspectrophotometrical analysis can be used to measure the <i>in vitro</i> antipathogenic properties of a composition (<nplcit id="ncit0054" npl-type="s"><text>Hu et al. (1997) Plant Mol. Biol. 34:949-959</text></nplcit> and <nplcit id="ncit0055" npl-type="s"><text>Cammue et al. (1992) J. Biol. Chem. 267: 2228-2233</text></nplcit>, both of which are herein incorporated by reference).

In specific embodiments, methods for increasing pathogen resistance in a plant comprise stably transforming a plant with a DNA construct comprising an anti-pathogenic nucleotide sequence of the invention operably linked to promoter that drives expression in a plant. Such methods find use in agriculture particularly in limiting the impact of plant pathogens on crop plants. While the choice of promoter will depend on the desired timing and location of expression of the anti-pathogenic nucleotide sequences, preferred promoters include constitutive and pathogen-inducible promoters.

It is understood in the art that plant DNA viruses and fungal pathogens remodel the control of the host replication and gene expression machinery to accomplish their own replication and effective infection. The present invention may be useful in preventing such corruption of the cell.

The defensin sequences find use in disrupting cellular function of plant pathogens or insect pests as well as altering the defense mechanisms of a host plant to enhance resistance to disease or insect pests. While the invention is not bound by any particular mechanism of action to enhance disease resistance, the gene products of the defensin sequences function to inhibit or prevent diseases in a plant.

The methods of the invention can be used with other methods available in the art for enhancing disease resistance in plants. For example, any one of a variety of second nucleotide sequences may be utilized, embodiments of the invention encompass those second nucleotide sequences that, when expressed in a plant, help to increase the resistance of a plant to pathogens. It is recognized that such second nucleotide sequences may be used in either the sense or antisense orientation depending on the desired outcome. Other plant defense proteins include those described in <patcit id="pcit0010" dnum="WO9943823A"><text>PCT patent publications WO 99/43823</text></patcit> and <patcit id="pcit0011" dnum="WO9943821A"><text>WO 99/43821</text></patcit>, both of which are herein incorporated by reference.

Pathogens of the invention include, but are not limited to, viruses or viroids, bacteria, insects, nematodes, fungi, and the like. Viruses include any plant virus, for example, tobacco or cucumber mosaic virus, ringspot virus, necrosis virus, maize dwarf mosaic virus, etc. Specific fungal and viral pathogens for the major crops include: <u>Soybeans</u>: <i>Phytophthora megasperma</i> f.sp, <i>glycinea, Macrophomina phaseolina, Rhizoctonia solani, Sclerotinia sclerotiorum, Fusarium oxysporum, Diaporthe phaseolorum</i> var. <i>sojae (Phomopsis sojae), Diaporthe phaseolorum</i> var. <i>caulivora, Sclerotium rolfsii, Cercospora kikuchii, Cercospora sojina, Peronospora manshurica, Colletotrichum dematium (Colletotrichum truncatum), Corynespora cassiicola, Septoria glycines, Phyllosticta sojicola, Alternaria alternata, Pseudomonas syringae</i> p.v. <i>glycinea, Xanthomonas campestris</i> p.v. <i>phaseoli, Microsphaera diffusa, Fusarium semitectum, Phialophora gregata,</i> Soybean mosaic virus, <i>Glomerella glycines,</i> Tobacco Ring spot virus, Tobacco Streak virus, <i>Phakopsora pachyrhizi, Pythium aphanidermatum, Pythium ultimum, Pythium debaryanum,</i> Tomato spotted wilt virus, <i>Heterodera glycines, Fusarium solani</i>; <u>Canola</u>: <i>Albugo candida, Alternaria brassicae, Leptosphaeria maculans, Rhizoctonia solani, Sclerotinia sclerotiorum, Mycosphaerella brassiccola, Pythium ultimum, Peronospora parasitica, Fusarium roseum, Alternaria altentata;</i><u>Alfalfa</u>: <i>Clavibacter Michigan's subsp. insidiosum, Pythium ultimum, Pythium irregulare, Pythium splendens, Pythium debaryanum, Pythium aphanidermatum, Phytophthora megasperma, Peronospora trifoliorum, Phoma medicaginis</i> var. <i>medicaginis, Cercospora medicaginis, Pseudopeziza medicaginis, Leptotrochila medicaginis, Fusarium spp., Xanthomonas campestris</i> p.v. <i>alfalfae, Aphanomyces euteiches, Stemphylium herbarium, Stemphylium alfalfae</i>; <u>Wheat</u>: <i>Pseudomonas syringae</i> p.v. <i>atrofaciens, Urocystis agropyri, Xanthomonas campestris</i> p.v. <i>translucens, Pseudomonas syringae</i> p.v. <i>syringae, Alternaria alternata, Cladosporium herbarum, Fusarium graminearum, Fusariurn avenaceum, Fusarium culmorum, Ustilago tritici, Ascochyta tritici, Cephalosporium gramineum, Collotetrichum graminicola, Erysiphe grantinis</i> f.sp. <i>tritici, Puccinia graminis</i> f.sp, <i>tritici, Puccinia recondita</i> f.sp. <i>tritici, Puccinia striiformis, Pyrenophora tritici-repentis, Septoria nodorum, Septoria tritici, Septoria avenae, Pseudocercosporella herpothchoides, Rhizoctonia solani, Rhizoctonia cerealis, Gaeumannomyces graminis</i> var. <i>tritici, Pythium aphanidermatum, Pythium arrhenomanes, Pythium ultimum, Bipolaris sorokiniana,</i> Barley Yellow Dwarf Virus, Brome Mosaic Virus, Soil Borne Wheat Mosaic Virus, Wheat Streak Mosaic Virus, Wheat Spindle Streak Virus, American Wheat Striate Virus, <i>Claviceps purpurea, Tilletia tritici, Tilletia laevis, Tilletia indica, Pythium gramicola,</i> High Plains Virus, European wheat striate virus; <u>Sunflower</u>: <i>Plasmophora halstedii, Sclerotinia sclerotiorum,</i> Aster Yellows, <i>Septoria helianthi, Phomopsis helianthi, Alternaria helianthi, Alternaria zinniae, Botrytis cinerea, Phoma macdonaldii, Macrophomina phaseolina, Erysiphe cichoracearum, Rhizopus oryzae, Rhizopus arrhizus, Rhizopus stolonifer, Puccinia helianthi, Verticillium dahliae, Erwinia carotovorum</i> p.v. <i>carotovora, Cephalosporium acremonium, Phytophthora cryptogea, Albugo tragopogonis;</i><u>Corn</u>: <i>Fusarium moniliforme</i> var. <i>subglutinans, Erwinia stewartii, Fusarium moniliforme, Gibberella zeae (Fusarium graminearum), Stenocatpella maydis (Diplodia maydis), Pythium irregulare, Pythium debaryanum, Pythium graminicola, Pythium splendens, Pythium ultimum, Pythium aphanidermatum, Aspergillus flavus, Bipolaris maydis</i> O, T <i>(Cochliobolus heterostrophus), Helminthosporium carbonum</i> I, II &amp; III <i>(Cochliobolus carbonum), Exserohilum turcicum</i> I, II &amp; III, <i>Helminthosporium pedicellatum, Physoderma maydis, Phyllosticta maydis, Kabatiella maydis, Cercospora sorghi, Ustilago maydis, Puccinia sorghi, Puccinia polysora, Macrophomina phaseolina, Penicillium oxalicum, Nigrospora oryzae, Cladosporium herbarum, Curvularia lunata, Curvularia inaequalis, Curvularia pallescens, Clavibacter michiganense</i> subsp. <i>nebraskense, Trichoderma viride,</i> Maize Dwarf Mosaic Virus A &amp; B, Wheat Streak Mosaic Virus, Maize Chlorotic Dwarf Virus, <i>Claviceps sorghi, Pseudomonas avenae, Erwinia chrysanthemi</i> p.v. <i>zea, Erwinia carotovora, Corn stunt spiroplasma, Diplodia macrospora, Sclerophthora macrospora, Peronosclerospora sorghi, Peronosclerospora philippinensis, Peronosclerospora maydis, Peronosclerospora sacchari, Spliacelotheca reiliana, Physopella zeae, Cephalosporium maydis, Cephalosporium acremonium,</i> Maize Chlorotic Mottle Virus, High Plains Virus, Maize Mosaic Virus, Maize Rayado Fino Virus, Maize Streak Virus, Maize Stripe Virus, Maize Rough Dwarf Virus; <u>Sorghum</u>: <i>Exserohilum turcicum, Colletotrichum graminicola (Glomerella graminicola), Cercospora sorghi, Gloeocercospora sorghi, Ascochyta sorghina, Pseudomonas syringae</i> p.v. <i>syringae, Xanthomonas campestris</i> p.v. <i>holcicola, Pseudomonas andropogonis, Puccinia purpurea, Macrophomina phaseolina, Periconia circinata, Fusarium moniliforme, Alternaria alternata, Bipolaris sorghicola, Helminthosporium sorghicola, Curvularia lunata, Phoma insidiosa, Pseudomonas avenae (Pseudomonas alboprecipitans), Ramulispora sorghi, Ramulispora sorghicola, Phyllachara sacchari, Sporisorium reilianum (Sphacelotheca reiliana), Sphacelotheca cruenta, Sporisorium sorghi,</i> Sugarcane mosaic H, Maize Dwarf Mosaic Virus A &amp; B, <i>Claviceps sorghi, Rhizoctonia solani, Acremonium strictum, Sclerophthona macrospora, Peronosclerospora sorghi, Peronosclerospora philippinensis, Sclerospora graminicola, Fusarium graminearum, Fusarium oxysporum, Pythium arrhenomanes, Pythium graminicola,</i> etc.

Nematodes include parasitic nematodes such as root-knot, cyst, and lesion nematodes, including <i>Heterodera</i> and <i>Globodera spp.;</i> particularly <i>Globodera rostochiensis</i> and <i>Globodera pailida</i> (potato cyst nematodes); <i>Heterodera glycines</i> (soybean cyst nematode); <i>Heterodera schachtii</i> (beet cyst nematode); and <i>Heterodera avenae</i> (cereal cyst nematode). Additional nematodes include: <i>Heterodera cajani; Heterodera trifolii</i>; <i>Heterodera oryzae</i>; <i>Globodera tabacum; Meloidogyne incognita; Meloidogyne javonica</i>; <i>Meloidogyne hapla</i>; <i>Meloidogyne arenaria; Meloidogyne naasi; Meloidogyne exigua; Xiphinema index; Xiphinema italiae; Xiphinema americanum; Xiphinema diversicaudatum</i>; <i>Pratylenchus penetrans</i>; <i>Pratylenchus brachyurus; Pratylenchus zeae; Pratylenchus coffeae</i>; <i>Pratylenchus thornei</i>; <i>Pratylenchus scribneri; Pratylenchus vulnus</i>; <i>Pratylenchus curvitatus; Radopholus similis; Radopholus citrophilus; Ditylenchus dipsaci; Helicotylenchus multicintus; Rotylenchulus reniformis</i>; <i>Belonolaimus spp.; Paratrichodorus anemones; Trichodorus spp.; Primitivus spp.; Anguina tritici; Bider avenae</i>; <i>Subanguina radicicola</i>; <i>Tylenchorhynchus spp.; Haplolaimus seinhorsti</i>; <i>Tylenchulus semipenetrans</i>; <i>Hemicycliophora arenaria; Belonolaimus langicaudatus</i>; <i>Paratrichodorus xiphinema; Paratrichodorus christiei; Rhadinaphelenchus cocophilus; Paratrichodorus minor; Hoplolaimus galeatus; Hoplolaimus columbus; Criconemella spp.; Paratylenchus spp.; Nacoabbus aberrans; Aphelenchoides besseyi</i>; <i>Ditylenchus angustus; Hirchmaniella spp.; Scutellonema spp.; Hemicriconemoides kanayaensis</i>; <i>Tylenchorynchus claytoni</i>; and <i>Cacopaurus pestis.</i>

Insect pests include insects selected from the orders Coleoptera, Diptera, Hymenoptera, Lepidoptera, Mallophaga, Homoptera, Hemiptera, Orthoptera, Thysanoptera, Dermaptera, Isoptera, Anoplura, Siphonaptera, Trichoptera, etc., particularly Coleoptera and Lepidoptera. Insect pests of the invention for the major crops include: <u>Maize</u>: <i>Ostrinia nubilalis,</i> European corn borer; <i>Agrotis ipsilon,</i> black cutworm; <i>Helicoverpa zea,</i> corn earworm; <i>Spodoptera frugiperda,</i> fall armyworm; <i>Diatraea grandiosella,</i> southwestern corn borer; <i>Elasmopalpus lignosellus,</i> lesser cornstalk borer; <i>Diatraea saccharalis,</i> sugarcane borer; <i>Diabrotica virgifera,</i> western corn rootworm; <i>Diabrotica longicornis barberi,</i> northern corn rootworm; <i>Diabrotica undecimpunctata howardi,</i> southern corn rootworm; <i>Melanotus spp</i>., wireworms; <i>Cyclocephala borealis,</i> northern masked chafer (white grub); <i>Cyclocephala immaculata,</i> southern masked chafer (white grub); <i>Popillia japonica,</i> Javanese beetle; <i>Chaetocnema pulicaria,</i> corn flea beetle; <i>Sphenophorus maidis,</i> maize billbug; <i>Rhopalosiphum maidis,</i> corn leaf aphid; <i>Anuraphis maidiradicis,</i> corn root aphid; <i>Blissus leucopterus leucopterus,</i> chinch bug; <i>Melanoplus femurrubrum,</i> redlegged grasshopper; <i>Melanoplus sanguinipes,</i> migratory grasshopper; <i>Hylemya platura,</i> seedcorn maggot; <i>Agromyza parvicornis,</i> corn blotch leafminer; <i>Anaphothrips obscrurus,</i> grass thrips; <i>Solenopsis milesta,</i> thief ant; <i>Tetranychus urticae,</i> twospotted spider mite; <u>Sorghum</u>: <i>Chilo partellus,</i> sorghum borer; <i>Spodoptera frugiperda,</i> fall armyworm; <i>Helicoverpa zea,</i> corn earworm; <i>Elasmopalpus lignosellus,</i> lesser cornstalk borer; <i>Feltia subterranea,</i> granulate cutworm; <i>Phyllophaga crinita,</i> white grub; <i>Eleodes, Conoderus,</i> and <i>Aeolus spp.,</i> wireworms; <i>Oulema melanopus,</i> cereal leaf beetle; <i>Chaetocnema pulicaria,</i> corn flea beetle; <i>Sphenophorus maidis,</i> maize billbug; <i>Rhopalosiphum maidis</i>; corn leaf aphid; <i>Sipha flava,</i> yellow sugarcane aphid; <i>Blissus leucopterus leucopterus,</i> chinch bug; <i>Contarinia sorghicola,</i> sorghum midge; <i>Tetranychus cinnabarinus,</i> carmine spider mite; <i>Tetranychus urticae,</i> twospotted spider mite; <u>Wheat:</u><i>Pseudaletia unipunctata,</i> army worm; <i>Spodoptera frugiperda,</i> fall armyworm; <i>Elasmopalpus lignosellus,</i> lesser cornstalk borer; <i>Agrotis orthogonia,</i> western cutworm; <i>Elasmopalpus lignosellus,</i> lesser cornstalk borer; <i>Oulema melanopus,</i> cereal leaf beetle; <i>Hypera punctata,</i> clover leaf weevil; <i>Diabrotica undecimpunctata howardi,</i> southern corn rootworm; Russian wheat aphid; <i>Schizaphis graminum,</i> greenbug; <i>Macrosiphum avenae,</i> English grain aphid; <i>Melanoplus femurrubrum,</i> redlegged grasshopper; <i>Melanoplus differentialis,</i> differential grasshopper; <i>Melanoplus sanguinipes,</i> migratory grasshopper; <i>Mayetiola destructor,</i> Hessian fly; <i>Sitodiplosis mosellana,</i> wheat midge; <i>Meromyza americana,</i> wheat stem maggot; <i>Hylemya coarctata,</i> wheat bulb fly; <i>Frankliniella fusca,</i> tobacco thrips; <i>Cephus cinctus,</i> wheat stem sawfly; <i>Aceria tulipae,</i> wheat curl mite; <u>Sunflower</u>: <i>Suleima helianthana</i>, sunflower bud moth; <i>Homoeosoma electellum,</i> sunflower moth; <i>Zygogramma exclamationis,</i> sunflower beetle; <i>Bothyrus gibbosus,</i> carrot beetle; <i>Neolasioptera murtfeldtiana,</i> sunflower seed midge; <u>Cotton</u>: <i>Heliothis virescens,</i> cotton budworm; <i>Helicoverpa zea,</i> cotton bollworm; <i>Spodoptera exigua,</i> beet armyworm; <i>Pectinophora gossypiella,</i> pink bollworm; <i>Anthonomus grandis,</i> boll weevil; <i>Aphis gossypii,</i> cotton aphid; <i>Pseudatomoscelis seriatus,</i> cotton fleahopper; <i>Trialeurodes abutilonea,</i> bandedwinged whitefly; <i>Lygus lineolaris,</i> tarnished plant bug; <i>Melanoplus femurrubrum,</i> redlegged grasshopper; <i>Melanoplus differentialis,</i> differential grasshopper; <i>Thrips tabaci,</i> onion thrips; <i>Franklinkiella fusca,</i> tobacco thrips; <i>Tetranychus cinnabarinus,</i> carmine spider mite; <i>Tetranychus urticae,</i> twospotted spider mite; <u>Rice:</u><i>Diatraea saccharalis,</i> sugarcane borer; <i>Spodoptera frugiperda,</i> fall armyworm; <i>Helicoverpa zea,</i> corn earworm; <i>Colaspis brunnea,</i> grape colaspis; <i>Lissorhoptrus oryzophilus,</i> rice water weevil; <i>Sitophilus oryzae,</i> rice weevil; <i>Nephotettix nigropictus,</i> rice leafhopper; <i>Blissus leucopterus leucopterus,</i> chinch bug; <i>Acrosternum hilare,</i> green stink bug; <u>Soybean</u>: <i>Pseudoplusia includens,</i> soybean looper; <i>Anticarsia gemmatalis,</i> velvetbean caterpillar; <i>Plathypena scabra,</i> green cloverworm; <i>Ostrinia nubilalis,</i> European corn borer; <i>Agrotis ipsilon,</i> black cutworm; <i>Spodoptera exigua,</i> beet armyworm; <i>Heliothis virescens,</i> cotton budworm; <i>Helicoverpa zea,</i> cotton bollworm; <i>Epilachna varivestis,</i> Mexican bean beetle; <i>Myzus persicae,</i> green peach aphid; <i>Empoasca fabae,</i> potato leafhopper; <i>Acrosternum hilare,</i> green stink bug; <i>Melanoplus femurrubrum,</i> redlegged grasshopper; <i>Melanoplus differentialis,</i> differential grasshopper; <i>Hylemya platura,</i> seedcorn maggot; <i>Sericothrips variabilis,</i> soybean thrips; <i>Thrips tabaci,</i> onion thrips; <i>Tetranychus turkestani,</i> strawberry spider mite; <i>Tetranychus urticae,</i> twospotted spider mite; <u>Barley</u>: <i>Ostrinia nubilalis,</i> European corn borer; <i>Agrotis ipsilon,</i> black cutworm; <i>Schizaphis graminum,</i> greenbug; <i>Blissus leucopterus leucopterus,</i> chinch bug; <i>Acrosternum hilare,</i> green stink bug; <i>Euschistus servus,</i> brown stink bug; <i>Delia platura,</i> seedcorn maggot; <i>Mayetiola destructor,</i> Hessian fly; <i>Petrobia latens,</i> brown wheat mite; <u>Oil Seed Rape</u>: <i>Brevicoryne brassicae,</i> cabbage aphid; <i>Phyllotreta cruciferae,</i> Flea beetle; <i>Mamestra configurata,</i> Bertha armyworm; <i>Plutella xylostella,</i> Diamond-back moth; <i>Delia spp.,</i> Root maggots.

Expression of Sequences

The nucleic acid sequences of the present invention can be expressed in a host cell such as bacterial, fungal, yeast, insect, mammalian, or preferably plant cells. It is expected that those of skill in the art are knowledgeable in the numerous expression systems available for expression of a nucleic acid encoding a protein of the present invention. No attempt to describe in detail the various methods known for the expression of proteins in prokaryotes or eukaryotes will be made.

As used herein, "heterologous" in reference to a nucleic acid is a nucleic acid that originates from a foreign species, or, if from the same species, is substantially modified from its native form in composition and/or genomic locus by deliberate human intervention. For example, a promoter operably linked to a heterologous nucleotide sequence can be from a species different from that from which the nucleotide sequence was derived, or, if from the same species, the promoter is not naturally found operably linked to the nucleotide sequence. A heterologous protein may originate from a foreign species, or, if from the same species, is substantially modified from its original form by deliberate human intervention.

By "host cell" a cell, which comprises a heterologous nucleic acid sequence of the invention is meant. Host cells may be prokaryotic cells such as <i>E. coli,</i> or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells. Preferably, host cells are monocotyledonous or dicotyledonous plant cells. A particularly preferred monocotyledonous host cell is a maize host cell.

The defensin sequences of the invention are provided in expression cassettes or DNA constructs for expression in the plant of interest. The cassette will include 5' and 3' regulatory sequences operably linked to a defensin sequence of the invention. By "operably linked" a functional linkage between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence is intended. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame. The cassette may additionally contain at least one additional gene to be cotransformed into the organism. Alternatively, the additional gene(s) can be provided on multiple expression cassettes.

Such an expression cassette is provided with a plurality of restriction sites for insertion of the defensin sequence to be under the transcriptional regulation of the regulatory regions. The expression cassette may additionally contain selectable marker genes.

The expression cassette will include in the 5'-3' direction of transcription, a transcriptional and translational initiation region, a defensin DNA sequence of the invention, and a transcriptional and translational termination region functional in plants. The transcriptional initiation region, the promoter, may be native or analogous or foreign or heterologous to the plant host. Additionally, the promoter may be the natural sequence or alternatively a synthetic sequence. By "foreign" is intended that the transcriptional initiation region is not found in the native plant into which the transcriptional initiation region is introduced. As used herein, a chimeric gene comprises a coding sequence operably linked to a transcription initiation region that is heterologous to the coding sequence.

While it may be preferable to express the sequences using heterologous promoters, the native promoter sequences may be used. Such constructs would change expression levels of defensin in the host cell (<i>i.e</i>., plant or plant cell). Thus, the phenotype of the host cell (i.e., plant or plant cell) is altered.

The termination region may be native with the transcriptional initiation region, may be native with the operably linked DNA sequence of interest, or may be derived from another source. Convenient termination regions are available from the Tiplasmid of <i>A</i>. <i>tumefaciens,</i> such as the octopine synthase and nopaline synthase termination regions. See also <nplcit id="ncit0056" npl-type="s"><text>Guerineau et al. (1991) Mol. Gen. Genet. 262:141-144</text></nplcit>; <nplcit id="ncit0057" npl-type="s"><text>Proudfoot (1991) Cell 64:671-674</text></nplcit>; <nplcit id="ncit0058" npl-type="s"><text>Sanfacon et al. (1991) Genes Dev. 5:141-149</text></nplcit>; <nplcit id="ncit0059" npl-type="s"><text>Mogen et al. (1990) Plant Cell 2:1261-1272</text></nplcit>; <nplcit id="ncit0060" npl-type="s"><text>Munroe et al. (1990) Gene 91:151-158</text></nplcit>; <nplcit id="ncit0061" npl-type="s"><text>Ballas et al. (1989) Nucleic Acids Res. 17:7891-7903</text></nplcit>; and <nplcit id="ncit0062" npl-type="s"><text>Joshi et al. (1987) Nucleic Acid Res. 15:9627-9639</text></nplcit>.

Where appropriate, the gene(s) may be optimized for increased expression in the transformed plant. That is, the genes can be synthesized using plant-preferred codons for improved expression. See, for example, <nplcit id="ncit0063" npl-type="s"><text>Campbell and Gowri (1990) Plant Physiol. 92:1-11</text></nplcit> for a discussion of host-preferred codon usage. Methods are available in the art for synthesizing plant-preferred genes. See, for example, <patcit id="pcit0012" dnum="US5380831A"><text>U.S. Patent Nos. 5,380,831</text></patcit>, <patcit id="pcit0013" dnum="US5436391A"><text>5,436,391</text></patcit>, and <nplcit id="ncit0064" npl-type="s"><text>Murray et al. (1989) Nucleic Acids Res. 17:477-498</text></nplcit>, herein incorporated by reference.

Additional sequence modifications are known to enhance gene expression in a cellular host. These include elimination of sequences encoding spurious polyadenylation signals, exon-intron splice site signals, transposon-like repeats, and other such well-characterized sequences that may be deleterious to gene expression. The G-C content of the sequence may be adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell. When possible, the sequence is modified to avoid predicted hairpin secondary mRNA structures.

The expression cassettes may additionally contain 5' leader sequences in the expression cassette construct. Such leader sequences can act to enhance translation. Translation leaders are known in the art and include: picornavirus leaders, for example, EMCV leader (Encephalomyocarditis 5' noncoding region) (<nplcit id="ncit0065" npl-type="s"><text>Elroy-Stein et al. (1989) PNAS USA 86:6126-6130</text></nplcit>); potyvirus leaders, for example, TEV leader (Tobacco Etch Virus) (<nplcit id="ncit0066" npl-type="s"><text>Allison et al. (1986); MDMV leader (Maize Dwarf Mosaic Virus); Virology 154:9-20</text></nplcit>), and human immunoglobulin heavy-chain binding protein (BiP), (<nplcit id="ncit0067" npl-type="s"><text>Macejak et al. (1991) Nature 353:90-94</text></nplcit>); untranslated leader from the coat protein mRNA of alfalfa mosaic virus (AMV RNA 4) (<nplcit id="ncit0068" npl-type="s"><text>Jobling et al. (1987) Nature 325:622-625</text></nplcit>); tobacco mosaic virus leader (TMV) (<nplcit id="ncit0069" npl-type="b"><text>Gallie et al. (1989) in Molecular Biology of RNA, ed. Cech (Liss, New York), pp. 237-256</text></nplcit>); and maize chlorotic mottle virus leader (MCMV) (<nplcit id="ncit0070" npl-type="s"><text>Lommel et al. (1991) Virology 81:382-385</text></nplcit>). See also, <nplcit id="ncit0071" npl-type="s"><text>Della-Cioppa et al. (1987) Plant Physiol. 84:965-968</text></nplcit>. Other methods known to enhance translation can also be utilized, for example, introns, and the like.

In preparing the expression cassette, the various DNA fragments may be manipulated, so as to provide for the DNA sequences in the proper orientation and, as appropriate, in the proper reading frame. Toward this end, adapters or linkers may be employed to join the DNA fragments or other manipulations may be involved to provide for convenient restriction sites, removal of superfluous DNA, removal of restriction sites, or the like. For this purpose, <i>in vitro</i> mutagenesis, primer repair, restriction, annealing, resubstitutions, e.g., transitions and transversions, may be involved.

Generally, the expression cassette will comprise a selectable marker gene for the selection of transformed cells. Selectable marker genes are utilized for the selection of transformed cells or tissues. Marker genes include genes encoding antibiotic resistance, such as those encoding neomycin phosphotransferase II (NEO) and hygromycin phosphotransferase (HPT), as well as genes conferring resistance to herbicidal compounds, such as glyphosate, glufosinate ammonium, bromoxynil, imidazolinones, and 2,4-dichlorophenoxyacetate (2,4-D). See generally, <nplcit id="ncit0072" npl-type="s"><text>Yarranton (1992) Curr. Opin. Biotech. 3:506-511</text></nplcit>; <nplcit id="ncit0073" npl-type="s"><text>Christopherson et al. (1992) Proc. Natl. Acad. Sci. USA 89:6314-6318</text></nplcit>; <nplcit id="ncit0074" npl-type="s"><text>Yao et al. (1992) Cell 71:63-72</text></nplcit>; <nplcit id="ncit0075" npl-type="s"><text>Reznikoff (1992) Mol. Microbiol. 6:2419-2422</text></nplcit>; <nplcit id="ncit0076" npl-type="s"><text>Barkley et al. (1980) in The Operon, pp. 177-220</text></nplcit>; <nplcit id="ncit0077" npl-type="s"><text>Hu et al. (1987) Cell 48:555-566</text></nplcit>; <nplcit id="ncit0078" npl-type="s"><text>Brown et al. (1987) Cell 49:603-612</text></nplcit>; <nplcit id="ncit0079" npl-type="s"><text>Figge et al. (1988) Cell 52:713-722</text></nplcit>; <nplcit id="ncit0080" npl-type="s"><text>Deuschle et al. (1989) Proc. Natl. Acad. Sci. USA 86:5400-5404</text></nplcit>; <nplcit id="ncit0081" npl-type="s"><text>Fuerst et al. (1989) Proc. Natl. Acad. Sci. USA 86:2549-2553</text></nplcit>; <nplcit id="ncit0082" npl-type="s"><text>Deuschle et al. (1990) Science 248:480-483</text></nplcit>; <nplcit id="ncit0083" npl-type="s"><text>Gossen (1993) Ph.D. Thesis, University of Heidelberg</text></nplcit>;<nplcit id="ncit0084" npl-type="s"><text> Reines et al. (1993) Proc. Natl. Acad. Sci. USA 90:1917-1921</text></nplcit>; <nplcit id="ncit0085" npl-type="s"><text>Labow et al. (1990) Mol. Cell. Biol. 10:3343-3356</text></nplcit>; <nplcit id="ncit0086" npl-type="s"><text>Zambretti et al. (1992) Proc. Natl. Acad. Sci. USA 89:3952-3956</text></nplcit>; <nplcit id="ncit0087" npl-type="s"><text>Baim et al. (1991) Proc. Natl. Acad. Sci. USA 88:5072-5076</text></nplcit>; <nplcit id="ncit0088" npl-type="s"><text>Wyborski et al. (1991) Nucleic Acids Res. 19:4647-4653</text></nplcit>; <nplcit id="ncit0089" npl-type="s"><text>Hillenand-Wissman (1989) Topics Mol. Struc. Biol. 10:143-162</text></nplcit>; <nplcit id="ncit0090" npl-type="s"><text>Degenkolb et al. (1991) Antimicrob. Agents Chemother. 35:1591-1595</text></nplcit>; <nplcit id="ncit0091" npl-type="s"><text>Kleinschnidt et al. (1988) Biochemistry 27:1094-1104</text></nplcit>; <nplcit id="ncit0092" npl-type="s"><text>Bonin (1993) Ph.D. Thesis, University of Heidelberg</text></nplcit>; <nplcit id="ncit0093" npl-type="s"><text>Gossen et al. (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551</text></nplcit>; <nplcit id="ncit0094" npl-type="s"><text>Oliva et al. (1992) Antimicrob. Agents Chemother. 36:913-919</text></nplcit>; <nplcit id="ncit0095" npl-type="b"><text>Hlavka et al. (1985) Handbook of Experimental Pharmacology, Vol. 78 ( Springer-Verlag, Berl</text></nplcit>in); <nplcit id="ncit0096" npl-type="s"><text>Gill et al. (1988) Nature 334:721-724</text></nplcit>. Such disclosures are herein incorporated by reference.

The above list of selectable marker genes is not meant to be limiting. Any selectable marker gene can be used in the present invention.

A number of promoters can be used in the practice of the invention. The promoters can be selected based on the desired outcome. That is, the nucleic acids can be combined with constitutive, tissue-preferred, or other promoters for expression in the host cell of interest. Such constitutive promoters include, for example, the core promoter of the Rsyn7 promoter and other constitutive promoters disclosed in <patcit id="pcit0014" dnum="WO9943838A"><text>WO 99/43838</text></patcit> and <patcit id="pcit0015" dnum="US6072050A"><text>U.S. Patent No. 6,072,050</text></patcit>; the core CaMV 35S promoter (<nplcit id="ncit0097" npl-type="s"><text>Odell et al. (1985) Nature 313:810-812</text></nplcit>); rice actin (<nplcit id="ncit0098" npl-type="s"><text>McElroy et al. (1990) Plant Cell 2:163-171</text></nplcit>); ubiquitin (<nplcit id="ncit0099" npl-type="s"><text>Christensen et al. (1989) Plant Mol. Biol. 12:619-632</text></nplcit> and <nplcit id="ncit0100" npl-type="s"><text>Christensen et al. (1992) Plant Mol. Biol. 18:675-689</text></nplcit>); pEMU (<nplcit id="ncit0101" npl-type="s"><text>Last et al. (1991) Theor. Appl. Genet. 81:581-588</text></nplcit>); MAS (<nplcit id="ncit0102" npl-type="s"><text>Velten et al. (1984) EMBO J. 3:2723-2730</text></nplcit>); ALS promoter (<patcit id="pcit0016" dnum="US5659026A"><text>U.S. Patent No. 5,659,026</text></patcit>), and the like. Other constitutive promoters include, for example, those disclosed in <patcit id="pcit0017" dnum="US5608149A"><text>U.S. Patent Nos. 5,608,149</text></patcit>; <patcit id="pcit0018" dnum="US5608144A"><text>5,608,144</text></patcit>; <patcit id="pcit0019" dnum="US5604121A"><text>5,604,121</text></patcit>; <patcit id="pcit0020" dnum="US5569597A"><text>5,569,597</text></patcit>; <patcit id="pcit0021" dnum="US5466785A"><text>5,466,785</text></patcit>; <patcit id="pcit0022" dnum="US5399680A"><text>5,399,680</text></patcit>; <patcit id="pcit0023" dnum="US5268463A"><text>5,268,463</text></patcit>; <patcit id="pcit0024" dnum="US5608142A"><text>5,608,142</text></patcit>; and <patcit id="pcit0025" dnum="US6177611A"><text>6,177,611</text></patcit>, herein incorporated by reference.

Generally, it will be beneficial to express the gene from an inducible promoter, particularly from a pathogen-inducible promoter. Such promoters include those from pathogenesis-related proteins (PR proteins), which are induced following infection by a pathogen; <i>e.g.,</i> PR proteins, SAR proteins, beta-1,3-glucanase, chitinase, etc. See, for example, <nplcit id="ncit0103" npl-type="s"><text>Redolfi et al. (1983) Neth. J. Plant Pathol. 89:245-254</text></nplcit>; <nplcit id="ncit0104" npl-type="s"><text>Uknes et al. (1992) Plant Cell 4:645-656</text></nplcit>; and <nplcit id="ncit0105" npl-type="s"><text>Van Loon (1985) Plant Mol. Virol. 4:111-116</text></nplcit>. See also <patcit id="pcit0026" dnum="WO9943819A"><text>WO 99/43819 published September 9, 1999</text></patcit>, herein incorporated by reference.

Of interest are promoters that are expressed locally at or near the site of pathogen infection. See, for example, <nplcit id="ncit0106" npl-type="s"><text>Marineau et al. (1987) Plant Mol. Biol. 9:335-342</text></nplcit>; <nplcit id="ncit0107" npl-type="s"><text>Matton et al. (1989) Molecular Plant-Microbe Interactions 2:325-33 1</text></nplcit>; <nplcit id="ncit0108" npl-type="s"><text>Somsisch et al. (1986) Proc. Natl. Acad. Sci. USA 83:2427-2430</text></nplcit>; <nplcit id="ncit0109" npl-type="s"><text>Somsisch et al. (1988) Mol. Gen. Genet. 2:93-98</text></nplcit>; and <nplcit id="ncit0110" npl-type="s"><text>Yang (1996) Proc. Natl. Acad. Sci. USA 93:14972-14977</text></nplcit>. See also, <nplcit id="ncit0111" npl-type="s"><text>Chen et al. (1996) Plant J. 10:955-966</text></nplcit>; <nplcit id="ncit0112" npl-type="s"><text>Zhang et al. (1994) Proc. Natl. Acad. Sci. USA 91:2507-2511</text></nplcit>; <nplcit id="ncit0113" npl-type="s"><text>Warner et al. (1993) Plant J. 3:191-201</text></nplcit>; <nplcit id="ncit0114" npl-type="s"><text>Siebertz et al. (1989) Plant Cell 1:961-968</text></nplcit>; <patcit id="pcit0027" dnum="US5750386A"><text>U.S. Patent No. 5,750,386</text></patcit> (nematode-inducible); and the references cited therein. Of particular interest is the inducible promoter for the maize PRms gene, whose expression is induced by the pathogen <i>Fusarium moniliforme</i> (see, for example, <nplcit id="ncit0115" npl-type="s"><text>Cordero et al. (1992) Physiol. Mol. Plant Path. 41:189-200</text></nplcit>).

Additionally, as pathogens find entry into plants through wounds or insect damage, a wound-inducible promoter may be used in the constructions of the invention. Such wound-inducible promoters include potato proteinase inhibitor (pin II) gene (<nplcit id="ncit0116" npl-type="s"><text>Ryan (1990) Ann. Rev. Phytopath. 28:425-449</text></nplcit>; <nplcit id="ncit0117" npl-type="s"><text>Duan et al. (1996) Nature Biotechnology 14:494-498</text></nplcit>); wun1 and wun2, <patcit id="pcit0028" dnum="US5428148A"><text>U.S. Patent No. 5,428,148</text></patcit>; win1 and win2 (<nplcit id="ncit0118" npl-type="s"><text>Stanford et al. (1989) Mol. Gen. Genet. 215:200-208</text></nplcit>); systemin (<nplcit id="ncit0119" npl-type="s"><text>McGurl et al. (1992) Science 225:1570-1573</text></nplcit>); WIP1 (<nplcit id="ncit0120" npl-type="s"><text>Rohmeier et al. (1993) Plant Mol. Biol. 22:783-792</text></nplcit>; <nplcit id="ncit0121" npl-type="s"><text>Eckelkamp et al. (1993) FEBS Letters 323:73-76</text></nplcit>); MPI gene (<nplcit id="ncit0122" npl-type="s"><text>Corderok et al. (1994) Plant J. 6(2):141-150</text></nplcit>); and the like, herein incorporated by reference.

Chemical-regulated promoters can be used to modulate the expression of a gene in a plant through the application of an exogenous chemical regulator. Depending upon the objective, the promoter may be a chemical-inducible promoter, where application of the chemical induces gene expression, or a chemical-repressible promoter, where application of the chemical represses gene expression. Chemical-inducible promoters are known in the art and include, but are not limited to, the maize In2-2 promoter, which is activated by benzenesulfonamide herbicide safeners, the maize GST promoter, which is activated by hydrophobic electrophilic compounds that are used as pre-emergent herbicides, and the tobacco PR-1a promoter, which is activated by salicylic acid. Other chemical-regulated promoters of interest include steroid-responsive promoters (see, for example, the glucocorticoid-inducible promoter in <nplcit id="ncit0123" npl-type="s"><text>Schena et al. (1991) Proc. Natl. Acad. Sci. USA 88:10421-10425</text></nplcit> and <nplcit id="ncit0124" npl-type="s"><text>McNellis et al. (1998) Plant J. 14(2):247-257</text></nplcit>) and tetracycline-inducible and tetracycline-repressible promoters (see, for example,<nplcit id="ncit0125" npl-type="s"><text> Gatz et al. (1991) Mol. Gen. Genet. 227:229-237</text></nplcit>, and <patcit id="pcit0029" dnum="US5814618A"><text>U.S. Patent Nos. 5,814,618</text></patcit> and <patcit id="pcit0030" dnum="US5789156A"><text>5,789,156</text></patcit>), herein incorporated by reference.

Tissue-preferred promoters can be utilized to target enhanced defensin expression within a particular plant tissue. Tissue-preferred promoters include <nplcit id="ncit0126" npl-type="s"><text>Yamamoto et al. (1997) Plant J. 12(2):255-265</text></nplcit>; <nplcit id="ncit0127" npl-type="s"><text>Kawamata et al. (1997) Plant Cell Physiol. 38(7):792-803</text></nplcit>; <nplcit id="ncit0128" npl-type="s"><text>Hansen et al. (1997) Mol. Gen Genet. 254(3):337-343</text></nplcit>; <nplcit id="ncit0129" npl-type="s"><text>Russell et al. (1997) Transgenic Res. 6(2):157-168</text></nplcit>; <nplcit id="ncit0130" npl-type="s"><text>Rinehart et al. (1996) Plant Physiol. 112(3):1331-1341</text></nplcit>; <nplcit id="ncit0131" npl-type="s"><text>Van Camp et al. (1996) Plant Physiol. 112(2):525-535</text></nplcit>; <nplcit id="ncit0132" npl-type="s"><text>Canevascini et al. (1996) Plant Physiol. 112(2):513-524</text></nplcit>; <nplcit id="ncit0133" npl-type="s"><text>Yamamoto et al. (1994) Plant Cell Physiol. 35(5):773-778</text></nplcit>; <nplcit id="ncit0134" npl-type="s"><text>Lam (1994) Results Probl. Cell Differ. 20:181-196</text></nplcit>; <nplcit id="ncit0135" npl-type="s"><text>Orozco et al. (1993) Plant Mol Biol. 23(6):1129-1138</text></nplcit>; <nplcit id="ncit0136" npl-type="s"><text>Matsuoka et al. (1993) Proc Natl. Acad. Sci. USA 90(20):9586-9590</text></nplcit>; and <nplcit id="ncit0137" npl-type="s"><text>Guevara-Crarcia et al. (1993) Plant J. 4(3):495-505</text></nplcit>. Such promoters can be modified, if necessary, for weak expression.

Leaf-specific promoters are known in the art. See, for example, <nplcit id="ncit0138" npl-type="s"><text>Yamamoto et al. (1997) Plant J. 12(2):255-265</text></nplcit>; <nplcit id="ncit0139" npl-type="s"><text>Kwon et al. (1994) Plant Physiol. 105:357-67</text></nplcit>; <nplcit id="ncit0140" npl-type="s"><text>Yamamoto et al. (1994) Plant Cell Physiol. 35(5):773-778</text></nplcit>; <nplcit id="ncit0141" npl-type="s"><text>Gotor et al. (1993) Plant J. 3:509-18</text></nplcit>; <nplcit id="ncit0142" npl-type="s"><text>Orozco et al. (1993) Plant Mol. Biol. 23(6):1129-1138</text></nplcit>; and <nplcit id="ncit0143" npl-type="s"><text>Matsuoka et al. (1993) Proc. Natl. Acad. Sci. USA 90(20):9586-9590</text></nplcit>.

"Seed-preferred" promoters include both "seed-specific" promoters (those promoters active during seed development such as promoters of seed storage proteins) as well as "seed-germinating" promoters (those promoters active during seed germination). See <nplcit id="ncit0144" npl-type="s"><text>Thompson et al. (1989) BioEssays 10:108</text></nplcit>, herein incorporated by reference. Such seed-preferred promoters include, but are not limited to, Cim1 (cytokinin-induced message); cZ19B1 (maize 19 kDa zein); milps (myo-inositol-1-phosphate synthase); and celA (cellulose synthase) (see <patcit id="pcit0031" dnum="WO0011177A"><text>WO 00/11177</text></patcit>, herein incorporated by reference). Gama-zein is a preferred endospenn-specific promoter. Glob-1 is a preferred embryo-specific promoter. For dicots, seed-specific promoters include, but are not limited to, bean β-phaseolin, napin, β-conglycinin, soybean lectin, cruciferin, and the like. For monocots, seed-specific promoters include, but are not limited to, maize 15 kDa zein, 22 kDa zein, 27 kDa zein, g-zein, waxy, shrunken 1, shrunken 2, globulin 1, etc. See also <patcit id="pcit0032" dnum="WO0012733A"><text>WO 00/12733</text></patcit>, where seed-preferred promoters from <i>end1</i> and <i>end2</i> genes are disclosed; herein incorporated by reference.

The method of transformation/transfection is not critical to the instant invention; various methods of transformation or transfection are currently available. As newer methods are available to transform crops or other host cells they may be directly applied. Accordingly, a wide variety of methods have been developed to insert a DNA sequence into the genome of a host cell to obtain the transcription and/or translation of the sequence to effect phenotypic changes in the organism. Thus, any method, which provides for effective transformation/transfection may be employed.

Transformation protocols as well as protocols for introducing nucleotide sequences into plants may vary depending on the type of plant or plant cell, i.e., monocot or dicot, targeted for transformation. Suitable methods of introducing nucleotide sequences into plant cells and subsequent insertion into the plant genome include microinjection (<nplcit id="ncit0145" npl-type="s"><text>Crossway et al. (1986) Biotechniques 4:320-334</text></nplcit>), electroporation (<nplcit id="ncit0146" npl-type="s"><text>Riggs et al. (1986) Proc. Natl. Acad. Sci. USA 83:5602-5606</text></nplcit>, <i>Agrobacterium-</i>mediated transformation (<patcit id="pcit0033" dnum="US5563055A"><text>Townsend et al., U.S. Patent No. 5,563,055</text></patcit>; <patcit id="pcit0034" dnum="US5981840A"><text>Zhao et al., U.S. Patent No. 5,981,840</text></patcit>), direct gene transfer (<nplcit id="ncit0147" npl-type="s"><text>Paszkowski et al. (1984) EMBO J. 3:2717-2722</text></nplcit>), and ballistic particle acceleration (see, for example, <patcit id="pcit0035" dnum="US4945050A"><text>Sanford et al., U.S. Patent No. 4,945,050</text></patcit>; <patcit id="pcit0036" dnum="US5879918A"><text>Tomes et al., U.S. Patent No. 5,879,918</text></patcit>; <patcit id="pcit0037" dnum="US5886244A"><text>Tomes et al., U.S. Patent No. 5,886,244</text></patcit>; <patcit id="pcit0038" dnum="US5932782A"><text>Bidney et al., U.S. Patent No. 5,932,782</text></patcit>; <nplcit id="ncit0148" npl-type="s"><text>McCabe et al. (1988) Biotechnology 6:923-926</text></nplcit>); and Lee1 transformation (<patcit id="pcit0039" dnum="WO0028058A"><text>WO 00/28058</text></patcit>). Also see <nplcit id="ncit0149" npl-type="s"><text>Weissinger et al. (1988) Ann. Rev. Genet. 22:421-477</text></nplcit>;<nplcit id="ncit0150" npl-type="s"><text> Sanford et al. (1987) Particulate Science and Technology 5:27-37</text></nplcit> (onion); <nplcit id="ncit0151" npl-type="s"><text>Christou et al. (1988) Plant Physiol. 87:671-674</text></nplcit> (soybean); <nplcit id="ncit0152" npl-type="s"><text>McCabe et al. (1988) Bio/Technology 6:923-926</text></nplcit> (soybean); <nplcit id="ncit0153" npl-type="s"><text>Finer and McMullen (1991) In Vitro Cell Dev. Biol. 27P:175-182 </text></nplcit> (soybean); <nplcit id="ncit0154" npl-type="s"><text>Singh et al. (1998) Theor. Appl. Genet. 96:319-324</text></nplcit> (soybean); <nplcit id="ncit0155" npl-type="s"><text>Datta et al. (1990) Biotechnology 8:736-740</text></nplcit> (rice); <nplcit id="ncit0156" npl-type="s"><text>Klein et al. (1988) Proc. Natl. Acad. Sci. USA 85:4305-4309</text></nplcit> (maize); <nplcit id="ncit0157" npl-type="s"><text>Klein et al. (1988) Biotechnology 6:559-563</text></nplcit> (maize); <patcit id="pcit0040" dnum="US5240855A"><text>Tomes, U.S. Patent No. 5,240,855</text></patcit>; <patcit id="pcit0041" dnum="US5322783A"><text>Buising et al., U.S. Patent Nos. 5,322,783</text></patcit> and <patcit id="pcit0042" dnum="US5324646A"><text>5,324,646</text></patcit>; <nplcit id="ncit0158" npl-type="b"><text>Tomes et al. (1995) "Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment," in Plant Cell, Tissue, and Organ Culture: Fundamental Methods, ed. Gamborg (Springer-Verlag, Berl</text></nplcit>in) (maize); <nplcit id="ncit0159" npl-type="s"><text>Klein et al. (1988) Plant Physiol. 91:440-444</text></nplcit> (maize); <nplcit id="ncit0160" npl-type="s"><text>Fromm et al. (1990) Biotechnology 8:833-839</text></nplcit> (maize); <nplcit id="ncit0161" npl-type="s"><text>Hooykaas-Van Slogteren et al. (1984) Nature (London) 311:763-764</text></nplcit>; Bowen <i>et al.,</i><patcit id="pcit0043" dnum="US5736369A"><text>U.S. Patent No. 5,736,369</text></patcit> (cereals); <nplcit id="ncit0162" npl-type="s"><text>Bytebier et al. (1987) Proc. Natl. Acad. Sci. USA 84:5345-5349</text></nplcit> (Liliaceae); <nplcit id="ncit0163" npl-type="b"><text>De Wet et al. (1985) in The Experimental Manipulation of Ovule Tissues, ed. Chapman et al. (Longman, New York), pp. 197-209</text></nplcit> (pollen); <nplcit id="ncit0164" npl-type="s"><text>Kaeppler et al. (1990) Plant Cell Reports 9:415-418</text></nplcit> and <nplcit id="ncit0165" npl-type="s"><text>Kaeppler et al. (1992) Theor. Appl. Genet. 84:560-566</text></nplcit> (whisker-mediated transformation); <nplcit id="ncit0166" npl-type="s"><text>D'Halluin et al. (1992) Plant Cell 4:1495-1505</text></nplcit> (electroporation);<nplcit id="ncit0167" npl-type="s"><text> Li et al. (1993) Plant Cell Reports 12:250-255</text></nplcit> and <nplcit id="ncit0168" npl-type="b"><text>Christou and Ford (1995) Annals of Botany 75:407-413</text></nplcit> (rice); <nplcit id="ncit0169" npl-type="s"><text>Osjoda et al. (1996) Nature Biotechnology 14:745-750</text></nplcit> (maize via <i>Agrobacterium tumefaciens</i>); all of which are herein incorporated by reference.

The cells that have been transformed may be grown into plants in accordance with conventional ways. See, for example, <nplcit id="ncit0170" npl-type="s"><text>McCormick et al. (1986) Plant Cell Reports 5:81-84</text></nplcit>. These plants may then be grown, and either pollinated with the same transformed strain or different strains, and the resulting hybrid having constitutive expression of the desired phenotypic characteristic identified. Two or more generations may be grown to ensure that expression of the desired phenotypic characteristic is stably maintained and inherited and then seeds harvested to ensure that expression of the desired phenotypic characteristic has been achieved.

The present invention may be used for transformation of any plant species, including, but not limited to, monocots and dicots. Examples of plants of interest include, but are not limited to, corn (<i>Zea mays</i>), <i>Brassica</i> sp. (<i>e.g</i>., <i>B. napus, B. rapa, B. juncea</i>), particularly those <i>Brassica</i> species useful as sources of seed oil, alfalfa (<i>Medicago sativa</i>), rice (<i>Oryza sativa</i>), rye (<i>Secale cereale</i>), sorghum (<i>Sorghum bicolor, Sorghum vulgare</i>), millet (<i>e.g.</i>, pearl millet (<i>Pennisetum glaucum</i>), proso millet (<i>Panicum miliaceum</i>), foxtail millet (<i>Setaria italica</i>), finger millet (<i>Eleusine coracana</i>)), sunflower (<i>Helianthus annuus</i>), safflower (<i>Carthamus tinctorius</i>), wheat (<i>Triticum aestivum</i>), soybean (<i>Glycine max</i>), tobacco (<i>Nicotiana tabacum</i>), potato (<i>Solanum tuberosum</i>), peanuts (<i>Arachis hypogaea</i>), cotton (<i>Gossypium barbadense, Gossypium hirsutum</i>), sweet potato (<i>Ipomoea batatas</i>), cassava (<i>Manihot esculenta</i>), coffee (<i>Coffea spp</i>.), coconut (<i>Cocos nucifera</i>), pineapple (<i>Ananas comosus</i>), citrus trees (<i>Citrus spp</i>.), cocoa (<i>Theobroma cacao</i>), tea (<i>Camellia sinensis</i>), banana (<i>Musa spp</i>.), avocado (<i>Persea americana</i>), fig (<i>Ficus casica</i>), guava (<i>Psidium guajava</i>), mango (<i>Mangifera indica</i>), olive (<i>Olea europaea</i>), papaya (<i>Carica papaya),</i> cashew (<i>Anacardium occidentale</i>), macadamia (<i>Macadamia integrifolia</i>), almond (<i>Prunus amygdalus</i>), sugar beets (<i>Beta vulgaris</i>), sugarcane (<i>Saccharum spp</i>.), oats, barley, vegetables, ornamentals, and conifers.

Vegetables include tomatoes (<i>Lycopersicon esculentum</i>), lettuce (<i>e.g</i>., <i>Lactuca sativa</i>), green beans (<i>Phaseolus vulgaris</i>), lima beans (<i>Phaseolus limensis</i>), peas (<i>Lathyrus spp., Pisum spp</i>.), and members of the genus <i>Cucumis</i> such as cucumber (<i>C</i>. <i>sativus</i>), cantaloupe (<i>C</i>. <i>cantalupensis</i>), and musk melon (<i>C. nielo</i>). Ornamental include azalea (<i>Rhododendron spp</i>.), hydrangea (<i>Hydrangea macrophylla</i>), hibiscus (<i>Hibiscus rosasanensis</i>), roses (<i>Rosa spp</i>.), tulips (<i>Tulipa spp</i>.), daffodils <i>(Narcissus spp</i>.), petunias <i>(Petunia hybrida</i>), carnation (<i>Dianthus caryophyllus</i>), poinsettia (<i>Euphorbia pulcherrima</i>), and chrysanthemum. Conifers that maybe employed in practicing the present invention include, for example, pines such as loblolly pine (<i>Pinus taeda</i>), slash pine (<i>Pinus elliotii</i>), ponderosa pine (<i>Pinus ponderosa</i>), lodgepole pine (<i>Pinus contorta</i>), and Monterey pine (<i>Pinus radiata</i>); Douglas-fir (<i>Pseudotsuga menziesii</i>); Western hemlock (<i>Tsuga canadensis</i>); Sitka spruce (<i>Picea glauca</i>); redwood (<i>Sequoia sempervirens</i>); true firs such as silver fir <i>(Abies amabilis</i>) and balsam fir <i>(Abies balsamea</i>); and cedars such as Western red cedar (<i>Thuja plicata</i>) and Alaska yellow-cedar (<i>Chamaecyparis nootkatensis</i>). Preferably, plants of the present invention are crop plants (for example, corn, alfalfa, sunflower, <i>Brassica,</i> soybean, cotton, safflower, peanut, sorghum, wheat, millet, tobacco, etc.), more preferably corn and soybean plants, yet more preferably corn plants.

Prokaryotic cells may be used as hosts for expression. Prokaryotes most frequently are represented by various strains of <i>E</i>. <i>coli</i>; however, other microbial strains may also be used. Commonly used prokaryotic control sequences which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding sequences, include such commonly used promoters as the beta lactamase (penicillinase) and lactose (lac) promoter systems (<nplcit id="ncit0171" npl-type="s"><text>Chang et al. (1977) Nature 198:1056</text></nplcit>), the tryptophan (trp) promoter system (<nplcit id="ncit0172" npl-type="s"><text>Goeddel et al. (1980) Nucleic Acids Res. 8:4057</text></nplcit>) and the lambda derived PL promoter and N-gene ribosome binding site (Simatake and Rosenberg (1981) <i>Nature 292</i>:128). Examples of selection markers for <i>E. coli</i> include, for example, genes specifying resistance to ampicillin, tetracycline, or chloramphenicol.

The vector is selected to allow introduction into the appropriate host cell. Bacterial vectors are typically of plasmid or phage origin. Appropriate bacterial cells are infected with phage vector particles or transfected with naked phage vector DNA. If a plasmid vector is used, the bacterial cells are transfected with the plasmid vector DNA. Expression systems for expressing a protein of the present invention are available using <i>Bacillus sp.</i> and <i>Salmonella</i> (<nplcit id="ncit0173" npl-type="s"><text>Palva et al. (1983) Gene 22:229-235</text></nplcit> and <nplcit id="ncit0174" npl-type="s"><text>Mosbach et al. (1983) Nature 302:543-545</text></nplcit>).

A variety of eukaryotic expression systems such as yeast, insect cell lines, plant and mammalian cells, are known to those of skill in the art. As explained briefly below, a polynucleotide of the present invention can be expressed in these eukaryotic systems. In some embodiments, transformed/transfected plant cells, as discussed <i>infra,</i> are employed as expression systems for production of the proteins of the instant invention. Such antimicrobial proteins can be used for any application including coating surfaces to target microbes as described further <i>infra.</i>

Synthesis of heterologous nucleotide sequences in yeast is well known. <nplcit id="ncit0175" npl-type="b"><text>Sherman, F., et al. (1982) Methods in Yeast Genetics, Cold Spring Harbor Laboratory</text></nplcit> is a well recognized work describing the various methods available to produce proteins in yeast. Two widely utilized yeasts for production of eukaryotic proteins are <i>Saccharomyces cerevisiae</i> and <i>Pichia pastoris.</i> Vectors, strains, and protocols for expression in <i>Saccharomyces</i> and <i>Pichia</i> are known in the art and available from commercial suppliers (<i>e.g</i>., Invitrogen). Suitable vectors usually have expression control sequences, such as promoters, including 3-phosphoglycerate kinase or alcohol oxidase, and an origin of replication, termination sequences and the like, as desired.

A protein of the present invention, once expressed, can be isolated from yeast by lysing the cells and applying standard protein isolation techniques to the lysates. The monitoring of the purification process can be accomplished by using Western blot techniques, radioimmunoassay, or other standard immunoassay techniques.

The sequences of the present invention can also be ligated to various expression vectors for use in transfecting cell cultures of, for instance, mammalian, insect, or plant origin. Illustrative cell cultures useful for the production of the peptides are mammalian cells. A number of suitable host cell lines capable of expressing intact proteins have been developed in the art, and include the HEK293, BHK21, and CHO cell lines. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter (<i>e.g.</i> the CMV promoter, a HSV <i>tk</i> promoter or <i>pgk</i> (phosphoglycerate kinase) promoter), an enhancer (<nplcit id="ncit0176" npl-type="s"><text>Queen et al. (1986) Immunol. Rev. 89:49</text></nplcit>), and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites (<i>e.g.</i>, an SV40 large T Ag poly A addition site), and transcriptional terminator sequences. Other animal cells useful for production of proteins of the present invention are available, for instance, from the American Type Culture Collection.

Appropriate vectors for expressing proteins of the present invention in insect cells are usually derived from the SF9 baculovirus. Suitable insect cell lines include mosquito larvae, silkworm, armyworm, moth and <i>Drosophila</i> cell lines such as a Schneider cell line (See, <nplcit id="ncit0177" npl-type="s"><text>Schneider (1987) J. Embryol. Exp. Morphol. 27:353-365</text></nplcit>).

As with yeast, when higher animal or plant host cells are employed, polyadenylation or transcription terminator sequences are typically incorporated into the vector. An example of a terminator sequence is the polyadenylation sequence from the bovine growth hormone gene. Sequences for accurate splicing of the transcript may also be included. An example of a splicing sequence is the VP1 intron from SV40 (<nplcit id="ncit0178" npl-type="s"><text>Sprague, et al. (1983) J. Viral. 45:773-781</text></nplcit>). Additionally, gene sequences to control replication in the host cell may be incorporated into the vector such as those found in bovine papilloma virus type-vectors. <nplcit id="ncit0179" npl-type="b"><text>Saveria-Campo, M., (1985) Bovine Papilloma Virus DNA a Eukaryotic Cloning Vector in DNA Cloning Vol. II a Practical Approach, D.M. Glover, Ed., IRL Press, Arlington, Virginia pp. 213-238</text></nplcit>.

Animal and lower eukaryotic (<i>e.g.,</i> yeast) host cells are competent or rendered competent for transfection by various means. There are several well-known methods of introducing DNA into animal cells. These include: calcium phosphate precipitation, fusion of the recipient cells with bacterial protoplasts containing the DNA, treatment of the recipient cells with liposomes containing the DNA, DEAE dextrin, electroporation, biolistics, and micro-injection of the DNA directly into the cells. The transfected cells are cultured by means well known in the art. <nplcit id="ncit0180" npl-type="b"><text>Kuchler, R.J. (1997) Biochemical Methods in Cell Culture and Virology, Dowden, Hutchinson and Ross, Inc</text></nplcit>.

It is recognized that with these nucleotide sequences, antisense constructions, complementary to at least a portion of the messenger RNA (mRNA) for the defensin sequences can be constructed. Antisense nucleotides are constructed to hybridize with the corresponding mRNA. Modifications of the antisense sequences may be made as long as the sequences hybridize to and interfere with expression of the corresponding mRNA. In this manner, antisense constructions having 70%, preferably 80%, more preferably 85% sequence identity to the corresponding antisensed sequences may be used. Furthermore, portions of the antisense nucleotides may be used to disrupt the expression of the target gene. Generally, sequences of at least 50 nucleotides, 100 nucleotides, 200 nucleotides, or greater may be used.

The nucleotide sequences of the present invention may also be used in the sense orientation to suppress the expression of endogenous genes in plants. Methods for suppressing gene expression in plants using nucleotide sequences in the sense orientation are known in the art. The methods generally involve transforming plants with a DNA construct comprising a promoter that drives expression in a plant operably linked to at least a portion of a nucleotide sequence that corresponds to the transcript of the endogenous gene. Typically, such a nucleotide sequence has substantial sequence identity to the sequence of the transcript of the endogenous gene, preferably greater than about 65% sequence identity, more preferably greater than about 85% sequence identity, most preferably greater than about 95% sequence identity. See <patcit id="pcit0044" dnum="US5283184A"><text>U.S. Patent Nos. 5,283,184</text></patcit> and <patcit id="pcit0045" dnum="US5034323A"><text>5,034,323</text></patcit>; herein incorporated by reference.

In some embodiments, the content and/or composition of polypeptides of the present invention in a plant may be modulated by altering, <i>in vivo</i> or <i>in vitro,</i> the promoter of the nucleotide sequence to up- or down-regulate expression. For instance, an isolated nucleic acid comprising a promoter sequence operably linked to a polynucleotide of the present invention is transfected into a plant cell. Subsequently, a plant cell comprising the promoter operably linked to a polynucleotide of the present invention is selected for by means known to those of skill in the art such as, but not limited to, Southern blot, DNA sequencing, or PCR analysis using primers specific to the promoter and to the gene and detecting amplicons produced therefrom. A plant or plant part altered or modified by the foregoing embodiments is grown under plant forming conditions for a time sufficient to modulate the concentration and/or composition of polypeptides of the present invention in the plant. Plant forming conditions are well known in the art and discussed briefly, <i>supra.</i> Detection of expression of a polypeptide of the invention occurs through any method known to one of skill in the art including, but not limited to, immunolocalization.

In general, concentration or composition of the polypeptides of the invention is increased or decreased by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% relative to a native control plant, plant part, or cell lacking the aforementioned recombinant expression cassette. Modulation in the present invention may occur during and/or subsequent to growth of the plant to the desired stage of development. Modulating nucleic acid expression temporally and/or in particular tissues can be controlled by employing the appropriate promoter operably linked to a polynucleotide of the present invention in, for example, sense or antisense orientation as discussed in greater detail, <i>supra.</i> Induction of expression of a polynucleotide of the present invention can also be controlled by exogenous administration of an effective amount of inducing compound. Inducible promoters and inducing compounds, which activate expression from these promoters, are well known in the art. In various embodiments, the polypeptides of the present invention are modulated in crop plants, particularly maize, wheat, soybean, alfalfa, barley, oats, and rice.

The methods of the invention can be used with other methods available in the art for enhancing disease resistance in plants. Similarly, the antimicrobial compositions described herein may be used alone or in combination with other nucleotide sequences, polypeptides, or agents to protect against plant diseases and pathogens. Although any one of a variety of second nucleotide sequences may be utilized, specific embodiments of the invention encompass those second nucleotide sequences that, when expressed in a plant, help to increase the resistance of a plant to pathogens.

Proteins, peptides, and lysozymes that naturally occur in insects (<nplcit id="ncit0181" npl-type="s"><text>Jaynes et al. (1987) Bioassays 6:263-270</text></nplcit>), plants (<nplcit id="ncit0182" npl-type="s"><text>Broekaert et al. (1997) Critical Reviews in Plant Science 16:297-323</text></nplcit>), animals (<nplcit id="ncit0183" npl-type="s"><text>Vunnam et al. (1997) J. Peptide Res. 49:59-66</text></nplcit>), and humans (<nplcit id="ncit0184" npl-type="s"><text>Mitra and Zang (1994) Plant Physiol. 106:977-981</text></nplcit>; <nplcit id="ncit0185" npl-type="s"><text>Nakajima et al. (1997) Plant Cell Reports 16:674-679</text></nplcit>) are also a potential source of plant disease resistance (Ko, K. (2000) http://www.scisoc.org/featureBioTechnology/antimicrobial.html). Examples of such plant resistance-conferring sequences include those encoding sunflower rhoGTPase-Activating Protein (rhoGAP), lipoxygenase (LOX), Alcohol Dehydrogenase (ADH), and Sclerotinia-Inducible Protein-1 (SCIP-1) described in <patcit id="pcit0046" dnum="US714767A"><text>U.S. application 09/714,767</text></patcit>, herein incorporated by reference. These nucleotide sequences enhance plant disease resistance through the modulation of development, developmental pathways, and the plant pathogen defense system. Other plant defense proteins include those described in <patcit id="pcit0047" dnum="WO9943823A"><text>WO 99/43823</text></patcit> and <patcit id="pcit0048" dnum="WO9943821A"><text>WO 99/43821</text></patcit>, all of which are herein incorporated by reference. It is recognized that such second nucleotide sequences may be used in either the sense or antisense orientation depending on the desired outcome.

In another embodiment, the defensins comprise isolated polypeptides of the invention. The defensins of the invention find use in the decontamination of plant pathogens during the processing of grain for animal or human food consumption; during the processing of feedstuffs, and during the processing of plant material for silage. In this embodiment, the defensins of the invention are presented to grain, plant material for silage, or a contaminated food crop, or during an appropriate stage of the processing procedure, in amounts effective for antimicrobial activity. The compositions can be applied to the environment of a plant pathogen by, for example, spraying, atomizing, dusting, scattering, coating or pouring, introducing into or on the soil, introducing into irrigation water, by seed treatment, or dusting at a time when the plant pathogen has begun to appear or before the appearance of pests as a protective measure. It is recognized that any means that bring the defensive agent polypeptides in contact with the plant pathogen can be used in the practice of the invention.

Additionally, the compositions can be used in formulations used for their antimicrobial activities. Methods are provided for controlling plant pathogens comprising applying a decontaminating amount of a polypeptide or composition of the invention to the environment of the plant pathogen. The polypeptides of the invention can be formulated with an acceptable carrier into a composition(s) that is, for example, a suspension, a solution, an emulsion, a dusting powder, a dispersible granule, a wettable powder, an emulsifiable concentrate, an aerosol, an impregnated granule, an adjuvant, a coatable paste, and also encapsulations in, for example, polymer substances.

Such compositions disclosed above may be obtained by the addition of a surface-active agent, an inert carrier, a preservative, a humectant, a feeding stimulant, an attractant, an encapsulating agent, a binder, an emulsifier, a dye, a UV protectant, a buffer, a flow agent or fertilizers, micronutrient donors or other preparations that influence plant growth. One or more agrochemicals including, but not limited to, herbicides, insecticides, fungicides, bacteriocides, nematocides, molluscicides, acaracides, plant growth regulators, harvest aids, and fertilizers, can be combined with carriers, surfactants, or adjuvants customarily employed in the art of formulation or other components to facilitate product handling and application for particular target mycotoxins. Suitable carriers and adjuvants can be solid or liquid and correspond to the substances ordinarily employed in formulation technology, <i>e.g</i>., natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, binders, or fertilizers. The active ingredients of the present invention are normally applied in the form of compositions and can be applied to the crop area or plant to be treated, simultaneously or in succession, with other compounds. In some embodiments, methods of applying an active ingredient of the present invention or an agrochemical composition of the present invention (which contains at least one of the proteins of the present invention) are foliar application, seed coating, and soil application.

Suitable surface-active agents include, but are not limited to, anionic compounds such as a carboxylate of, for example, a metal; a carboxylate of a long chain fatty acid; an N-acylsarcosinate; mono or di-esters of phosphoric acid with fatty alcohol ethoxylates or salts of such esters; fatty alcohol sulfates such as sodium dodecyl sulfate, sodium octadecyl sulfate, or sodium cetyl sulfate; ethoxylated fatty alcohol sulfates; ethoxylated alkylphenol sulfates; lignin sulfonates; petroleum sulfonates; alkyl aryl sulfonates such as alkyl-benzene sulfonates or lower alkylnaphtalene sulfonates, <i>e.g</i>., butyl-naphthalene sulfonate; salts of sulfonated naphthalene-formaldehyde condensates; salts of sulfonated phenol-formaldehyde condensates; more complex sulfonates such as the amide sulfonates, <i>e.g</i>., the sulfonated condensation product of oleic acid and N-methyl taurine; or the dialkyl sulfosuccinates, <i>e.g.</i>, the sodium sulfonate or dioctyl succinate. Non-ionic agents include condensation products of fatty acid esters, fatty alcohols, fatty acid amides or fatty-alkyl- or alkenyl-substituted phenols with ethylene oxide, fatty esters of polyhydric alcohol ethers, <i>e.g.</i>, sorbitan fatty acid esters, condensation products of such esters with ethylene oxide, <i>e.g.</i> polyoxyethylene sorbitar fatty acid esters, block copolymers of ethylene oxide and propylene oxide, acetylenic glycols such as 2, 4, 7, 9-tetraethyl-5-decyn-4, 7-diol, or ethoxylated acetylenic glycols. Examples of a cationic surface-active agent include, for instance, an aliphatic mono-, di-, or polyamine such as an acetate, naphthenate, or oleate; or oxygen-containing amine such as an amine oxide of polyoxyethylene alkylamine; an atnide-linked amine prepared by the condensation of a carboxylic acid with a di- or polyamine; or a quaternary ammonium salt.

Examples of inert materials include, but are not limited to, inorganic minerals such as kaolin, phyllosilicates, carbonates, sulfates, phosphates, or botanical materials such as cork, powdered corncobs, peanut hulls, rice hulls, and walnut shells.

The compositions of the present invention can be in a suitable form for direct application or as concentrate of primary composition, which requires dilution with a suitable quantity of water or other diluent before application. The decontaminating concentration will vary depending upon the nature of the particular formulation, specifically, whether it is a concentrate or to be used directly.

In a further embodiment, the compositions, as well as the polypeptides of the present invention can be treated prior to formulation to prolong the activity when applied to the environment of a plant pathogen as long as the pretreatment is not deleterious to the activity. Such treatment can be by chemical and/or physical means as long as the treatment does not deleteriously affect the properties of the composition(s). Examples of chemical reagents include, but are not limited to, halogenating agents; aldehydes such as formaldehyde and glutaraldehyde; antiinfectives, such as zephiran chloride; alcohols, such as isopropanol and ethanol; and histological fixatives, such as Bouin's fixative and Helly's fixative (see, for example, <nplcit id="ncit0186" npl-type="b"><text>Humason (1967) Animal Tissue Techniques (W.H. Freeman and Co.</text></nplcit>)).

In an embodiment of the invention, the compositions of the invention comprise a microbe having stably integrated the nucleotide sequence of a defensive agent. The resulting microbes can be processed and used as a microbial spray. Any suitable microorganism can be used for this purpose. See, for example, <nplcit id="ncit0187" npl-type="b"><text>Gaertner et al. (1993) in Advanced Engineered Pesticides, Kim (Ed</text></nplcit>.). In one embodiment, the nucleotide sequences of the invention are introduced into microorganisms that multiply on plants (epiphytes) to deliver the defensins to potential target crops. Epiphytes can be, for example, gram-positive or gram-negative bacteria.

It is further recognized that whole, i.e., unlysed, cells of the transformed microorganism can be treated with reagents that prolong the activity of the polypeptide produced in the microorganism when the microorganism is applied to the environment of a target plant. A secretion signal sequence may be used in combination with the gene of interest such that the resulting enzyme is secreted outside the microorganism for presentation to the target plant.

In this manner, a gene encoding a defensive agent of the invention may be introduced via a suitable vector into a microbial host, and said transformed host applied to the environment, plants, or animals. Microorganism hosts that are known to occupy the "phytosphere" (phylloplane, phyllosphere, rhizosphere, and/or rhizoplane) of one or more crops of interest may be selected for transformation. These microorganisms are selected so as to be capable of successfully competing in the particular environment with the wild-type microorganisms, to provide for stable maintenance and expression of the gene expressing the detoxifying polypeptide, and for improved protection of the proteins of the invention from environmental degradation and inactivation.

Such microorganisms include bacteria, algae, and fungi. Illustrative prokaryotes, both Gram-negative and -positive, include <i>Enterobacteriaceae,</i> such as <i>Escherichia, Erwinia, Shigella, Salmonella,</i> and <i>Proteus</i>; <i>Bacillaceae; Rhizobiaceae,</i> such as <i>Rhizobium; Spirillaceae,</i> such as photobacterium, <i>Zymomonas, Serratia, Aeromonas, Vibrio, Desulfovibrio, Spirillum; Lactobacillaceae</i>; <i>Pseudomonadaceae,</i> such as <i>Pseudomonas</i> and <i>Acetobacter; Azotobacteraceae</i>; and <i>Nitrobacteraceae.</i> Among eukaryotes are fungi, such as <i>Phycomycetes</i> and <i>Ascomycetes,</i> which includes yeast, such as <i>Saccharomyces</i> and <i>Schizosaccharomyces</i>; and <i>Basidiomycetes</i> yeast, such as <i>Rhodotorula, Aureobasidium, Sporobolomyces,</i> and the like. Of particlular interest are microorganisms, such as bacteria, e.g., <i>Pseudomonas, Erwinia, Serratia, Klebsiella, Xanthomonas, Streptomyces, Rhizobium, Rhodopseudomonas, Methylius, Agrobacterium, Acetobacter, Lactobacillus, Arthrobacter, Azotobacter, Leuconostoc,</i> and <i>Alcaligenes</i>; fungi, particularly yeast, e.g., <i>Saccharomyces, Pichia, Cryptococcus, Kluyveromyces, Sporobolomyces, Rhodotorula, Aureobasidium,</i> and <i>Gliocladium.</i> Of particular interest are such phytosphere bacterial species as <i>Pseudomonas syringae, Pseudomonas fluorescens, Serratia marcescens, Acetobacter xylinum, Agrobacteria, Rhodopseudomonas spheroides, Xanthomonas campestris, Rhizobium melioti, Alcaligenes entrophus, Clavibacter xyli,</i> and <i>Azotobacter vinlandii;</i> and phytosphere yeast species such as <i>Rhodotorula rubra, R. glutinis, R. marina, R. aurantiaca, Cryptococcus albidus, C. diffluens, C. laurentii, Saccharomyces rosei, S. pretoriensis, S. cerevisiae, Sporobolomyces roseus, S. odorous, Kluyveronzyces veronae,</i> and <i>Aureobasidium pullulans.</i>

In an embodiment of the invention, the defensins of the invention may be used as a pharmaceutical compound for treatment of fungal and microbial pathogens in humans and other animals. Diseases and disorders caused by fungal and microbial pathogens include but are not limited to fungal meningoencephalitis, superficial fungal infections, ringworm, Athlete's foot, histoplasmosis, candidiasis, thrush, coccidioidoma, pulmonary cryptococcus, trichosporonosis, piedra, tinea nigra, fungal keratitis, onychomycosis, tinea capitis, chromomycosis, aspergillosis, endobronchial pulmonary aspergillosis, mucormycosis, chromoblastomycosis, dermatophytosis, tinea, fusariosis, pityriasis, mycetoma, pseudallescheriasis, and sporotrichosis.

In particular, the compositions of the invention may be used as pharmaceutical compounds to provide treatment for diseases and disorders associated with, but not limited to, the following fungal pathogens: <i>Histoplasma capsulatum, Candida spp. (C. albicans, C. tropicalis, C. parapsilosis, C. guilliermondii, C. glabrata</i>/<i>Torulopsis glabrata, C. krusei, C. lusitaniae), Aspergillus fumigatus, A. flavus, A. niger, Rhizopus spp., Rhizomucor spp., Cunninghamella spp., Apophysomyces spp., Saksenaee spp., Mucor spp.,</i> and <i>Absidia spp.</i> Efficacy of the compositions of the invention as anti-fungal treatments may be determined through anti-fungal assays known to one in the art.

The defensins may be administered to a patient through numerous means. Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art. The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in <patcit id="pcit0049" dnum="US4522811A"><text>U.S. Patent No. 4,522,811</text></patcit>.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated with each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Depending on the type and severity of the disease, about 1 µg/kg to about 15 mg/kg (e.g., 0.1 to 20 mg/kg) of active compound is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily dosage might range from about 1 µg/kg to about 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of disease symptoms occurs. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays. An exemplary dosing regimen is disclosed in <patcit id="pcit0050" dnum="WO9404188A"><text>WO 94/04188</text></patcit>. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

"Treatment" is herein defined as the application or administration of a therapeutic agent to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell line from a patient, who has a disease, a symptom of disease or a predisposition toward a disease, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disease, the symptoms of disease or the predisposition toward disease. A "therapeutic agent"comprises, but is not limited to, the small molecules, peptides, antibodies, and antisense oligonucleotides of the invention.

The defensins of the invention can be used for any application including coating surfaces to target microbes. In this manner, target microbes include human pathogens or microorganisms. Surfaces that might be coated with the defensins of the invention include carpets and sterile medical facilities. Polymer bound polypeptides of the invention may be used to coat surfaces. Methods for incorporating compositions with antimicrobial properties into polymers are known in the art. See <patcit id="pcit0051" dnum="US5847047A"><text>U.S. Patent No. 5,847,047</text></patcit> herein incorporated by reference.

An isolated polypeptide of the invention can be used as an immunogen to generate antibodies that bind defensins using standard techniques for polyclonal and monoclonal antibody preparation. The full-length defensins can be used or, alternatively, the invention provides antigenic peptide fragments of defensins for use as immunogens. The antigenic peptide of a defensive agent comprises at least 8, preferably 10, 15, 20, or 30 amino acid residues of the amino acid sequence shown in SEQ ID NO: 2, 3, 5, 6, 8, 9, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 32, 33, 35, 36, 38, 39, 41, 42, 44, 45, 47, 48, 50, 51, 53, 54, 56, 57, 59, 60, 62, 63, 65, 66, 68, 69, 71, 72, 74, 75, 77, 78, 80, 81, 83, 84, 86, 87, 89, 90, 92, 93, 95, 96, 98, 99, 101, 102, 104, 105, 107, 108, 110, 111, 113,114, 116,117, 119, 120, 122, 123, 125, 126, 128, 129, 131, 132, 134, 135, 137, 138, 140, 141, 143, 144, 146, 147, 149, 150, 152, 153,155, 156,158, 159, 161,162, 164,165, 167, 168,170, 171, 173,174, 176, 177, 179, 180, 182, 183, 185, 186,188, 189, 191, 192, 194, 195, 197, 198, 200, 201, 203, 204, 206, 207, 209, 210, 212, 213, 215, 216, 218, 219, 221, 222, 224, 225, 227, 228, 230, 231, 233, 234, 236, 237, 239, 240, 242, 243, 245, 246, 248, 249, 251, 252, 254, 255, 257, 258, 260, 261, 263, 264, 266, 267, 269, 270, 272, 273, 275, 276, 278, 279, 281, 282, 284, 285, 287, 288, 290, 291, 293, 294, 296, 297, 299, 300, 302, 303, 305, 306, 308, 309, 311, 312, 314, 315, 317, 318, 320, 321, 323, 324, 326, 327, 329, 330, 332, 333, 335, 336, 338, 339, 341, 342, 344, 345, 347, 348, 350, 351, 353, 354, 356, 357, 359, 360, 362, 363, 365, 366, 368, 369, 371, 372, 374, 375, 377, 378, 380, 381, 383, 384, 386, 387, 389, 390, 392, 393, 395, 396, 398, 399, 441, 402, 404, 405, 407, 408, 410, 411, 413, 414, 416, 417, 419, 420, 422, 423, 425, 426, 428, 429, 431, 432, 434, 435, 437, 438, 440, 441, 443, 444, 446, 447, 449, 450, 452, 453, 455, 456, 458,459,461,462,464,466, or 468 and encompasses an epitope of a defensin such that an antibody raised against the peptide forms a specific immune complex with the antimicrobial polypeptides. Epitopes encompassed by the antigenic peptide are regions of defensins that are located on the surface of the protein, e.g., hydrophilic regions, which are readily ascertainable by those of skill in the art.

Accordingly, another aspect of the invention pertains to anti-defensin polyclonal and monoclonal antibodies that bind a defensin. Polyclonal defensin-like antibodies can be prepared by immunizing a suitable subject (e.g., rabbit, goat, mouse, or other mammal) with an defensive agent immunogen. The anti-defensin antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized antimicrobial polypeptides. At an appropriate time after immunization, e.g., when the anti-defensive agent antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by <nplcit id="ncit0188" npl-type="s"><text>Kohler and Milstein (1975) Nature 256:495-497</text></nplcit>, the human B cell hybridoma technique (<nplcit id="ncit0189" npl-type="s"><text>Kozbor et al. (1983) Immunol. Today 4:72</text></nplcit>), the EBV-hybridoma technique (<nplcit id="ncit0190" npl-type="b"><text>Cole et al. (1985) in Monoclonal Antibodies and Cancer Therapy, ed. Reisfeld and Sell (Alan R. Liss, Inc., New York, NY), pp. 77-96</text></nplcit>) or trioma techniques. The technology for producing hybridomas is well known (see generally <nplcit id="ncit0191" npl-type="b"><text>Coligan et al., eds. (1994) Current Protocols in Immunology (John Wiley &amp; Sons, Inc., New York, NY</text></nplcit>); <nplcit id="ncit0192" npl-type="s"><text>Galfre et al. (1977) Nature 266:55052</text></nplcit>; <nplcit id="ncit0193" npl-type="b"><text>Kenneth (1980) in Monoclonal Antibodies: A New Dimension In Biological Analyses (Plenum Publishing Corp., NY</text></nplcit>; and<nplcit id="ncit0194" npl-type="s"><text> Lerner (1981) Yale J. Biol. Med., 54:387-402</text></nplcit>).

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-defensin-like antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with a defensin to thereby isolate immunoglobulin library members that bind the defensive agent. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia <i>Recombinant Phage Antibody System,</i> Catalog No. 27-9400-01; and the Stratagene <i>SurfZAP</i>™ <i>Phage Display Kit,</i> Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening an antibody display library can be found in, for example, <patcit id="pcit0052" dnum="US5223409A"><text>U.S. Patent No. 5,223,409</text></patcit>; <patcit id="pcit0053" dnum="WO9218619A"><text>PCT Publication Nos. WO 92/18619</text></patcit>; <patcit id="pcit0054" dnum="WO9117271A"><text>WO 91/17271</text></patcit>; <patcit id="pcit0055" dnum="WO9220791A"><text>WO 92/20791</text></patcit>; <patcit id="pcit0056" dnum="WO9215679A"><text>WO 92/15679</text></patcit>; <patcit id="pcit0057" dnum="WO9301288A"><text>93/01288</text></patcit>; <patcit id="pcit0058" dnum="WO9201047A"><text>WO 92/01047</text></patcit>; <patcit id="pcit0059" dnum="WO9209690A"><text>92/09690</text></patcit>; and <patcit id="pcit0060" dnum="WO9002809A"><text>90/02809</text></patcit>; <nplcit id="ncit0195" npl-type="s"><text>Fuchs et al. (1991) Bio/Technology 9:1370-1372</text></nplcit>; <nplcit id="ncit0196" npl-type="s"><text>Hay et al. (1992) Hum. Antibod. Hybridomas 3:81-85</text></nplcit>; <nplcit id="ncit0197" npl-type="s"><text>Huse et al. (1989) Science 246:1275-1281</text></nplcit>; <nplcit id="ncit0198" npl-type="s"><text>Griffiths et al. (1993) EMBO J. 12:725-734</text></nplcit>. The antibodies can be used to identify homologs of the defensins of the invention.

The following examples are offered by way of illustration and not by way of limitation.

EXPERIMENTAL

Example 1. Transformation and Regeneration of Transgenic Plants in Maize

Immature maize embryos from greenhouse donor plants are bombarded with a plasmid containing a defensin nucleotide sequence of the invention operably linked to a ubiquitin promoter and the selectable marker gene PAT (<nplcit id="ncit0199" npl-type="s"><text>Wohlleben et al. (1988) Gene 70:25-37</text></nplcit>), which confers resistance to the herbicide Bialaphos. Alternatively, the selectable marker gene is provided on a separate plasmid. Transformation is performed as follows. Media recipes follow below.

Preparation of Target Tissue

The ears are husked and surface sterilized in 30% Clorox bleach plus 0.5% Micro detergent for 20 minutes, and rinsed two times with sterile water. The immature embryos are excised and placed embryo axis side down (scutellum side up), 25 embryos per plate, on 560Y medium for 4 hours and then aligned within the 2.5-cm target zone in preparation for bombardment.

Preparation of DNA

A plasmid vector comprising a defensin nucleotide sequence of the invention operably linked to a ubiquitin promoter is made. This plasmid DNA plus plasmid DNA containing a PAT selectable marker is precipitated onto 1.1 µm (average diameter) tungsten pellets using a CaCl₂ precipitation procedure as follows: <ul id="ul0004" list-style="none" compact="compact"><li>100 µl prepared tungsten particles in water</li><li>10 µl (1 µg) DNA in Tris EDTA buffer (1 µg total DNA)</li><li>100 µl 2.5 M CaCl₂</li><li>10 µl 0.1 M spermidine</li></ul>

Each reagent is added sequentially to the tungsten particle suspension, while maintained on the multitube vortexer. The final mixture is sonicated briefly and allowed to incubate under constant vortexing for 10 minutes. After the precipitation period, the tubes are centrifuged briefly, liquid removed, washed with 500 ml 100% ethanol, and centrifuged for 30 seconds. Again the liquid is removed, and 105 µl 100% ethanol is added to the final tungsten particle pellet. For particle gun bombardment, the tungsten/DNA particles are briefly sonicated and 10 µl spotted onto the center of each macrocarrier and allowed to dry about 2 minutes before bombardment.

Particle Gun Treatment

The sample plates are bombarded at level #4 in particle gun #HE34-1 or #HE34-2. All samples receive a single shot at 650 PSI, with a total of ten aliquots taken from each tube of prepared particles/DNA.

Subsequent Treatment

Following bombardment, the embryos are kept on 560Y medium for 2 days, then transferred to 560R selection medium containing 3 mg/liter Bialaphos, and subcultured every 2 weeks. After approximately 10 weeks of selection, selection-resistant callus clones are transferred to 288J medium to initiate plant regeneration. Following somatic embryo maturation (2-4 weeks), well-developed somatic embryos are transferred to medium for germination and transferred to the lighted culture room. Approximately 7-10 days later, developing plantlets are transferred to 272V hormone-free medium in tubes for 7-10 days until plantlets are well established. Plants are then transferred to inserts in flats (equivalent to 2.5" pot) containing potting soil and grown for 1 week in a growth chamber, subsequently grown an additional 1-2 weeks in the greenhouse, then transferred to classic 600 pots (1.6 gallon) and grown to maturity. Plants are monitored and scored for altered defense response defensin activity, insect resistance, nematode resistance, viral resistance, or fungal resistance.

Bombardment and Culture Media

Bombardment medium (560Y) comprises 4.0 g/l N6 basal salts (SIGMA C-1416), 1.0 ml/l Eriksson's Vitamin Mix (1000X SIGMA-1511), 0.5 mg/l thiamine HCl, 120.0 g/l sucrose, 1.0 mg/l 2,4-D, and 2.88 g/l L-proline (brought to volume with D-I H₂0 following adjustment to pH 5.8 with KOH); 2.0 g/l Gelrite (added after bringing to volume with D-I H₂0); and 8.5 mg/l silver nitrate (added after sterilizing the medium and cooling to room temperature). Selection medium (560R) comprises 4.0 g/l N6 basal salts (SIGMA C-1416), 1.0 ml/l Eriksson's Vitamin Mix (1000X SIGMA-1511), 0.5 mg/l thiamine HCl, 30.0 g/l sucrose, and 2.0 mg/l 2,4-D (brought to volume with D-I H₂0 following adjustment to pH 5.8 with KOH); 3.0 g/l Gelrite (added after bringing to volume with D-I H₂0); and 0.85 mg/l silver nitrate and 3.0 mg/l Bialaphos (both added after sterilizing the medium and cooling to room temperature).

Plant regeneration medium (288J) comprises 4.3 g/l MS salts (GIBCO 11117-074), 5.0 ml/l MS vitamins stock solution (0.100 g nicotinic acid, 0.02 g/l thiamine HCL, 0.10 g/l pyridoxine HCL, and 0.40 g/l glycine brought to volume with polished D-I H₂0) (Murashige and Skoog (1962) <i>Physiol. Plant. 15</i>:473), 100 mg/l myo-inositol, 0.5 mg/l zeatin, 60 g/l sucrose, and 1.0 ml/l of 0.1 mM abscisic acid (brought to volume with polished D-I H₂0 after adjusting to pH 5.6); 3.0 g/l Gelrite (added after bringing to volume with D-I H₂0); and 1.0 mg/l indoleacetic acid and 3.0 mg/l Bialaphos (added after sterilizing the medium and cooling to 60°C). Hormone-free medium (272V) comprises 4.3 g/l MS salts (GIBCO 11117-074), 5.0 ml/l MS vitamins stock solution (0.100 g/l nicotinic acid, 0.02 g/l thiamine HCL, 0.10 g/l pyridoxine HCL, and 0.40 g/l glycine brought to volume with polished D-I H₂0), 0.1 g/l myo-inositol, and 40.0 g/l sucrose (brought to volume with polished D-I H₂0 after adjusting pH to 5.6); and 6 g/l bacto-agar (added after bringing to volume with polished D-I H₂0), sterilized and cooled to 60° C.

Example 2. <i>Agrobacterium</i>-mediated Transformation in Maize

For <i>Agrobacterium</i>-mediated transformation of maize with a defensin nucleotide sequence of the invention operably linked to a ubiquitin promoter, preferably the method of Zhao is employed (<patcit id="pcit0061" dnum="US5981840A"><text>U.S. Patent No. 5,981,840</text></patcit>, and <patcit id="pcit0062" dnum="WO9832326A"><text>PCT patent publication WO98/32326</text></patcit>; the contents of which are hereby incorporated by reference). Briefly, immature embryos are isolated from maize and the embryos contacted with a suspension of <i>Agrobacterium,</i> where the bacteria are capable of transferring the DNA construct containing the defensin nucleotide sequence to at least one cell of at least one of the immature embryos (step 1: the infection step). In this step the immature embryos are preferably immersed in an <i>Agrobacterium</i> suspension for the initiation of inoculation. The embryos are co-cultured for a time with the <i>Agrobacterium</i> (step 2: the co-cultivation step). Preferably the immature embryos are cultured on solid medium following the infection step. Following this co-cultivation period an optional "resting" step is contemplated. In this resting step, .the embryos are incubated in the presence of at least one antibiotic known to inhibit the growth of <i>Agrobacterium</i> without the addition of a selective agent for plant transformants (step 3: resting step). Preferably the immature embryos are cultured on solid medium with antibiotic, but without a selecting agent, for elimination of <i>Agrobacterium</i> and for a resting phase for the infected cells. Next, inoculated embryos are cultured on medium containing a selective agent and growing transformed callus is recovered (step 4: the selection step). Preferably, the immature embryos are cultured on solid medium with a selective agent resulting in the selective growth of transformed cells. The callus is then regenerated into plants (step 5: the regeneration step), and preferably calli grown on selective medium are cultured on solid medium to regenerate the plants.

Example 3. Soybean Embryo Transformation

Soybean embryos are bombarded with a plasmid containing the defensin nucleotide sequences operably linked to a ubiquitin promoter as follows. To induce somatic embryos, cotyledons, 3-5 mm in length dissected from surface-sterilized, immature seeds of the soybean cultivar A2872, are cultured in the light or dark at 26°C on an appropriate agar medium for six to ten weeks. Somatic embryos producing secondary embryos are then excised and placed into a suitable liquid medium. After repeated selection for clusters of somatic embryos that multiplied as early, globular-staged embryos, the suspensions are maintained as described below.

Soybean embryogenic suspension cultures can be maintained in 35 ml liquid media on a rotary shaker, 150 rpm, at 26°C with florescent lights on a 16:8 hour day/night schedule. Cultures are subcultured every two weeks by inoculating approximately 3 5 mg of tissue into 35 ml of liquid medium.

Soybean embryogenic suspension cultures may then be transformed by the method of particle gun bombardment (<nplcit id="ncit0200" npl-type="s"><text>Klein et al. (1987) Nature (London) 327:70-73</text></nplcit>, <patcit id="pcit0063" dnum="US4945050A"><text>U.S. Patent No. 4,945,050</text></patcit>). A Du Pont Biolistic PDS1000/HE instrument (helium retrofit) can be used for these transformations.

A selectable marker gene that can be used to facilitate soybean transformation is a transgene composed of the 35S promoter from Cauliflower Mosaic Virus (<nplcit id="ncit0201" npl-type="s"><text>Odell et al. (1985) Nature 313:810-812</text></nplcit>), the hygromycin phosphotransferase gene from plasmid pJR225 (from <i>E</i>. <i>coli;</i><nplcit id="ncit0202" npl-type="s"><text>Gritz et al. (1983) Gene 25:179-188</text></nplcit>), and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of <i>Agrobacterium tumefaciens.</i> The expression cassette comprising the defensin nucleotide sequence operably linked to the ubiquitin promoter can be isolated as a restriction fragment. This fragment can then be inserted into a unique restriction site of the vector carrying the marker gene.

To 50 µl of a 60 mg/ml 1 µm gold particle suspension is added (in order): 5 µl DNA (1 µg/µl), 20 µl spermidine (0.1 M), and 50 µl CaCl₂ (2.5 M). The particle preparation is then agitated for three minutes, spun in a microfuge for 10 seconds and the supernatant removed. The DNA-coated particles are then washed once in 400 µl 70% ethanol and resuspended in 40 µl of anhydrous ethanol. The DNA/particle suspension can be sonicated three times for one second each. Five microliters of the DNA-coated gold particles are then loaded on each macro carrier disk.

Approximately 300-400 mg of a two-week-old suspension culture is placed in an empty 60x15 mm petri dish and the residual liquid removed from the tissue with a pipette. For each transformation experiment, approximately 5-10 plates of tissue are normally bombarded. Membrane rupture pressure is set at 1100 psi, and the chamber is evacuated to a vacuum of 28 inches mercury. The tissue is placed approximately 3.5 inches away from the retaining screen and bombarded three times. Following bombardment, the tissue can be divided in half and placed back into liquid and cultured as described above.

Five to seven days post bombardment, the liquid media may be exchanged with fresh media, and eleven to twelve days post-bombardment with fresh media containing 50 mg/ml hygromycin. This selective media can be refreshed weekly. Seven to eight weeks post-bombardment, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated green tissue is removed and inoculated into individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Each new line may be treated as an independent transformation event. These suspensions can then be subcultured and maintained as clusters of immature embryos or regenerated into whole plants by maturation and germination of individual somatic embryos.

Example 4. Sunflower Meristem Tissue Transformation

Sunflower meristem tissues are transformed with an expression cassette containing the defensin sequence operably linked to a ubiquitin promoter as follows (see also European Patent Number <patcit id="pcit0064" dnum="EP0486233A"><text>EP 0 486233</text></patcit>, herein incorporated by reference, and <nplcit id="ncit0203" npl-type="s"><text>Malone-Schoneberg et al. (1994) Plant Science 103:199-207</text></nplcit>). Mature sunflower seed (<i>Helianthus annuus</i> L.) are dehulled using a single wheat-head thresher. Seeds are surface sterilized for 30 minutes in a 20% Clorox bleach solution with the addition of two drops of Tween 20 per 50 ml of solution. The seeds are rinsed twice with sterile distilled water.

Split embryonic axis explants are prepared by a modification of procedures described by Schrammeijer <i>et al.</i> (<nplcit id="ncit0204" npl-type="s"><text>Schralmmeijer et al.(1990) Plant Cell Rep. 9: 55-60</text></nplcit>). Seeds are imbibed in distilled water for 60 minutes following the surface sterilization procedure. The cotyledons of each seed are then broken off, producing a clean fracture at the plane of the embryonic axis. Following excision of the root tip, the explants are bisected longitudinally between the primordial leaves. The two halves are placed, cut surface up, on GBA medium consisting of Murashige and Skoog mineral elements (<nplcit id="ncit0205" npl-type="s"><text>Murashige et al. (1962) Physiol. Plant., 15: 473-497</text></nplcit>), Shepard's vitamin additions (<nplcit id="ncit0206" npl-type="b"><text>Shepard (1980) in Emergent Techniques for the Genetic Improvement of Crops University of Minnesota Press, St. Paul, Minnesota</text></nplcit>), 40 mg/l adenine sulfate, 30 g/l sucrose, 0.5 mg/l 6-benzyl-aminopurine (BAP), 0.25 mg/l indole-3-acetic acid (IAA), 0.1 mg/l gibberellic acid (GA₃), pH 5.6, and 8 g/l Phytagar.

The explants are subjected to microprojectile bombardment prior to <i>Agrobacterium</i> treatment (<nplcit id="ncit0207" npl-type="s"><text>Bidney et al. (1992) Plant Mol. Biol. 18: 301-313</text></nplcit>). Thirty to forty explants are placed in a circle at the center of a 60 X 20 mm plate for this treatment. Approximately 4.7 mg of 1.8 mm tungsten microprojectiles are resuspended in 25 ml of sterile TE buffer (10 mM Tris HCl, 1 mM-EDTA, pH 8.0) and 1.5 ml aliquots are used per bombardment. Each plate is bombarded twice through a 150 mm nytex screen placed 2 cm above the samples in a PDS 1000^® particle acceleration device.

Disarmed <i>Agrobacterium tumefaciens</i> strain EHA105 is used in all transformation experiments. A binary plasmid vector comprising the expression cassette that contains the defensin gene operably linked to the ubiquitin promoter is introduced into <i>Agrobacterium</i> strain EHA105 via freeze-thawing as described by <nplcit id="ncit0208" npl-type="s"><text>Holsters et al. (1978) Mol. Gen. Genet. 163:181-187</text></nplcit>. This plasmid further comprises a kanamycin selectable marker gene (i.e., <i>nptII</i>). Bacteria for plant transformation experiments are grown overnight (28 °C and 100 RPM continuous agitation) in liquid YEP medium (10 gm/l yeast extract, 10 gm/l Bactopeptone, and 5 gm/l NaCl, pH 7.0) with the appropriate antibiotics required for bacterial strain and binary plasmid maintenance. The suspension is used when it reaches an OD₆₀₀ of about 0.4 to 0.8. The <i>Agrobacterium</i> cells are pelleted and resuspended at a final OD₆₀₀ of 0.5 in an inoculation medium comprised of 12.5 mM MES pH 5.7, 1 gm/l NH₄Cl, and 0.3 gm/l MgSO₄.

Freshly bombarded explants are placed in an <i>Agrobacterium</i> suspension, mixed, and left undisturbed for 30 minutes. The explants are then transferred to GBA medium and co-cultivated, cut surface down, at 26°C and 18-hour days. After three days of co-cultivation, the explants are transferred to 374B (GBA medium lacking growth regulators and a reduced sucrose level of 1%) supplemented with 250 mg/l cefotaxime and 50 mg/l kanamycin sulfate. The explants are cultured for two to five weeks on selection and then transferred to fresh 374B medium lacking kanamycin for one to two weeks of continued development. Explants with differentiating, antibioticresistant areas of growth that have not produced shoots suitable for excision are transferred to GBA medium containing 250 mg/l cefotaxime for a second 3-day phytohormone treatment. Leaf samples from green, kanamycin-resistant shoots are assayed for the presence of NPTII by ELISA and for the presence of transgene expression by assaying for defensin-like activity.

NPTH-positive shoots are grafted to Pioneer^® hybrid 6440 <i>in vitro</i>-grown sunflower seedling rootstock. Surface sterilized seeds are germinated in 48-0 medium (half-strength Murashige and Skoog salts, 0.5% sucrose, 0.3% gelrite, pH 5.6) and grown under conditions described for explant culture. The upper portion of the seedling is removed, a 1 cm vertical slice is made in the hypocotyl, and the transformed shoot inserted into the cut. The entire area is wrapped with parafilm to secure the shoot. Grafted plants can be transferred to soil following one week of in <i>vitro</i> culture. Grafts in soil are maintained under high humidity conditions followed by a slow acclimatization to the greenhouse environment. Transformed sectors of T₀ plants (parental generation) maturing in the greenhouse are identified by NPTII ELISA and/or by defensin-like activity analysis of leaf extracts while transgenic seeds harvested from NPTII-positive T₀ plants are identified by defensin-like activity analysis of small portions of dry seed cotyledon.

An alternative sunflower transformation protocol allows the recovery of transgenic progeny without the use of chemical selection pressure. Seeds are dehulled and surface-sterilized for 20 minutes in a 20% Clorox bleach solution with the addition of two to three drops of Tween 20 per 100 ml of solution, then rinsed three times with distilled water. Sterilized seeds are imbibed in the dark at 26°C for 20 hours on filter paper moistened with water. The cotyledons and root radical are removed, and the meristem explants are cultured on 374E (GBA medium consisting of MS salts, Shepard vitamins, 40 mg/l adenine sulfate, 3% sucrose, 0.5 mg/l 6-BAP, 0.25 mg/l IAA, 0.1 mg/l GA, and 0.8% Phytagar at pH 5.6) for 24 hours under the dark. The primary leaves are removed to expose the apical meristem, around 40 explants are placed with the apical dome facing upward in a 2 cm circle in the center of 374M (GBA medium with 1.2% Phytagar), and then cultured on the medium for 24 hours in the dark.

Approximately 18.8 mg of 1.8 µm tungsten particles are resuspended in 150 µl absolute ethanol. After sonication, 8 µl of it are dropped on the center of the surface of macrocarrier. Each plate is bombarded twice with 650 PSI rupture discs in the first shelf at 26 mm of Hg helium gun vacuum.

The plasmid of interest is introduced into <i>Agrobacterium tumefaciens</i> strain EHA105 via freeze thawing as described previously. The pellet of overnight-grown bacteria at 28°C in a liquid YEP medium (10 g/l yeast extract, 10 g/l Bactopeptone, and 5 g/l NaCl, pH 7.0) in the presence of 50 µg/l kanamycin is resuspended in an inoculation medium (12.5 mM 2-mM 2-(N-morpholino) ethanesulfonic acid, MES, 1 g/l NH₄Cl and 0.3 g/l MgSO₄ at pH 5.7) to reach a final concentration of 4.0 at OD 600. Particle-bombarded explants are transferred to GBA medium (374E), and a droplet of bacteria suspension is placed directly onto the top of the meristem. The explants are co-cultivated on the medium for 4 days, after which the explants are transferred to 374C medium (GBA with 1% sucrose and no BAP, IAA, GA3 and supplemented with 250 µg/ml cefotaxime). The plantlets are cultured on the medium for about two weeks under 16-hour day and 26°C incubation conditions.

Explants (around 2 cm long) from two weeks of culture in 374C medium are screened for defensin-like activity using assays known in the art. After positive (<i>i.e.,</i> for defensin expression) explants are identified, those shoots that fail to exhibit defensin-like activity are discarded, and every positive explant is subdivided into nodal explants. One nodal explant contains at least one potential node. The nodal segments are cultured on GBA medium for three to four days to promote the formation of auxiliary buds from each node. Then they are transferred to 374C medium and allowed to develop for an additional four weeks. Developing buds are separated and cultured for an additional four weeks on 374C medium. Pooled leaf samples from each newly recovered shoot are screened again by the appropriate defensin-like protein activity assay. At this time, the positive shoots recovered from a single node will generally have been enriched in the transgenic sector detected in the initial assay prior to nodal culture.

Recovered shoots positive for defensin-like activity expression are grafted to Pioneer hybrid 6440 <i>in vitro</i>-grown sunflower seedling rootstock. The rootstocks are prepared in the following manner. Seeds are dehulled and surface-sterilized for 20 minutes in a 20% Clorox bleach solution with the addition of two to three drops of Tween 20 per 100 ml of solution, and are rinsed three times with distilled water. The sterilized seeds are germinated on the filter moistened with water for three days, then they are transferred into 48 medium (half-strength MS salt, 0.5% sucrose, 0.3% gelrite pH 5.0) and grown at 26°C under the dark for three days, then incubated at 16-hour-day culture conditions. The upper portion of selected seedling is removed, a vertical slice is made in each hypocotyl, and a transformed shoot is inserted into a V-cut. The cut area is wrapped with parafilm. After one week of culture on the medium, grafted plants are transferred to soil. In the first two weeks, they are maintained under high humidity conditions to acclimatize to a greenhouse environment.

Example 5. Assaying Defensin-Like Activity

The polypeptides described herein may be produced using any number of methods known to those skilled in the art. Such methods include, but are not limited to, expression in bacteria, eukaryotic cell cultures, in planta, and viral expression systems in suitably infected organisms or cell lines. The instant polypeptides may be expressed either as full-length polypeptides, mature forms, or as fusion proteins by covalent attachment to a variety of enzymes, proteins, or affinity tags. Common fusion protein partners include, but are not limited to, glutathione-S-transferase, thioredoxin, maltose binding protein, hexahistidine polypeptides, and chitin binding protein. The fusion proteins may be engineered with a protease recognition site at the fusion point so that fusion partners can be separated by protease digestion to yield intact mature peptides. Examples of such proteases include, but are not limited to, thrombin, enterokinase, and factor Xa. Indeed, any protease which specifically cleaves the peptide connecting the fusion protein and polypeptide of the invention can be used.

Purification of the polypeptides of the invention may utilize any number of separation technologies known to those skilled in the art of protein purification. Examples of such methods include, but are not limited to, homogenization, filtration, centrifugation, heat denaturation, ammonium sulfate precipitation, desalting, pH precipitation, ion exchange chromatography, hydrophobic interaction chromatography, and affinity chromatography. When the polypeptides of the invention are expressed as fusion proteins, the purification protocol may include the use of an affinity resin specific for the fusion protein partner or for the polypeptide of interest. Additional suitable affinity resins may be synthesized by linking the appropriate ligands to a suitable resin such as Sepharose-4B.

Crude, partially purified, or purified polypeptides of the invention, either alone or as a fusion protein, may be utilized in assays to verify expression levels of functional plant defensins in host cells and transgenic plants. Assays may be conducted under well known experimental conditions which permit optimal enzymatic activity. See, for example, assays for plant defensin activities presented by <nplcit id="ncit0209" npl-type="s"><text>Thevissen, K et al. (1996) J. Biol. Chem. 271:15018-15025</text></nplcit> and <patcit id="pcit0065" dnum="WO0068405A"><text>WO 00/68405</text></patcit>, herein incorporated by reference.

Example 6. Bioassay testing the Pesticidal Activity of Polypeptides against Southern Corn Rootworm (SCRW) and Western Corn Rootworm (WCRW)

Bio-Serv diet (catalog number F9800B, from: BIOSERV, Entomology Division, One 8^th Street, Suite 1, Frenchtown, New Jersey 08825) is dispensed in 128-well CD International Bioassay trays (catalog number BIO-BA-128 from CD International, Pitman, New Jersey 08071).

Protein samples are applied topically to the diet surface. Enough sample material is supplied to provide for replicate observations per sample. The trays are allowed to dry. Rootworms are dispensed into the wells of the bioassay trays. A lid (catalog number BIO-CV-16, CD International, Pitman, New Jersey, 08071) is placed on each tray, and the trays are placed in an incubator at 26°C for 4 to 7 days.

For the evaluation of pesticidal activity against SCRW and WCRW, insects are exposed to a solution comprising either buffer (50mM carbonate buffer (pH 10)) or a solution of protein sample at selected doses, for example, 50 or 5.0 µg/cm².

The bioassays are then scored by counting "live" versus "dead" larvae. Mortality is calculated as a percentage of dead larvae out of the total number of larvae tested.

Example 7. Bioassay Testing Pesticidal Activity of Polypeptides against the Colorado Potato Beetle (

Leptinotarsa decemlineata)

Briefly, bioassay parameters are as follows: Bio-Serv diet (catalog number F9800B, from: BIOSERV, Entomology Division, One 8th Street, Suite 1, Frenchtown, New Jersey 08825) is dispensed in a 96 well microtiter plate (catalog number 353918, Becton Dickinson, Franklin Lakes, NJ 07417-1886) having a surface area of 0.33 cm². Protein samples of the invention are applied topically to the diet surface. Enough sample material is supplied to provide for 8 observations/sample. After the samples dry, 1 Colorado potato beetle neonate is added to each well providing for a total of 8 larvae/sample. A Mylar® lid (Clear Lam Packaging, Inc., 1950 Pratt Blvd., Elk Grove Village, IL 60007-5993) is affixed to each tray. Bioassay trays are placed in an incubator at 25°C. The test is scored for mortality on the 7th day following live infesting.

Example 8. Bioassay Testing Pesticidal Activity of Polypeptides against Lepidopterans

Neonate larvae are reared according to standard protocols, such as those published by <nplcit id="ncit0210" npl-type="s"><text>Czapla and Lang, J. Economic Entomology 83:2480-2485 (1990</text></nplcit>). Test compounds are either applied topically to the diet or incorporated into the larvae diet (see <nplcit id="ncit0211" npl-type="s"><text>Czapla and Lang, J. Economic Entomology 83:2480-2485 (1990</text></nplcit>)). The larvae diet is dispensed to bioassay trays. One larva is applied per well of the bioassay tray. Weight and mortality are recorded 7 days following the start of the test.

Example 9. Homopteran Membrane Feeding Bioassay for Screening Proteins

This assay can be used for a variety ofhomopterans. The assay involves trapping the sample protein between two layers of maximally stretched parafilm which act as a sachet on top of a small vessel containing the insect of choice.

The assay is prepared as follows: 1 cm diameter polystyrene tubing is cut into 15 mm lengths. One end of the tube is then capped with a fine mesh screen. Five insects are then added to the chamber after which the first layer of parafilm is stretched over the remaining open end. 25 µl of sample (polypeptide in a 5% sucrose solution containing McCormick green food coloring) is then placed on top of the stretched parafilm. A second layer of parafilm is then stretched by hand and placed over the sample. The sample is spread between the two layers of parafilm to make a continuous sachet on which the insects feed. The sachet is then covered tightly with saran wrap to prevent evaporation and produce a slightly pressurized sample. The assay tubes are monitored for insect reproduction and death on a 24 hour basis and compared to the 5% sucrose control.

Example 10. SCN Bioassay of Transgenic T0 Events

Soybean Cyst Nematodes (SCN) are used to infest transgenic T0 soybean plants in soil. SCN egg inoculum is acquired by harvesting cysts from plants infested 4-6 weeks earlier. Briefly, the soil is rinsed from the roots and passed through nested 20 mesh and 60 mesh screens. The material retained by the 20 mesh screen is discarded but the material retained by the 60 mesh screen is washed thoroughly and the creamy white cysts are recovered (older brown cysts are ignored). Similarly, the plant's root system is scrubbed against the 20 mesh screen nested over the 60 mesh screen. Cysts are harvested from the debris on the 60 mesh screen. Eggs are released from the cysts by means of a dounce homogenizer in the presence of 0.5% Clorox for 2.5 minutes. Following this treatment the eggs are washed with sterile water from the homogenizer onto the surface of a 200 mesh screen. The eggs are then rinsed in water for an additional 5 minutes. Eggs are transferred to a 50 ml conical tube and counted. The eggs are diluted to 5000 eggs/ml. Plants grown in 15cm conical tubes are inoculated with about 5000 eggs. Plants are maintained in a 26°C growth chamber with 12:12 light:dark cycle for 1 month prior to harvest and counting of cysts.

Example 11. Bioactivity of Polypeptides Against Fungal Pathogens

The proteins of the invention are suspended in dH2O to a final concentration of about 4 µg/µl. 12 µg of purified protein is added to 200 µl of ½ strength potato dextrose broth (PDB) containing a spore suspension of the fungal pathogen to be tested. The spore suspension contains approximately 2500 spores/ml. This results in a stock solution with a starting concentration of 10 µM. A 0.5X dilution series for the protein sample to be tested from10 µM through to about 0.05 µM is prepared by removing 100µl of the 10µM stock and adding it to 100 µl of spore suspension (2500 spores/ml), mixing thoroughly to achieve a 5 µM protein sample concentration, transferring 100µl of the 5 µM suspension to a fresh 100 µl spore suspension etc., until about 0.005 µM is reached. Two replicates per pathogen are performed. The fungal assay plate is scored for inhibition of fungal growth after a 48 hour incubation at 28°C. Inhibition of fungal growth is defined as little to no spore germination without detectable hyphae growth.

All publications, patents and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. All publications, patents and patent applications are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

<u>FURTHER EMBODIMENTS OF THE INVENTION</u>

<ol id="ol0001" compact="compact" ol-style=""><li>1. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: <ul id="ul0005" list-style="none" compact="compact"><li>(a) a nucleotide sequence set forth in SEQ ID NO: 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76, 79, 82, 85, 88, 91, 94, 97, 100, 103, 106, 109, 112, 115, 118, 121, 124, 127, 130, 133, 136, 139, 142, 145, 148, 151, 154, 157, 160, 163, 166, 169, 172, 175, 178, 181, 184, 187, 190, 193, 196, 199, 202, 205, 208, 211, 214, 217, 220, 223, 226, 229, 232, 235, 238, 241, 244, 247, 250, 253, 256, 259, 262, 265, 268, 271, 274, 277, 280, 283, 286, 289, 292, 295, 298, 301, 304, 307, 310, 313, 316, 319, 322, 325, 328, 331, 334, 337, 340, 343, 346, 349, 352, 355, 358, 361, 364, 367, 370, 373, 376, 379, 382, 385, 388, 391, 394, 397, 400, 403, 406, 409, 412, 415, 418, 421, 424, 427, 430, 433, 436, 439, 442, 445, 448, 451, 454, 457, 460, 463, or 465;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 2, 3, 5, 6, 8, 9, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 32, 33, 35, 36, 38, 39, 41, 42, 44, 45, 47, 48, 50, 51, 53, 54, 56, 57, 59, 60, 62, 63, 65, 66, 68, 69, 71, 72, 74, 75, 77, 78, 80, 81, 83, 84, 86, 87, 89, 90, 92, 93, 95, 96, 98, 99, 101, 102, 104, 105, 107, 108, 110, 111, 113, 114, 116, 117, 119, 120, 122, 123, 125, 126, 128, 129, 131, 132, 134, 135, 137, 138, 140, 141, 143, 144, 146, 147, 149, 150, 152, 153, 155, 156, 158, 159, 161, 162, 164, 165, 167, 168, 170, 171, 173, 174, 176, 177, 179, 180, 182, 183, 185, 186, 188, 189, 191, 192, 194, 195, 197, 198, 200, 201, 203, 204, 206, 207, 209, 210, 212, 213, 215, 216, 218, 219, 221, 222, 224, 225, 227, 228, 230, 231, 233, 234, 236, 237, 239, 240, 242, 243, 245, 246, 248, 249, 251, 252, 254, 255, 257, 258, 260, 261, 263, 264, 266, 267, 269, 270, 272, 273, 275, 276, 278, 279, 281, 282, 284, 285, 287, 288, 290, 291, 293, 294, 296, 297, 299, 300, 302, 303, 305, 306, 308, 309, 311, 312, 314, 315, 317, 318, 320, 321, 323, 324, 326, 327, 329, 330, 332, 333, 335, 336, 338, 339, 341, 342, 344, 345, 347, 348, 350, 351, 353, 354, 356, 357, 359, 360, 362, 363, 365, 366, 368, 369, 371, 372, 374, 375, 377, 378, 380, 381, 383, 384, 386, 387, 389, 390, 392, 393, 395, 396, 398, 399, 401, 402, 404, 405, 407, 408, 410, 411, 413, 414, 416, 417, 419, 420, 422, 423, 425, 426, 428, 429, 431, 432, 434, 435, 437, 438, 440, 441, 443, 444, 446, 447, 449, 450, 452, 453, 455, 456, 458, 459, 461, 462, 464, or 466;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 117, 120, 123, 126, 129, 132, 135, 138, 141, 144, 147, 150, 153, 156, 159, 162, 165, 168, 171, 174, 177, 180, 183, 186, 189, 192, 195, 198, 201, 204, 207, 210, 213, 216, 219, 222, 225, 228, 231, 234, 237, 240, 243, 246, 249, 252, 255, 258, 261, 264, 267, 270, 273, 276, 279, 282, 285, 288, 291, 294, 297, 300, 303, 306, 309, 312, 315, 318, 321, 324, 327, 330, 333, 336, 339, 342, 345, 348, 351, 354, 357, 360, 363, 366, 369, 372, 375, 378, 381, 384, 387, 390, 393, 396, 399, 402, 405, 408, 41 l, 414, 417, 420, 423, 426, 429, 432, 435, 438, 441, 444, 447, 450, 453, 456, 459, 462, 464, or 466;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 117, 120, 123, 126, 129, 132, 135, 138, 141, 144, 147, 150, 153, 156, 159, 162, 165, 168, 171, 174, 177, 180, 183, 186, 189, 192, 195, 198, 201, 204, 207, 210, 213, 216, 219, 222, 225, 228, 231, 234, 237, 240, 243, 246, 249, 252, 255, 258, 261, 264, 267, 270, 273, 276, 279, 282, 285, 288, 291, 294, 297, 300, 303, 306, 309, 312, 315, 318, 321, 324, 327, 330, 333, 336, 339, 342, 345, 348, 351, 354, 357, 360, 363, 366, 369, 372, 375, 378, 381, 384, 387, 390, 393, 396, 399, 402, 405, 408, 411, 414, 417, 420, 423, 426, 429, 432, 435, 438, 441, 444, 447, 450, 453, 456, 459, 462, 464, or 466, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76, 79, 82, 85, 88, 91, 94, 97, 100, 103, 106, 109, 112, 115, 118, 121, 124, 127, 130, 133, 136, 139, 142, 145, 148, 151, 154, 157, 160, 163, 166, 169, 172, 175, 178, 181, 184, 187, 190, 193, 196, 199, 202, 205, 208, 211, 214, 217, 220, 223, 226, 229, 232, 235, 238, 241, 244, 247, 250, 253, 256, 259, 262, 265, 268, 271, 274, 277, 280, 283, 286, 289, 292, 295, 298, 301, 304, 307, 310, 313, 316, 319, 322, 325, 328, 331, 334, 337, 340, 343, 346, 349, 352, 355, 358, 361, 364, 367, 370, 373, 376, 379, 382, 385, 388, 391, 394, 397, 400, 403, 406, 409, 412, 415, 418, 421, 424, 427, 430, 433, 436, 439, 442, 445, 448, 451, 454, 457, 460, 463, or 465, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ul></li><li>2. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0002" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 1, 4, or 7;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 2, 5, or 8;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 3, 6, or 9;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 3, 6, or 9, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 1, 4, or 7, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>3. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0003" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 10;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 11;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 12;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 12, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 10, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>4. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0004" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 13 or 16;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 14 or 17;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 15 or 18;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 15 or 18, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 13 or 16, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>5. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0005" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, or 55;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, or 56;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, or 57;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, or 57, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, or 55, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>6. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0006" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 58, 61, 64, or 67;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 59, 62, 65, or 68;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 60, 63, 66, or 69;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 60, 63, 66, or 69, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 58, 61, 64, or 67, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>7. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0007" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 70 or 73;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 71 or 74;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 72 or 75;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 72 or 75, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 70 or 73, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>8. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0008" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 76 or 79;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 77 or 80;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 78 or 81;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 78 or 81, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 76 or 79, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>9. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0009" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO:82 or 85;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO:83 or 86;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 84 or 87;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 84 or 87, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 82 or 85 or, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>10. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0010" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 88;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 89;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 90;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 90, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 88, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>11. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0011" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 91 or 94;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 92 or 95;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 93 or 96;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 93 or 96, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 91 or 94, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>12. The isolated nucleic acid molecules of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0012" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 97, 100, 103, or 106;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 98, 101, 104, or 107;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 99, 102, 105, or 108;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 99, 102, 105, or 108, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 97, 100, 103, or 106, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>13. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0013" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 109 or 112;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 110 or 113;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 111 or 114;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 111 or 114, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 109 or 112, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>14. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0014" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 115 or 118;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO:116 or 119;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 117 or 120;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 117 or 120, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 115 or 118, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>15. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0015" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO:121 or 124;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 122 or 125;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 123 or 126;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 123 or 126, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 121 or 124, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>16. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0016" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 127 or 130;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 128 or 131;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 129 or 132;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 129 or 132, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 127 or 130, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>17. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0017" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 133 or 136;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 134 or 137;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ II) NO: 135 or 138;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 135 or 138, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 133 or 136, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>18. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0018" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 139, 142, 145, 148, 151, 154, 157, 160, 163, 166, 169, 172, 175, 178, 181, 184, 187, 190, 193, 196, 199, 202, 205, or 208;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 140, 143, 146, 149, 152, 155, 158, 161, 164, 167, 170, 173, 176, 179, 182, 185, 188, 191, 194, 197, 200, 203, 206, or 209;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 141, 144, 147, 150, 153, 156, 159, 162, 165, 168, 171, 174, 177, 180, 183, 186, 189, 192, 195, 198, 201, 204, 207, or 210;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 141, 144, 147, 150, 153, 156, 159, 162, 165, 168, 171, 174, 177, 180, 183, 186, 189, 192, 195, 198, 201, 204, 207, or 210, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 139, 142, 145, 148, 151, 154, 157, 160, 163, 166, 169, 172, 175, 178, 181, 184, 187, 190, 193, 196, 199, 202, 205, or 208, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>19. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0019" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 211, 214, 217, 220, or 223;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 212, 215, 218, 221, or 224;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 213, 216, 219, 222, or 225;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 213, 216, 219, 222, or 225, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 211, 214, 217, 220, or 223, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>20. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0020" compact="compact" ol-style=""><li>a) a nucleotide sequence set forth in SEQ ID NO: 226, 229, or 232;</li><li>b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 227, 230, or 233;</li><li>c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 228, 231, or 234;</li><li>d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 228, 231, or 234, wherein said polypeptide retains defensin-like activity;</li><li>e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 226, 229, or 232, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>21. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0021" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 235;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 236;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 237;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 237, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 235, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>22. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0022" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 238;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 239;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 240;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 240, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 238, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>23. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0023" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 241;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 242;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 243;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 243, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 241, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>24. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0024" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 244;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 245;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 246;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 246, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 244, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>25. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0025" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 247;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 248;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 249;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 249, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 247, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>26. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0026" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 250;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 251;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 252;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 252, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 250, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>27. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0027" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 253;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 254;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 255;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 255, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 253, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>28. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0028" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 256;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 257;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 258;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 258, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 256, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>29. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0029" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 259;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 260;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 261;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 261, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 259, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>30. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0030" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 262;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 263;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 264;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 264, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 262, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>31. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0031" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 265;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 266;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 267;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 267, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 265, wherein said, nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>32. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0032" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 268;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 269;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 270;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 270, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 268, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>33. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0033" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 271;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 272;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 273;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 273, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 271, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>34. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0034" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 274;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 275;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 276;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 276, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 274, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>35. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0035" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 277;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 278;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 279;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 279, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 277, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>36. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0036" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 280;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 281;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 282;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 282, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 280, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>37. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0037" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 283;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 284;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 285;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 285, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 283, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>38. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0038" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 286;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 287;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 288;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 288, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 286, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e):</li></ol></li><li>39. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0039" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 289;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 290;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 291;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 291, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 289, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>40. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0040" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 292;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 293;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 294;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 294, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 292, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>41. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0041" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 295;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 296;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 297;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 297, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 295, wherein said nucleotide sequence encodes a polypeptide that retains defensin-.like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>42. The isolated nucleic acid molecule of item I wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0042" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 298;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 299;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 300;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 300, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 298, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>43. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0043" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 301;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 302;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 303;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 303, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 301, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>44. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0044" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 304;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 305;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 306;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 306, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 304, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>45. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0045" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 307;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 308;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 309;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 80 percent identity to the amino acid sequence set forth in SEQ ID NO: 309, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 307, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>46. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0046" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 310;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 311;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 312;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 80 percent identity to the amino acid sequence set forth in SEQ ID NO: 312, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 310, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>47. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0047" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 313;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 314;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 315;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 80 percent identity to the amino acid sequence set forth in SEQ ID NO: 315, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 313, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>48. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0048" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 316, 319 or 322;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 317, 320, or 323;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 318, 321, or 324;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 80 percent identity to the amino acid sequence set forth in SEQ ID NO: 318, 321, or 324, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 316, 319 or 322, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>49. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0049" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 325, 328, or 331;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 326, 329, or 332;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 327, 330, or 333;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 80 percent identity to the amino acid sequence set forth in SEQ ID NO: 327, 330, or 333, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 325, 328, or 331, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>50. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0050" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 334, 337, 340, or 343;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 335, 338, 341, or 344;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO :336, 339, 342, or 345;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 80 percent identity to the amino acid sequence set forth in SEQ ID NO: 336, 339, 342, or 345, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 334, 337, 340, or 343, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>51. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0051" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 346;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 347;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 348;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 80 percent identity to the amino acid sequence set forth in SEQ ID NO: 348, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 346, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>52. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0052" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 349;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 350;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 351;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 80 percent identity to the amino acid sequence set forth in SEQ ID NO: 351, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 349, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>53. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0053" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 352;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 353;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 354;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 80 percent identity to the amino acid sequence set forth in SEQ ID NO: 354, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 352, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>54. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0054" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 355;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 356;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 357;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 80 percent identity to the amino acid sequence set forth in SEQ ID NO: 357, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 355, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>55. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0055" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 358;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 359;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 360;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 80 percent identity to the amino acid sequence set forth in SEQ ID NO: 360, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 358, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>56. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0056" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 361;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 362;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 363;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 80 percent identity to the amino acid sequence set forth in SEQ ID NO: 363, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 361, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>57. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0057" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 364;</li><li>(b) a nucleotide sequence that-encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 365;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 366;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 80 percent identity to the amino acid sequence set forth in SEQ ID NO: 366, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 364, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>58. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0058" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 367;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 368;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 369;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 80 percent identity to the amino acid sequence set forth in SEQ ID NO: 369, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 367, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>59. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0059" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 370;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 371;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 372;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 80 percent identity to the amino acid sequence set forth in SEQ ID NO: 372, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 370, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>60. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0060" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 373;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 374;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 375;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 80 percent identity to the amino acid sequence set forth in SEQ ID NO: 375, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 373, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>61. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0061" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 376;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 377;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 378;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 85 percent identity to the amino acid sequence set forth in SEQ ID NO: 378, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 376, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>62. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0062" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 379;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 380;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 381;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 85 percent identity to the amino acid sequence set forth in SEQ ID NO: 381, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 379, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>63. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0063" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 382;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 383;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 384;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 85 percent identity to the amino acid sequence set forth in SEQ ID NO: 384, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 382, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>64. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0064" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 385;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 386;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 387;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 85 percent identity to the amino acid sequence set forth in SEQ ID NO: 387, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 385, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>65. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0065" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 388 or 391;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 389 or 392;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 390 or 393;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 85 percent identity to the amino acid sequence set forth in SEQ ID NO: 390 or 393, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 388 or 391, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>66. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0066" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 394;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 395;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 396;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 85 percent identity to the amino acid sequence set forth in SEQ ID NO: 396, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 394, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>67. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0067" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 397 or 400;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 398 or 401;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 399 or 402;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 85 percent identity to the amino acid sequence set forth in SEQ ID NO: 399 or 402, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 397 or 400, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>68. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0068" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 403;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 404;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 405;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 85 percent identity to the amino acid sequence set forth in SEQ ID NO: 405, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 403, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>69. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0069" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 406 or 409;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 407 or 410;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 408 or 411;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 85 percent identity to the amino acid sequence set forth in SEQ ID NO: 408 or 411, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 406 or 409, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>70. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0070" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 412;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQID NO: 413;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 414;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 85 percent identity to the amino acid sequence set forth in SEQ ID NO: 414, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 412, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>71. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0071" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 415, 418, or 421;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 416, 419, or 422;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 417, 420, or 423;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 90 percent identity to the amino acid sequence set forth in SEQ ID NO: 417, 420, or 423, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 415, 418, or 421, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>72. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0072" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 424;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 425;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 426;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 90 percent identity to the amino acid sequence set forth in SEQ ID NO: 426, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 424, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>73. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0073" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 427;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 428;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 429;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 90 percent identity to the amino acid sequence set forth in SEQ ID NO: 429, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 427, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>74. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0074" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 430;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 431;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 432;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 90 percent identity to the amino acid sequence set forth in SEQ ID NO: 432, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 430, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>75. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0075" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 433;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 434;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 435;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 90 percent identity to the amino acid sequence set forth in SEQ ID NO: 435, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 433, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>76. The isolated nucleic acid molecule of item I wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0076" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 436;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 437;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 438;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 90 percent identity to the amino acid sequence set forth in SEQ ID NO: 438, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 436, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>77. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0077" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 439;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 440;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 441;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 90 percent identity to the amino acid sequence set forth in SEQ ID NO: 441, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 439, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>78. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0078" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 442;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 443;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 444;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 95% percent identity to the amino acid sequence set forth in SEQ ID NO: 444, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 442, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>79. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0079" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 445 or 448;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 446 or 449;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 447 or 450;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 95 percent identity to the amino acid sequence set forth in SEQ ID NO: 447 or 450, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 445 or 448, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>80. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0080" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 451;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 452;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 453;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 95 percent identity to the amino acid sequence set forth in SEQ ID NO: 453, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 451, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>81. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0081" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 454;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 455;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 456;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 99 percent identity to the amino acid sequence set forth in SEQ ID NO: 456, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 454, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>82. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0082" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 457;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 458;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 459;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 459, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 457, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>83. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0083" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 460;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 461;</li><li>(c) a nucleotide sequence that encodes a mature polypeptide having the amino acid sequence set forth in SEQ ID NO: 462;</li><li>(d) a nucleotide sequence that encodes a polypeptide having at least about 70 percent identity to the amino acid sequence set forth in SEQ ID NO: 462, wherein said polypeptide retains defensin-like activity;</li><li>(e) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 460, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(f) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b), (c), (d), or (e).</li></ol></li><li>84. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0084" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 463;</li><li>(b) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 463, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(c) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a) or (b).</li></ol></li><li>85. The isolated nucleic acid molecule of item 1 wherein the nucleotide sequence is selected from the group consisting of: <ol id="ol0085" compact="compact" ol-style=""><li>(a) a nucleotide sequence set forth in SEQ ID NO: 465;</li><li>(b) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 466;</li><li>(c) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence having a sequence set forth in SEQ ID NO: 465 or, wherein said nucleotide sequence encodes a polypeptide that retains defensin-like activity; or</li><li>(d) a nucleotide sequence consisting of a complement of any one of the nucleotide sequences in (a), (b) or (c).</li></ol></li><li>86. A DNA construct comprising a nucleotide sequence of item 1, wherein said nucleotide sequence is operably linked to a promoter that drives expression in a host cell.</li><li>87. An expression vector comprising the DNA construct of item 86.</li><li>88. A host cell having stably incorporated into its genome at least one DNA construct of item 86, wherein said promoter is a heterologous promoter that drives expression in the host cell.</li><li>89. The host cell of item 88, wherein said host cell is a plant cell.</li><li>90. A plant having stably incorporated into its genome the DNA construct of item 86.</li><li>91. Seed of the plant of item 90.</li></ol><img file="EP2270184A2_D0001.tif" /><img file="EP2270184A2_D0002.tif" /><img file="EP2270184A2_D0003.tif" /><img file="EP2270184A2_D0004.tif" /><img file="EP2270184A2_D0005.tif" /><img file="EP2270184A2_D0006.tif" /><img file="EP2270184A2_D0007.tif" /><img file="EP2270184A2_D0008.tif" /><img file="EP2270184A2_D0009.tif" /><img file="EP2270184A2_D0010.tif" /><img file="EP2270184A2_D0011.tif" /><img file="EP2270184A2_D0012.tif" /><img file="EP2270184A2_D0013.tif" /><img file="EP2270184A2_D0014.tif" /><img file="EP2270184A2_D0015.tif" /><img file="EP2270184A2_D0016.tif" /><img file="EP2270184A2_D0017.tif" /><img file="EP2270184A2_D0018.tif" /><img file="EP2270184A2_D0019.tif" /><img file="EP2270184A2_D0020.tif" /><img file="EP2270184A2_D0021.tif" /><img file="EP2270184A2_D0022.tif" /><img file="EP2270184A2_D0023.tif" /><img file="EP2270184A2_D0024.tif" /><img file="EP2270184A2_D0025.tif" /><img file="EP2270184A2_D0026.tif" /><img file="EP2270184A2_D0027.tif" /><img file="EP2270184A2_D0028.tif" /><img file="EP2270184A2_D0029.tif" /><img file="EP2270184A2_D0030.tif" /><img file="EP2270184A2_D0031.tif" /><img file="EP2270184A2_D0032.tif" /><img file="EP2270184A2_D0033.tif" /><img file="EP2270184A2_D0034.tif" /><img file="EP2270184A2_D0035.tif" /><img file="EP2270184A2_D0036.tif" /><img file="EP2270184A2_D0037.tif" /><img file="EP2270184A2_D0038.tif" /><img file="EP2270184A2_D0039.tif" /><img file="EP2270184A2_D0040.tif" /><img file="EP2270184A2_D0041.tif" /><img file="EP2270184A2_D0042.tif" /><img file="EP2270184A2_D0043.tif" /><img file="EP2270184A2_D0044.tif" /><img file="EP2270184A2_D0045.tif" /><img file="EP2270184A2_D0046.tif" /><img file="EP2270184A2_D0047.tif" /><img file="EP2270184A2_D0048.tif" /><img file="EP2270184A2_D0049.tif" /><img file="EP2270184A2_D0050.tif" /><img file="EP2270184A2_D0051.tif" /><img file="EP2270184A2_D0052.tif" /><img file="EP2270184A2_D0053.tif" /><img file="EP2270184A2_D0054.tif" /><img file="EP2270184A2_D0055.tif" /><img file="EP2270184A2_D0056.tif" /><img file="EP2270184A2_D0057.tif" /><img file="EP2270184A2_D0058.tif" /><img file="EP2270184A2_D0059.tif" /><img file="EP2270184A2_D0060.tif" /><img file="EP2270184A2_D0061.tif" /><img file="EP2270184A2_D0062.tif" /><img file="EP2270184A2_D0063.tif" /><img file="EP2270184A2_D0064.tif" /><img file="EP2270184A2_D0065.tif" /><img file="EP2270184A2_D0066.tif" /><img file="EP2270184A2_D0067.tif" /><img file="EP2270184A2_D0068.tif" /><img file="EP2270184A2_D0069.tif" /><img file="EP2270184A2_D0070.tif" /><img file="EP2270184A2_D0071.tif" /><img file="EP2270184A2_D0072.tif" /><img file="EP2270184A2_D0073.tif" /><img file="EP2270184A2_D0074.tif" /><img file="EP2270184A2_D0075.tif" /><img file="EP2270184A2_D0076.tif" /><img file="EP2270184A2_D0077.tif" /><img file="EP2270184A2_D0078.tif" /><img file="EP2270184A2_D0079.tif" /><img file="EP2270184A2_D0080.tif" /><img file="EP2270184A2_D0081.tif" /><img file="EP2270184A2_D0082.tif" /><img file="EP2270184A2_D0083.tif" /><img file="EP2270184A2_D0084.tif" /><img file="EP2270184A2_D0085.tif" /><img file="EP2270184A2_D0086.tif" /><img file="EP2270184A2_D0087.tif" /><img file="EP2270184A2_D0088.tif" /><img file="EP2270184A2_D0089.tif" /><img file="EP2270184A2_D0090.tif" /><img file="EP2270184A2_D0091.tif" /><img file="EP2270184A2_D0092.tif" /><img file="EP2270184A2_D0093.tif" /><img file="EP2270184A2_D0094.tif" /><img file="EP2270184A2_D0095.tif" /><img file="EP2270184A2_D0096.tif" /><img file="EP2270184A2_D0097.tif" /><img file="EP2270184A2_D0098.tif" /><img file="EP2270184A2_D0099.tif" /><img file="EP2270184A2_D0100.tif" /><img file="EP2270184A2_D0101.tif" /><img file="EP2270184A2_D0102.tif" /><img file="EP2270184A2_D0103.tif" /><img file="EP2270184A2_D0104.tif" /><img file="EP2270184A2_D0105.tif" /><img file="EP2270184A2_D0106.tif" /><img file="EP2270184A2_D0107.tif" /><img file="EP2270184A2_D0108.tif" /><img file="EP2270184A2_D0109.tif" /><img file="EP2270184A2_D0110.tif" /><img file="EP2270184A2_D0111.tif" /><img file="EP2270184A2_D0112.tif" /><img file="EP2270184A2_D0113.tif" /><img file="EP2270184A2_D0114.tif" /><img file="EP2270184A2_D0115.tif" /><img file="EP2270184A2_D0116.tif" /><img file="EP2270184A2_D0117.tif" /><img file="EP2270184A2_D0118.tif" /><img file="EP2270184A2_D0119.tif" /><img file="EP2270184A2_D0120.tif" /><img file="EP2270184A2_D0121.tif" /><img file="EP2270184A2_D0122.tif" /><img file="EP2270184A2_D0123.tif" /><img file="EP2270184A2_D0124.tif" /><img file="EP2270184A2_D0125.tif" /><img file="EP2270184A2_D0126.tif" /><img file="EP2270184A2_D0127.tif" /><img file="EP2270184A2_D0128.tif" /><img file="EP2270184A2_D0129.tif" /><img file="EP2270184A2_D0130.tif" /><img file="EP2270184A2_D0131.tif" /><img file="EP2270184A2_D0132.tif" /><img file="EP2270184A2_D0133.tif" /><img file="EP2270184A2_D0134.tif" /><img file="EP2270184A2_D0135.tif" /><img file="EP2270184A2_D0136.tif" /><img file="EP2270184A2_D0137.tif" /><img file="EP2270184A2_D0138.tif" /><img file="EP2270184A2_D0139.tif" /><img file="EP2270184A2_D0140.tif" /><img file="EP2270184A2_D0141.tif" /><img file="EP2270184A2_D0142.tif" /><img file="EP2270184A2_D0143.tif" /><img file="EP2270184A2_D0144.tif" /><img file="EP2270184A2_D0145.tif" /><img file="EP2270184A2_D0146.tif" /><img file="EP2270184A2_D0147.tif" /><img file="EP2270184A2_D0148.tif" /><img file="EP2270184A2_D0149.tif" /><img file="EP2270184A2_D0150.tif" /><img file="EP2270184A2_D0151.tif" /><img file="EP2270184A2_D0152.tif" /><img file="EP2270184A2_D0153.tif" /><img file="EP2270184A2_D0154.tif" /><img file="EP2270184A2_D0155.tif" /><img file="EP2270184A2_D0156.tif" /><img file="EP2270184A2_D0157.tif" /><img file="EP2270184A2_D0158.tif" /><img file="EP2270184A2_D0159.tif" /><img file="EP2270184A2_D0160.tif" /><img file="EP2270184A2_D0161.tif" /><img file="EP2270184A2_D0162.tif" /><img file="EP2270184A2_D0163.tif" /><img file="EP2270184A2_D0164.tif" /><img file="EP2270184A2_D0165.tif" /><img file="EP2270184A2_D0166.tif" /><img file="EP2270184A2_D0167.tif" /><img file="EP2270184A2_D0168.tif" /><img file="EP2270184A2_D0169.tif" /><img file="EP2270184A2_D0170.tif" /><img file="EP2270184A2_D0171.tif" /><img file="EP2270184A2_D0172.tif" /><img file="EP2270184A2_D0173.tif" /><img file="EP2270184A2_D0174.tif" /><img file="EP2270184A2_D0175.tif" /><img file="EP2270184A2_D0176.tif" /><img file="EP2270184A2_D0177.tif" /><img file="EP2270184A2_D0178.tif" /><img file="EP2270184A2_D0179.tif" /><img file="EP2270184A2_D0180.tif" /><img file="EP2270184A2_D0181.tif" /><img file="EP2270184A2_D0182.tif" />